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ABSTRACT
Protein phosphorylation is a central regulatory mechanism in signal transduction
pathways and cellular migration. Current genetic strategies for the study of
phosphorylation, including gene knockout and point mutation, are limited in providing
temporal information. As a complement to these techniques, the synthesis and
semisynthesis of probes that enable researchers to observe the downstream effects of
kinase-mediated phosphorylation in "real time" are presented in this thesis.
The release of a physiologically-relevant concentration of a phosphopeptide with
temporal and spatial control is accomplished by the photolysis of a photolabile precursor,
a caged phosphopeptide. The synthesis and application of NI-Fmoc-protected 1-(2-
nitrophenyl) ethyl (NPE) caged phosphothreonine, serine, and tyrosine building blocks
facilitate the straightforward assembly of any caged phosphopeptide through Fmoc-based
solid phase peptide synthesis. Removal of the NPE caging group by irradiation with
long-wavelength UV light generates a concentration burst of the corresponding
phosphopeptide.
In addition, the installation of a caged phosphoamino acid into a full-length,
multi-domain protein, the cellular migration protein paxillin, is described. A strategy,
which is applicable to any expressible protein target, is detailed for the semisynthesis of a
paxillin variant with a caged phosphorylated tyrosine at residue 31 of the 557-residue
protein using native chemical ligation. Paxillin is a 61-kDa protein known to orchestrate
the interaction of signaling proteins involved in cell migration by acting as a molecular
adaptor, with the creation of specific binding sites dependent on paxillin phosphorylation.
Therefore, the semisynthetic probe comprises the entire paxillin macromolecule,
including all other binding and localization domains, which are essential for creating a
native-like system to probe the effect of phosphorylation. The comprehensive
biochemical characterization of the paxillin probe and quantification of uncaging
following irradiation with long-wavelength UV light are also described.
Additionally, the strategy developed for the paxillin semisynthesis was applied to
incorporate a different unnatural amino acid, the fluorescent chemosensing residue Sox,
into a protein-domain sensor for ERK2 kinase activity. The protein domain sensor
demonstrated significantly improved sensitivity for ERK2 phosphorylation over the
corresponding peptide probe.
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Chapter 1. Introduction
NCL: Semisynthesis of post-translationally modified proteins and biological probes
A version of this chapter has been submitted for publication in Protein Engineering.
Copyright © 2006 Springer.
1-1. Introduction to native chemical ligation
Methods for the modification of proteins to introduce novel chemical
functionalities and for the preparation of homogenous samples of post-translationally-
modified proteins are critical for probing protein structure/function relationships and
protein/protein interactions. Native chemical ligation is a chemoselective reaction that
joins synthetic or biologically-expressed protein fragments via a native amide bond,
enabling the construction of modified proteins in multi-milligram quantities sufficient for
biophysical and biochemical studies.' Native chemical ligation can be carried out with
fully deprotected peptide and protein fragments in neutral aqueous media, enabling
modified peptides to be incorporated into target peptides or proteins. Required for the
reaction are an N-terminal fragment containing a C-terminal (c-thioester, and a C-terminal
fragment with an N-terminal cysteine residue. The general reaction is shown in Fig. 1.1 a.
The transformation begins with a reversible transthioesterification to associate the two
fragments via a thioester bond involving the cysteine residue of the C-terminal fragment.
An energetically favorable acyl rearrangement involving a 5-membered ring transition
state then occurs to form a stable amide bond. Since the thioester-linked intermediates
have never been observed, it is presumed that the rate-limiting step of NCL is
transthioesterification. Typically, the reaction is run in the presence of thiol additives,
which both suppress cysteine oxidation and catalyze the reaction by generating more
reactive thioesters.2 Importantly, NCL is compatible with the presence of fully-
deprotected internal cysteine residues in either protein fragment (Fig. 1.1b). Thioester
exchange is fully reversible, and it is only upon reaction with the terminal cysteine that
the S - N acyl rearrangement can occur, resulting in the thermodynamically stable
product and accounting for the chemoselective nature of the reaction.
NCL was first introduced in 1994 with the synthesis of a 72-residue polypeptide
comprising entirely native peptide bonds, thus overcoming the practical limits of SPPS
through the ligation of two fully deprotected peptide fragments.' While NCL was
originally limited to ligations involving a-thioesters generated by chemical synthesis, the
scope of the reaction was advantageously extended to proteins of any size through the
application of 'expressed protein ligation' (EPL), in which a-thioester or N-terminal Cys-
containing fragments that are generated via recombinant methods are used for the
semisynthesis of protein domains and full-length proteins. 3-5 EPL was originally defined
specifically as the extension of NCL that involves recombinant a-thioester peptides, but
the term is now used more generally to designate NCL processes involving any
recombinant fragments, either thioester or N-terminal Cys-containing. 6
0
transthioesterification thiol,
neutral pH
N-terminal (N4
polypeptide
C-terminalH2N polypeptide
S--N acyl
rearrangement
b
0O
N-terminal (4
polypeptide eSR
HS
H2N C-terminal
2N polypeptide
transthioesterification
IN-termmalI
polypeptide
H21
H!
e
0 S
N-terminal N C-terminal
polypeptide H polypeptide
Figure 1.1. a) Native chemical ligation (NCL) of unprotected polypeptide fragments. b)
Reversible transthioesterification with internal cysteine residues.
1.2 Engineering design considerations for NCL
An important consideration in the design of semisynthetic proteins is the
designation of a ligation junction, Xaa-Cys. Since the practical limit of solid phase
peptide synthesis (SPPS) is between 40 and 60 residues, junction sites for ligations
involving a synthetic peptide must fall within those distances from the N- or C-terminus
of the protein target. In some cases naturally-occurring cysteine residues are present in
the protein of interest at a suitable position for the ligation. However, in the absence of a
suitably placed cysteine, one may be introduced in the place of a non-essential residue.
Appropriate residues may be selected based on structural knowledge or previous
experiments that demonstrate that the residues are not involved in protein function. The
ease of site-directed mutagenesis allows for further confirmation that the cysteine
mutation does not significantly alter protein structure or function. In general, ideal
ligation sites are in segments of a protein that lack secondary structure, such as in
terminal regions, loop regions or linker regions between two domains. If the reaction is
carried out under non-denaturing conditions, and if the protein will not be subjected to
refolding, it is particularly important that the folded state of the protein is not disturbed
by the ligation site, regardless of whether a naturally-occurring or an introduced cysteine
residue is used as the Xaa-Cys junction.
While standard NCL dictates that a cysteine residue be present at the N-terminus
of the C-terminal fragment, it is also important to consider the effect of the C-terminal
residue of the a-thioester fragment, -Xaa-SR, on the ligation. It has been reported that a-
thioester peptides containing any of the 20 encoded amino acid residues at the terminal
position are compatible with NCL, but the kinetics of ligation differ dramatically
depending on the properties of that residue.7 In general, the reaction proceeds most
rapidly when the C-terminal position is occupied by the sterically-unhindered glycine
residue, or by histidine or cysteine residues, which are hypothesized to increase the rate
of thioester exchange by catalysis with the imidazole or thiol side-chain functionalities.
Other terminal residues shown to result in rapid product formation are phenylalanine,
methionine, tyrosine, alanine, and tryptophan. Ligation has been found to be
prohibitively slow only with two of the n-branched amino acids (valine and isoleucine)
and proline, although it may be possible to overcome these residue limitations using
highly-activated thioesters.
In another study, ligations involving aspartic or glutamic acid residues in the C-
terminal position of an a-thioester were shown to result in significant side product
formation.8 In this case, the proximity of the carboxyl functionality in the amino acid
side chains to the activated thioester can result in the formation of backbone isomers, in
which a 3- or y- amide bond forms between the Cys-containing peptide and the aspartate
or glutamate residues respectively (Fig. 1.2a). Side product formation can be avoided by
orthogonal protection of the carboxyl side chains. However, when possible, selecting an
Xaa-Cys ligation site that avoids sluggish ligations or side reactions is beneficial to
ensure maximal product formation.
Another factor affecting the efficiency of NCL is the presence of thiol additives, 2
which potentially combat difficult ligation reactions. The alkylthioesters commonly used
in NCL react slowly because of the poor leaving group properties of the corresponding
alkyl thiols, requiring thiol-thioester exchange with the thiol additive to promote ligation
with the Cys-containing fragment. (To minimize confusion, this exogenous thiol
replacement will be referred to throughout the chapter as thiol-thioester exchange to
distinguish it from the attack of a Cys residue in the first step of NCL, which will be
referred to as transthioesterification.) Rapid and complete ligation is best facilitated by
thiols that are both good nucleophiles, to promote the in situ formation of a more reactive
thioester, and good leaving groups, to favor the transthioesterification (Fig. 1.2b). For
NCL involving peptide fragments, a benzylmercaptan/thiophenol mixture is commonly
employed in an aqueous/organic buffer (Fig. 1.2c). Thiophenol promotes rapid thiol-
thioester exchange and serves as a good leaving group, but has poor aqueous solubility
and therefore can only be used at very low concentrations for ligations involving proteins
that cannot tolerate the addition of organic solvent. MESNA (2-mercaptoethanesulfonic
acid) has excellent solubility in water and is a popular choice for ligations using
recombinant protein fragments. However, a recent investigation of a number of thiol
additives revealed that MESNA, an alkanethiol with pKa of 9.2, shows rapid thiol-
thioester exchange, but has poor leaving group properties.9 In the case of MESNA, the
rate limiting step for NCL is transthioesterification, whereas with certain other thiols the
thiol-thioester exchange is rate limiting. In general alkylthioesters, such as those
generated by MESNA or benzyl mercaptan, were found to be less reactive than
phenylthioesters. The investigators found (4-carboxymethyl)thiophenol (MPPA) to be a
superior catalyst with peptide-based test ligations and recommend use of MPPA for
protein ligations as well, predicting that it may be more effective than MESNA for EPL.
Since this report was published within one month of writing this chapter, there have been
no other reports to date that apply MPPA, and it will be interesting to see if MESNA is
eventually replaced as the predominantly used thiol for EPL by MPPA or another aryl
thiol catalyst. Another option for rapid ligation is the use of preformed aryl
thioesters, 1' 1'(", which eliminate the thiol-thioester exchange step that is rate limiting with
certain thiol additives.
o
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Figure 1.2. a) Generation of a 3-amide-linked side product for NCL with an Asp-Cys
ligation junction. b) Mechanism for NCL with thiol catalysis. An ideal thiol additive
results in rapid thiol-thioeser exchange of the thioester fragment and provides a good
leaving group for transthioesterification with the Cys-fragment. c) Thiols used for NCL.
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1.3 Thioester generation
1 Synthetic thioester peptides
The synthesis of a-thioester peptides for NCL can be accomplished using a
variety of SPPS-based methods. The modular nature of SPPS allows facile replacement
of any residue of the target peptide thioester with non-encoded amino acids, as well as the
site-specific incorporation of tags and probes. Initially most investigators employed acid-
labile Boc-protection strategies for SPPS, 1"12 since the thioester linkage is not stable to the
basic deprotection treatment with piperidine used in Fmoc-based SPPS. However, a
number of approaches have been developed to circumvent the sulfur-carbonyl cleavage
associated with Fmoc deprotection, allowing the generation of thioester peptides without
the harsh cleavage conditions employed in Boc-based SPPS. This use of milder
conditions is particularly important for the synthesis of glycopeptide and phosphopeptide
thioesters, since glycoside and phosphoryl linkages are labile to the anhydrous HF
required for peptide cleavage in Boc-based SPPS.
In one Fmoc-based approach, deblocking agents were developed as alternatives to
piperidine to effectively remove the Fmoc protecting group without nucleophilic cleavage
of the thioester linkage. 13,14 In an alternative strategy, a backbone amide linkage (BAL)
is used to anchor the penultimate residue, which contains an orthogonally protected C-
terminus, to the solid support. 15 The peptide can be elaborated using standard Fmoc-
based SPPS protocols, and subsequently deprotected at the C-terminus prior to being
coupled to a thioester amino acid and finally fully deprotected and cleaved from the resin
(Fig. 1.3a). Additional BAL and side-chain linkage-based approaches have been
reported, 16 including an example that masks the terminal glycine thioester as a
trithioortho-ester and releases the deprotected thioester by acid treatment. 17
A more commonly applied strategy utilizes an alkanesulfonamide "safety-catch"
linker, in which a peptide is assembled on solid support linked via the C-terminus by a
sulfonamide bond. This sulfonamide linkage is stable to the repeated piperidine
deprotection treatments in Fmoc-based SPPS. Following peptide synthesis, the
sulfonamide is activated by N-alkylation and subsequently cleaved from solid support by
nucleophilic attack of a thiol additive. The thioester bond is stable in TFA, and peptide
can therefore be deprotected with a standard TFA cleavage cocktail (Fig. 1.3b).'8 19 A
similar method employs an aryl hydrazide linker that can be activated following peptide
synthesis by mild oxidation.2 0
Arguably the most straightforward Fmoc-based SPPS approach for generating
thioesters involves peptide synthesis on highly acid-labile resin, such as commercially
available 2-chlorotrityl or TGT resin, followed by cleavage of the fully-protected peptide
from solid support with mild acid treatment. The acid releases the peptide as a C-
terminal carboxylic acid, but does not affect the Fmoc-compatible side-chain protecting
groups. The protected peptide is then derivatized to a C-terminal thioester in situ by
treatment with the desired thiol and standard peptide-coupling activating agents.
2 1' 22
Side-chain deprotection affords the corresponding free thioester (Fig. 1.3c). An
evaluation of activating agents for this strategy has identified conditions, specifically
phosphonium-salt based activating agents, that result in high yields and low levels of
epimerization (<1.4%).10
While still in a preliminary stage of development, a final method of o-thioester
formation is worth mentioning both for its creative approach and its similarity to the
protein splicing mechanism that is exploited for the generation of recombinant protein a-
thioesters (Sect. 1.3.2). This method involves the generation of a thioester-linked peptide
by utilizing an N-S acyl shift facilitated by a protected thiol-containing auxiliary
attached to the peptide backbone (Fig. 1.3d).23 Following Fmoc-based SPPS of a peptide
linked to resin by an amide bond, deprotection of the peptide side chains with a TFA
cleavage cocktail concurrently deprotects the thiol moiety of the auxiliary, initiating an
acyl shift that results in a thioester bond-linkage of the peptide to solid support.
Subsequent thiolysis releases the corresponding peptide thioester.
A recent review of methods for thioester synthesis can provide more information
on these and other approaches. 24
2. Recombinant thioester fragments
While direct synthesis is suitable for peptide fragments under approximately 60
residues in length, the scope of NCL was initially limited by the lack of recombinant
methods to generate longer peptide or protein fragments containing C-terminal a-
thioesters. This limitation was overcome in 1998 with the introduction of EPL, which
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applies a modified protein splicing mechanism to generate thioesters suitable for
ligation.3'4 To place the technology developed for recombinant protein thioesters in
context, a brief explanation of protein splicing follows.
Protein splicing Protein splicing is a protein processing event that results in the
extrusion of an internal protein segment, termed an intein, and the concomitant joining of
two flanking regions, termed N- and C-exteins, through an amide bond.25 Inteins, which
are functionally analogous to self-splicing RNA introns, are protein segments that
catalyze the intramolecular protein rearrangement that mediates their excision (Fig. 1.4a).
A number of conserved or key residues in inteins contribute to the splicing event through
structural or electronic influences. 26 In general, inteins contain a cysteine or serine
residue at the N-terminal position (termed the 1 position), a conserved asparagine residue
at the C-terminal position, and a cysteine, serine, or threonine residue at the first position
of their flanking C-extein (termed the +1 position). In the initial step of standard protein
splicing, an N-S (or 0) acyl shift occurs, involving the cysteine (or serine) at position 1,
transferring the N-extein from the backbone to the side chain of residue 1 of the intein.
While this step appears thermodynamically unfavorable, it is favored by the conformation
of the intein, which is thought to distort the scissile amide bond into a higher energy
conformation. In the next step, transesterification involving the cysteine (or serine or
threonine) at position +1 joins the two exteins through a thioester bond. In the third step,
the asparagine residue cyclizes, resulting in cleavage at the C-terminal splice junction to
liberate the intein as a C-terminal succinimide. In the final step, which is the sole
reaction that does not require catalysis by the intein, a spontaneous acyl rearrangement
produces the spliced exteins with an amide linkage.6
Mutant (Asn to Ala) inteins to generate recombinant thioesters Protein splicing
has been exploited with great success for the generation of recombinant thioesters.
Inteins have been engineered with an asparagine to alanine mutation, which permits the
initial step of the protein splicing mechanism involving an N - S acyl shift to produce a
thioester linkage, but prevents subsequent succinimide formation. 27 Addition of
exogenous thiols results in release of the N-extein as the corresponding C-terminal
thioester. The isolation of recombinant thioesters from a resin-bound intein system has
been commercialized by New England Biolabs as the IMPACTTM (intein-mediated
purification with an affinity chitin binding tag) -system. In this system, a target gene,
functioning as the N-extein, is cloned immediately N-terminal to a genetically modified
(Asn to Ala) intein gene. A chitin binding domain (CBD) is cloned C-terminal to the
intein, functioning as the C-extein and facilitating immobilization of the resulting protein
construct on chitin beads. Thus, the expressed three-segment (target protein-intein-CBD)
construct can be isolated from all other cellular proteins by immobilization and washing,
and the target protein thioester can be released by subsequent thiolysis (Fig. 1.4b).28
Expressed protein ligation can be performed with the eluted thioester or directly
on the chitin beads.3' 4' 29  For solid phase ligation, the thiol and Cys-containing
peptide/protein fragment can be simultaneously incubated with the resin-bound protein
fusion, enabling concurrent thiolysis and ligation.
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1-4. N-terminal Cys fragments
The synthesis of peptides containing an N-terminal cysteine residue is
straightforward using SPPS and requires no additional manipulations. For longer
fragments, there are several approaches for accessing biochemically-expressed proteins
with an N-terminal cysteine. The most commonly applied methods involve the
generation of a precursor protein designed with a cysteine residue immediately C-
terminal to a protease cleavage site (Fig. 1.5a). The first example of affinity cleavage for
NCL used factor Xa, a protease that cuts C-terminal to its Ile-Glu-Gly-Arg recognition
sequence. 5  Other C-terminal cleaving proteases include enterokinase, ubiquitin C-
terminal hydrolase, and furin. The single disadvantage with employing proteases is the
possibility for undesired cleavage at secondary sites. For instance, factor Xa can cleave
after Gly-Arg pairs or other basic residues in a target protein.
Recently tobacco etch virus (TEV) protease, a highly specific cysteine protease
with a seven-residue recognition sequence, was applied for the generation of N-terminal
Cys fragments. 30 TEV typically recognizes a Ser or Gly residue in the Pl' site, but will
also tolerate a Cys in that position. TEV demonstrates high sequence selectivity and
overexpresses well on a large scale, making it an ideal protease for EPL applications.
Endogenous Met aminopeptidases have also been utilized to access N-terminal
Cys proteins from the corresponding Met-Cys containing precursor proteins (Fig. 1.5b).
The resulting Cys-polypeptides can be isolated from cell lysate using aldehyde-
functionalized resin,3 1 or reacted directly for in vivo NCL.32 For exogenous cleavage of a
Met-Cys junction, cyanogen bromide (CNBr) was successfully applied to access an N-
terminal Cys in a recombinant glycoprotein that was insoluble in buffers compatible with
the commonly employed proteases. 33
An intein-based strategy can also be applied to generate N-terminal Cys proteins
(Fig. 1.5c). Several commercially available expression vectors contain genetically
modified inteins that lack the conserved cysteine (or serine) residue at the N-terminus (1
position) of the intein for this purpose. Cleavage of the intein by succinimide formation,
induced by lowering the pH and increasing temperature, simultaneously releases the N-
terminal Cys protein. 28 The limitation to this method is the possibility for spontaneous
intein cleavage.
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Figure 1.5. Recombinant methods for generating N-terminal Cys-containing protein
fragments using a) exogenous protease, b) endogenous methionine aminopeptidase, and
c) a genetically modified intein system.
1-5. Extensions of NCL
1. Sequential NCL
Although many NCL applications require the ligation of only two fragments, the
technique is not limited to a single ligation step. Multiple modifications throughout a
protein or modification in the middle of a large protein can be accomplished by
sequential ligations (Fig. 1.6a).34 In sequential NCL, an initial ligation is carried out
between an N-terminal Cys-containing fragment and a second fragment containing a
thioester moiety and a protected N-terminal Cys residue, masked to prevent the thioester
fragment from undergoing intra- or intermolecular ligations. Strategies used to mask the
cysteine residue include the incorporation of the factor Xa pro-sequence immediately N-
terminal to the cysteine residue,34 acetamidomethyl (Acm) protection of the side-chain
thiol,3 5 thiazolidine cysteine protection,36 and photolabile protection of the thiol or amino
group. 37 Following the initial ligation, the cysteine is deprotected and a second ligation is
carried out. Theoretically there is no limit to the number of fragments that can be ligated
in this fashion. Segmental ligation has been performed on solid support, in a strategy
analogous to SPPS,38 as well as in situ, either in "one pot" reactions 37,39 or with HPLC or
affinity-tag purification of the ligated intermediates. 39
2. Accessing Xaa-Ala and Xaa-Gly ligation junctions
The only major limitation of NCL is the general requirement for a cysteine residue at
the ligation site. For specific applications, the requisite N-terminal Cys residue can be
replaced by another nucleophilic residue, such as selenocysteine. 40 Alternatively, NCL
can be combined with post-ligation desulfurization with palladium or H2/Raney nickel to
convert the resultant cysteine to an alanine, and thereby access peptides or proteins with
an Xaa-Ala ligation junction.41 This method has been applied to several proteins that
lack cysteine residues,42'43 but cannot be used for proteins that contain a cysteine
anywhere in the protein sequence, since all thiols will be reduced by the desulfurization
step.
In a more generally applicable strategy, NCL can be performed with a removable
Cys-mimic to ultimately produce an Xaa-Gly ligation junction (Fig. 1.6b).44 In this
approach the C-terminal ligation fragment is linked via the N-terminal amine to a thiol-
containing auxiliary that facilitates thioester exchange with the Qo-thioester fragment.
Following transthioesterification, an S - N acyl shift results, and subsequent cleavage of
the N-linked auxiliary yields a native amide bond at the ligation site. Rapid ligation is
best promoted by auxiliaries that proceed through a five-membered ring acyl
rearrangement intermediate, and most of these utilize a 2-aryl mercaptoethyl group as the
Cys-mimic. Depending on the aryl substituents, removal of the auxiliary is accomplished
with strong acid treatment,45 milder TFA treatment,46 or photolysis.47
1.6 Applications
The strongest testament to the utility and generality of NCL is the impressive
number of applications that have been reported for the study of complex biological
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Figure 1.6. a) Sequential NCL. PG = Cys protecting group. b) NCL with a 2-aryl
mercaptoethyl ligation auxiliary to produce an Xaa-Gly ligation junction.
systems using ligation methodology to access homogenous samples of native or modified
proteins or protein analogs. Due to the vast number of applications reported in the twelve
years since NCL was first introduced, only a fraction of these can be covered with
adequate detail in this chapter. Since a number of excellent reviews are available,
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particular focus is on reports from the past three years.
1. Post-translational modifications
Post- (and co-) translational modification of proteins increases the diversity of the
proteome by more than an order of magnitude beyond that programmed by the genetic
code.4 9 Direct characterization of the impact of post-translational modifications,
including phosphorylation, glycosylation, lipidation, and acetylation, on the structure and
function of proteins can be prohibitively complex due to the difficulty of obtaining
homogenously modified protein in high yields. The nature of this difficulty stems from
the lack of genetic encoding for these modifications, the heterogeneity of biological
samples, and the inherent non-specificity in the enzymes that catalyze post-translational
modifications. NCL and EPL allow the generation of modified proteins in milligram
quantities by the reaction of a biologically-expressed non-modified fragment with a
synthetic fragment containing the desired modification. Many post-translational
modifications occur within the N- or C-terminus of proteins, making the corresponding
modified proteins ideal targets for NCL. However, segmental ligation can be used to
incorporate modifications within the central regions of a protein as well.
Phosphorylation Phosphorylation is the most prevalent post-translational
modification, affecting an estimated one third of human proteins.49 Protein kinases,
enzymes which catalyze transfer of the y-phosphoryl from ATP to a serine, threonine, or
tyrosine side chain within a peptide or protein, can have tens or hundreds or substrates,
and may modify multiple sites in a single protein, making the production of discretely
phosphorylated proteins challenging. NCL has facilitated the preparation of
homogeneous samples of phosphoproteins, enabling investigators to isolate the specific
roles of phosphorylation on protein function in vitro.
In one example, synthetic variants of a Cys 2His2 zinc finger protein were prepared
by NCL in various phosphorylated forms and used to study the effects of linker
phosphorylation on DNA binding. 50  Cys2His2 zinc finger proteins are a class of
transcription factors comprising zinc-binding domains joined by highly conserved linker
regions, which each include a single threonine or serine residue. These linker regions are
known to be phosphorylated, but previous studies on the effects of phosphorylation were
limited to using partially-purified protein isolated from cell lysates, prohibiting detailed
quantitative evaluation. NCL enabled the preparation of pure phosphorylated variants of
a representative 86-residue protein containing three zinc finger domains joined by two
linker regions. The proteins were synthesized by sequential ligation of peptide fragments
to access variants with either a single phosphothreonine residue in the N-terminal or C-
terminal linker, phosphothreonine residues in both linkers, or no linker phosphorylation
(Fig. 1.7a). Direct comparison of the DNA-binding affinity of the three phosphorylated
variants and the non-phosphorylated protein using a fluorescence anisotropy-based assay
indicated that phosphorylation of either linker resulted in a - 40-fold decrease in DNA
binding affinity, and that phosphorylation of both linkers resulted in a 130-fold loss.
These quantitative measurements, made possible by pure preparations of phosphorylated
variants, provide strong support for a model the authors set out to evaluate, in which
coordinated regulation of zinc finger transcription factors is achieved by cellular
phosphorylation of the linker regions.
In another study, singly- and dually-phosphorylated variants of a signaling
protein, Smad2, were prepared using EPL, allowing investigators to deconvolute the
impact of each phosphoryl group on protein oligomerization and on further Smad2
phosphorylation by an upstream kinase. 51 Phosphorylation of receptor-activated Smad
(R-Smad) proteins, such as Smad2, occurs on the final two serine residues of a C-
terminal phosphorylation sequence. Phosphorylation of this C-terminus results in the
dissociation of the R-Smad from the membrane-bound receptor complex, and the
formation of a new heteromeric complex between the R-Smad and a related co-Smad
protein, which subsequently translocates to the nucleus and regulates gene expression.
Phosphorylated R-Smads can also form homotrimers in vitro. With the serine residues
under investigation located at the extreme C-terminus, Smad2 and the three possible
phosphorylated variants were ideal candidates for EPL and were prepared by ligation of
an expressed ox-thioester corresponding to Smad2 (residues 241-462) with one of four
synthetic pentapeptides containing a phosphoserine residue at either position 465 or 467,
both 465 and 467, or at neither position (Fig. 1.7b). Biophysical studies on the
oligomerization state of the variants, including analytical ultracentrifugation, revealed
that stable Smad2 oligomer formation requires phosphorylation at both serine residues
but that phosphorylation of Ser465 provides the driving force for oligomerization. In
addition, phosphorylation of Smad2 at Ser467 proceeds more rapidly when the protein is
already phosphorylated at Ser465, while the rate of phosphorylation of Smad2 at Ser465
does not significantly increase by prephosphorylation at Ser467. Since Smad2 is
enzymatically phosphorylated on both sites by the same kinase, a semisynthetic strategy
was critical to enable access to pure samples of singly phosphorylated Smad2 for these
studies. Interestingly, the receptor kinase that phosphorylates Smad2, TPfRI, is itself
activated by phosphorylation and a tetraphosphorylated variant of this kinase was among
the first applications of NCL to produce phosphoproteins 52,53 and was utilized in the
Smad2 phosphorylation assay.
Glycosylation Homogenous samples of glycosylated proteins are particularly
challenging to access because cellular glycoproteins exist as complex mixtures of
glycoforms, which are difficult to purify or even characterize. 54  Similar to
phosphorylation, enzymatic glycosylation results in heterogeneous samples due to
modification of multiple residues, and glycoprotein mixtures may be further complicated
by the diversity of oligosaccharides and possible sugar linkages. Tremendous effort has
been devoted to the chemical and chemoenzymatic synthesis of glycopeptides,5 5 and
these advances have been applied to the synthesis and semisynthesis of homogenous
glycoproteins by NCL. 19,56-59 For the preparation of glycopeptide a-thioesters, Fmoc-
based SPPS strategies are exclusively applied, since glycosidic linkages are not stable to
the repetitive acid treatments required in Boc-based SPPS.
In an impressive synthetic undertaking, a 132-residue mucin-like glycoprotein,
GlyCAM-1, was semisynthesized in three distinct glycoforms containing up to 13
glycans for future investigations on the effect of glycosylation on GlyCAM-1 structure
and function.35 GlyCAM1 consists of a central unglycosylated domain flanked by two
mucin domains, characterized by dense groups of a-O-linked N-acetylgalactosamine
(GalNAc) on serine and threonine residues. All glycans were introduced as the mono-
saccharide GalNAc derivative, which, in principle, can be elaborated enzymatically to
produce fully active glycoprotein. The semisynthetic glycoforms generated in this study
include GlyCAM-1 variants glycosylated exclusively in either the N-terminal or C-
terminal mucin domain and a variant glycosylated in both mucin domains. The authors
applied three different NCL approaches to achieve all the glycoforms, including a
sequential strategy using two ligations and involving a recombinant a-thioester with a
masked N-terminal cysteine to generate the GlyCAM-1 variant glycosylated on both
mucin domains (Fig. 1.7c).
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Figure 1.7. Semisynthesis of a) a dually-phosphorylated zinc finger protein, b) Smad2
phosphorylated on residues 465 and 467 of the C-terminal tail, c) GlyCAM- 1 with 13
GalNAc modifications on two mucin-like domains, and d) an N-linked glycoprotein
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NCL has also been applied to the semisynthesis of an N-linked glycoprotein
variant of a well-studied bacterial protein, Im7, to investigate the influence of
glycosylation on protein folding.60 N-linked glycosylation is a co-translational event that
is thought to assist in the correct folding of expressed proteins. The four-helix Im7
protein, which is not naturally glycosylated, served as a tractable model for folding
studies due to the significant quantity of data available on the kinetics and
thermodynamics of its three-state folding mechanism. The glycoprotein analogue was
prepared with an Asn-linked chitobiose building block at residue 13 on helix I by the
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ligation of a glycosylated a-thioester to an expressed C-terminal fragment comprising
Im7 residues 29-87 (Fig. 1.7d). Biophysical analysis of the glycosylated and non-
glycosylated semisynthetic Im7 variants revealed that glycosylation at position 13 had
minimal effect on protein folding. Investigations of other Im7 glycovariants are currently
underway to probe the effect of glycosylation at other sites.
Lipidation The post-translational lipidation of proteins is involved in regulating
function by targeting modified proteins to specific membranes. The covalent addition of
lipid anchors can be divided into four main classes: N-terminal myristoylation, C-
terminal addition of a glycosyl phosphatidylinositol (GPI), acetylation, and prenylation.4 9
As with other post-translationally modified proteins, lipoproteins are challenging to
access by genetic or enzymatic methods and have become exciting targets for NCL.
Prenylation involves the addition of a farnesyl or geranylgeranyl group to one or
two cysteines at the C-terminus of a protein. The C-terminal location of the modified
cysteine residues renders prenylated proteins well suited for semisynthesis by EPL. A
successful application has been the semisynthesis of fluorescently-labeled mono- and
diprenylated variants of Rab7, a Rab guanosine triphosphatase (GTPase) of the Ras-
GTPase superfamily.61 An expressed a-thioester corresponding to Rab7 (residues 1-201)
was reacted with fluorescently-labeled and prenylated hexapeptides to generate Rab7
variants with geranylgeranyl modifications on either Cys205 or Cys 207, or on both
Cys205 and Cys207 of the C-terminus (Fig. 1.8a). Semisynthesis involving the
hydrophobic lipopeptides required several modifications to standard EPL protocol,
including the addition of specific detergents and an organic extraction of unreacted
peptide, which binds to the protein non-covalently, from precipitated protein. In addition,
a Rab chaperone protein was necessary to stabilize the denatured Rab7 variants during
refolding. A novel fluorescence-based prenylation assay, utilizing the environment-
sensitive properties of the dansyl fluorophore, was developed to probe the mechanism of
diprenylation. The results of the prenylation assay support a proposed random sequential
mechanism of prenylation. The straightforward assay, facilitated by the creative
application of a fluorescent tag, was possible because the researchers were able to
generate homogenous monoprenylated protein.
As with glycosylation, a primary challenge in the EPL of prenylated proteins is
the synthesis of modified peptides. Comparison of a number of solution-phase and solid-
phase methods for synthesizing prenylated peptides revealed the strength of a hydrazide
linker-based solid-phase approach that was used to incorporate several prenylated and
fluorescently labeled peptides onto the oz-thioester fragment of Rab7.62 The extensive
semisynthetic work with Rab7 was recently extended to other Ras-type GTPases: those in
the Ras subfamily. 63 Prenylated Ras proteins pose additional semisynthetic challenges
because they are not known to interact with a chaperone, the use of which was essential
for the stabilization and purification of Rab7. This challenge was successfully addressed
by the use of polybasic prenylated peptides, which eliminated non-specific
peptide/protein aggregation and enabled ligation and purification in non-denaturing
conditions.
Progress has also been made in the preparation of proteins with GPI anchors. GPI
proteins are modified via a C-terminal amide linkage with a lipo-pentasaccharide anchor.
Using EPL, lipidated analogs of green fluorescent protein (GFP) were created with a
simplified GPI anchor, a phospholipid without glycans, to demonstrate a flexible strategy
for generating proteins lipidated at the C-terminus. 64 The lipidated GFP variants were
shown to incorporate stably into supported membranes, and quantification of their lateral
fluidity was achieved by fluorescence imaging. This strategy can therefore be applied to
the semisynthesis of naturally lipidated proteins and their study in lipid bilayers.
Acetylation Reversible acetylation involves modification of proteins, notably
histones and transcription factors, on the E-amino group of lysine residues. In core
histones, which comprise the octomeric protein core of nucleosomes, post-translational
modification of the N-terminus alters histone-DNA interactions and is implicated in
regulating gene transcription.49 NCL has been employed to generate pure samples of
modified histones, acetylated or methylated on the N-terminal tail.42,65 In a recent
example, a homogenous monoacetylated variant of histone H4 was prepared by NCL to
characterize the structural and functional effects of acetylation of Lysl6.66 Toward this
end, a synthesized peptide thioester acetylated at Lysl6 and corresponding to residues 1-
22 of histone H4 was ligated to a recombinant C-terminal fragment (residues 23 to 102)
(Fig. 1.8b). The H4 variant was incorporated into nucleosomal arrays and found to
inhibit the formation of higher order chromatin structures and prevent the functional
interaction of histones with a specific chromatin-associated protein. This characterization
of a selectively acetylated variant complements previous peptide competition studies and
provides direct evidence not accessible with truncated or randomly hyperacetylated
histone derivatives.
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2. Fluorescent probes
Genetically-encoded fluorophores are widely used for imaging proteins in live
cells. Green fluorescent protein (GFP) and the ever increasing number of GFP variants
with improved properties and a spectrum of excitation and emission wavelengths are
invaluable probes for imaging protein localization and examining intramolecular and
intermolecular protein interactions. One powerful application of fluorophore-labeled
proteins is fluorescence resonance energy transfer (FRET). FRET results when two
fluorophores are within close proximity and the emission spectrum of the "donor
fluorophore" overlaps with the excitation spectrum of the "acceptor fluorophore." The
proximity and spectral overlap enable a transfer of energy and a corresponding increase
in the intensity of the acceptor fluorophore emission, allowing for quantification of the
distance between the two fluorophores. The major drawback of using genetically-
encoded fluorophores for FRET and other fluorescence-based imaging is the significant
size of the fluorophores (27 kDa for GFP) appended onto the protein of interest,
potentially altering native interactions and localization. Organic fluorophores are
significantly smaller (< 1 kDa) and often possess superior photophysical properties, such
as higher extinction coefficients and greater resistance to photobleaching, but can be
challenging to incorporate into proteins in a chemoselective manner.
NCL has been used to chemoselectively install a donor-accepter pair of organic
fluorophores into proteins to study both intramolecular conformational changes38 and
intermolecular interactions 67 using FRET. In an example of the latter, variants of
serotonin N-acetyltransferase (AANAT), a circadian rhythm enzyme, were constructed
via EPL with a fluorescein or rhodamine-containing peptide at the C-terminus.67 Since
standard methods for determining oligomerization state, such as size-exclusion
chromatography and dynamic light scattering, proved inconclusive with AANAT, FRET
was employed to probe for homo-oligomerization (Fig. 1.9a). Fluorescence studies
showed a significant increase in FRET upon incubation of the donor (fluorescein) and
acceptor (rhodamine)-containing AANAT variants, indicating a preference for AANAT
to oligomerize.
Along with FRET, there have been numerous applications reported for fluorescent
probes incorporated into proteins by NCL, some of which are discussed in the context of
other sections in this chapter. Examples include the C-terminal labeling of proteins for
anisotropy-based binding studies,68 the domain-specific replacement of tryptophan
residues with a red-shifted and environment-sensitive tryptophan analog to probe domain
function in the context of a full-length protein, 69 and the site-specific incorporation of an
environment-sensitive fluorophore into an effecter domain to monitor protein-domain
interactions."M Fluorescent labeling of proteins has also been accomplished in vivo. 7 1 A
cell permeable fluorescent thioester was introduced into cells expressing a target protein
with an N-terminal cysteine, generated by intein-mediated splicing, resulting in NCL to
generate a protein variant labeled at the C-terminus (Fig. 1.9b).
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3. Unnatural amino acids
The power of NCL is even more pronounced in its application to the
semisynthesis of protein domains or full-length proteins containing unnatural amino
acids. Amino acid analogs chemoselectively introduced by NCL can be used to probe
specific aspects of amino acid or protein function. This approach can involve introducing
residues that differ from the natural amino acid at a position of interest in a single aspect,
such as side-chain geometry, steric effects, or electronic effects. In one example, variants
.N.
of Src, a substrate of the kinase Crk, were prepared, in which a tyrosine residue known to
be phosphorylated was replaced with one of five tyrosine analogs in order to dissect the
contribution of individual factors affecting tyrosine phosphorylation (Fig. 1.10a).72
Evaluation of the semisynthetic substrates in a radioactivity-based kinase assay led the
authors to conclude that the phenolic hydroxyl of tyrosine is not involved in ground-state
Src/Crk interactions and that stabilization of tyrosine conformers increases the efficiency
of phosphorylation. In another study, EPL was used to generate analogs of the blue
copper protein azurin, an electron transfer protein, to study the role of the copper-
coordinating methionine residue on reduction potential (Fig. 1.10b). 73 The methionine
residue was replaced with either a norleucine (Nle) or a selenomethionine (SeM) using
NCL; subsequent spectroscopic and biochemical studies of the semisynthetic variants
revealed hydrophobicity to be the most significant factor affecting reduction potential.
Introduction of unnatural amino acids has also been used to confer proteins with new
properties or functions. For example, a variant of the enzyme ribonucease A (RNase A)
was engineered with a fP-peptide module in place of two natural amino acids, generating
an enzyme with increased conformational stability without compromising catalytic
activity (Fig. 1.10 ).74 NCL has similarly been used to create proteins with more potent
binding properties. Src, a protein substrate of Csk, was prepared by EPL with an ATPyS
conjugate in place of the tyrosine at the site of phosphorylation, creating a Csk kinase
inhibitor (Fig. 1.10d). 75 That report demonstrates a strategy that could potentially be used
to identify unknown kinases through pull-down assays, or to generate tightly bound
kinase/substrate pairs for X-ray crystallography. In another example in which unnatural
amino acid introduction leads to modulation of protein binding, a DNA-binding zinc
finger protein was tuned to recognize a specific DNA sequence by incorporating
citrulline (Cit), an amino acid which combines the side-chain length of arginine with an
alternative functional group (Fig. 1.10e).76 While tandem zinc finger domains provide a
flexible framework for creating discriminating DNA-binding proteins, the domains
almost exclusively require a guanosine at the 5'-end of the DNA for specific binding.
Replacement of the DNA-interacting arginine residue with citrulline, which provides
both a hydrogen-bond donor and acceptor, created a variant that binds preferentially to
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adenosine at the 5'-end of the DNA, a function not possible with zinc finger domain
variants restricted to the 20 encoded amino acids.
The reports described above represent the use of unnatural amino acids to
modulate or probe protein function but are by no means comprehensive. Several
particularly creative applications that utilize NCL for the incorporation of unnatural
amino acids are covered in detail below.
Phosphatase-resistant phosphoamino acid analogs Characterizing the role of
protein phosphorylation in vivo is complicated by the presence of protein phosphatases,
which are promiscuous enzymes that catalyze the removal of phosphoryl groups from
phosphoproteins. Phosphatases can cause unanticipated and undetected hydrolysis of the
phosphoprotein being studied. The phosphatases themselves can be modulated by
phosphorylation, creating phosphoproteins challenging to study both in vivo and in vitro,
since phosphatases have the propensity to autodephosphorylate. The introduction by EPL
of nonhydrolyzable phosphotyrosine analogs into full-length protein has been used to
great effect in the study of protein tyrosine phosphatase SHP-2 (Fig. 1.11a).77,78 Two
phosphatase-resistant phosphoTyr analogs were incorporated into the C-terminal tail (at
either residue 542 or 580, or both 542 and 580) of SHP-2: phosphonomethylene
phenylalanine (Pmp), which is commercially available as the N-Boc derivative, and
difluoromethylene phosphonate (F2Pmp), which is a superior mimic of phosphotyrosine
but requires synthesis of the amino acid for introduction into peptides. Biochemical
investigations of the SHP-2 variants revealed that phosphonates at Tyr542 and Tyr580
bind to N-terminal and C-terminal SH-2 domains respectively within SHP-2, disrupting
basal inhibition and thereby increasing phosphatase activity. Near additive effects were
observed for the doubly-phosphonylated mutant. Similar incorporation of Pmp into a
related phosphatase, SHP-1, provided equally illuminating mechanistic insight into the
role of tyrosine phosphorylation on phosphatase regulation.79 More recently, single and
double phosphonate substitutions were incorporated by EPL into the low molecular
weight protein tyrosine phosphatase (LMW-PTP) and shown to inhibit dephosphorylation
of phosphopeptide substrates, representing the first example of negative regulation of a
tyrosine phosphatase by phosphorylation.8 0 Also noteworthy, the effect of
phosphorylation on cellular stability and localization was investigated following the
microinjection of the phosphonate variants into cells, an experiment that would not be
possible with native phosphoproteins, which are susceptible to cellular phosphatases.
Phosphonate isosteres of phosphothreonine and phosphoserine,
phosphonomethylenealanine (Pma) and phosphono-difluoro-methylenealanine (Pfa),
have also been introduced into a full-length protein by NCL (Fig. 1.11b).8 1'82 Unlike
phosphotyrosine, which has no suitable surrogate within the encodable amino acids,
glutamic and aspartic acid are commonly used as stable phosphoThr or phosphoSer
mimics. However, these residues are not always successful mimics, as was reported with
replacement of phosphoThr and phosphoSer residues in the protein AANAT, a regulatory
enzyme involved in the production and secretion of melatonin. In contrast, the
replacement of an N-terminal Thr31 or a C-terminal Ser205 with Pma by NCL enabled
direct analysis of the role of phosphorylation on AANAT stability. Microinjection of the
phosphonate mutants into cells provided direct support of increased AANAT stability by
intermolecular binding facilitated by phosphorylation of Thr31 and Ser205.
Caged phosphorylated amino acids The caging, or photolabile protection, of
biomolecules enables spatial and temporal control over the release of an activated
species. The application of caged proteins holds great potential for elucidating protein
function and signaling pathways but traditionally has been limited by the difficulty of
preparing proteins containing masked functionalities. EPL was successfully applied to
the semisynthesis of a caged variant of the signaling protein Smad2, which included two
phosphoserine residues protected by the 2-nitrophenylethyl (NPE) photolabile protecting
group (Fig. 1.1 ic). 83 Previous investigations by the same laboratory used homogenous
phosphoSmad2 variants to explore the effect of phosphorylation on Smad2
oligomerization (Sect. 1.6.1). 51 The authors wished to expand on that work by using a
dually-caged phosphoserine variant as a probe to study Smad2 pathway dynamics with
spatial and temporal resolution in cellular experiments. To generate the probe, a peptide
corresponding to the final five residues (463-467) of Smad2 and containing two caged
phosphoserine residues was synthesized on the solid phase and ligated to a biologically-
expressed ox-thioester of the Smad2-MH2 domain (residues 241-462). Prior to
phosphorylation, Smad2 interacts with a membrane-bound complex, which includes 1:1
binding with a protein called SARA (Smad anchor for receptor activation). Upon
phosphorylation, Smad2 releases from the SARA complex and can form homotrimers or
heterocomplexes with a co-Smad, resulting in an active complex that localizes to the
nucleus for gene expression regulation. The caged phosphoSmad2 variant was shown to
mimic a nonphosphorylated Smad MH2 domain, forming a 1:1 complex with SARA.
Upon irradiation, the release of the corresponding phosphodomain was detected, resulting
in protein homotrimerization. In addition, a nuclear import assay was used to
characterize the localization of the caged Smad2 variant before and after irradiation. As
expected, prior to irradiation, caged Smad2-MH2 was excluded from the nucleus, similar
to nonphosphorylated Smad2, while irradiation led to nuclear accumulation consistent
with the release of phosphoSmad2. The caged phosphoSmad variant will be used in
future experiments to provide quantitative information on Smad2 nuclear import and
export in live cells.
Photocross-linkers Another recent application of EPL has been the semisynthesis
of protein variants incorporating a photoactivatable crosslinker, introduced as benzoyl
phenylalanine, to study a central binding interaction in the phototransduction cascade
involved in vision.84 The inactive form of cGMP phosphodiesterase (PDE) is known to
be activated by nanomolar binding of the GTP-bound form of the a-subunit of transducin
(Gca-GTP) with the PDE inhibitory y-subunit (PDEy). To further characterize this
interaction, a series of seven full-length PDEy photoprobes were constructed using EPL
to install the benzophenone amino acid in place of selected C-terminal hydrophobic
residues (Fig. 1.11 d). The semisynthetic domains also included a biotin affinity tag at the
C-terminus for analysis. Photocrosslinking experiments were performed between each of
the PDEy photoprobes and an activated form of Gat (Gat-GTPyS). The investigators
observed crosslinking with several of the photoprobes and were able to narrow down the
region of photoinsertion into Gal, thereby revealing several previously unknown binding
interactions.
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4. Probes for magnetic resonance: isotopic labeling and spin labeles
Structural analysis of proteins by nuclear magnetic resonance spectroscopy
(NMR) is facilitated by the incorporation of carbon, nitrogen, and hydrogen isotopes,
which may be uniformly introduced into biologically expressed proteins. At high
molecular weights, despite isotopic labeling, NMR analysis becomes complicated due to
decreased resolution, caused by longer correlation times, and highly complex spectra.
EPL has been used to selectively introduce isotopic labels into protein domains within a
full-length protein. This strategy has enabled NMR analysis of discrete protein domains
or fragments within the context of large proteins, rendering a single section of the protein
spectroscopically visible without disrupting domain-domain interactions. Specifically,
EPL has been used to introduce a labeled domain at the terminus of a protein85 and, using
two sequential ligation reactions, to demonstrate the possibility of introducing an internal
isotopically-labeled domain flanked by two non-labeled domains. 86
In a recent example, the a subunit of a G protein (Ga) was semisynthesized with
13C-labeled residues within the C-terminal tail to enable NMR characterization of
conformational changes upon Gc subunit activation. 87 To construct the labeled full-
length subunit, a synthetic nonapeptide (Go residues 346-354) containing three 13C-
labeled amino acids was ligated to a recombinant thioester fragment corresponding to Gx
residues 1-345. NMR characterization of the Gx subunit in its inactive (GDP-bound)
form and in an active form (mimicked by the addition of A1F4-, a GTP y-phosphate
analog) provided evidence for an increase in the conformational order of the C-terminal
tail upon Gac subunit activation.
EPL has also been employed for the incorporation of a paramagnetic amino acid
into a full-length protein for electron paramagnetic resonance (EPR) spectroscopy.88 A
spin-labeled peptide containing a nitroxide-labeled lysine was ligated to a recombinant
thioester of the Ras-binding domain (RBD) of c-Rafl. The ligation reaction, carried out
in the presence of a thiol catalyst, resulted in reduction of the spin label, which was
reoxidized prior to EPR analysis of the labeled RBD and a labeled RBD/Ras complex.
5. Immobilization by NCL and use in microarrays
The chemoselective nature of the NCL reaction has been exploited for
immobilizing proteins on solid support in strategies aimed at the development of protein
microarrays. Protein microarrays have the potential to facilitate high-throughput analysis
of protein interactions, including protein/protein, protein/small molecule, and
protein/antibody binding. A major challenge in the construction of protein microarrays is
the uniform orientation of proteins on the glass support. In several examples, NCL has
been used to install a reactive group at the terminus of proteins for subsequent
immobilization. For example, researchers have used EPL to C-terminally label proteins
with a biotin moiety by the ligation of the expressed protein thioesters with a biotin-
labeled Cys residue.89 The biotinylated proteins were subsequently immobilized on
avidin-labeled glass slides, taking advantage of the stable biotin-avidin interaction. The
immobilization of an oxidoreductase enzyme, AKRIA1, for future microarray
applications was also accomplished using a similar biotin-labeling strategy.90 In another
immobilization strategy, researchers used EPL in the semisynthesis of protein-nucleic
acid conjugates, in which recombinant thioester-containing proteins were ligated to
peptides containing a C-terminal polyamide nucleic acid (PNA).91 The proteins were
then incorporated into small microarrays by DNA-directed immobilization (DDI) based
on interaction of DNA on a glass slide to the complementary protein-conjugated PNA.
Proteins have also been attached to a solid surface through the stable amide bond
formed directly by NCL (Fig. 1.12). Expressed protein ac-thioesters have been shown to
selectively immobilize onto a Cys-functionalized glass slide.92 The reverse approach has
also been accomplished, in which proteins containing N-terminal cysteines were
immobilized onto thioester-containing slides.93 In that case, the Cys-containing proteins
were expressed using an intein-mediated strategy, and both the subsequently purified
proteins and the crude cell lysates were used effectively to immobilize the N-terminal
Cys-containing proteins onto the thioester-functionalized plates.
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Figure 1.12. Immobilization of proteins onto microarrays by a) reaction of a thioester-
containing protein with a Cys-functionalized slide and b) reaction of an N-terminal Cys-
containing protein with a thioester-functionalized slide.
Conclusion
Advances in recombinant methods for the generation of a-thioester and N-Cys-
containing proteins, and in synthetic approaches for peptide a-thioester synthesis,
particularly methods compatible with peptides including posttranslational modifications
and non-canonical amino acids, have facilitated the semisynthesis of proteins and protein
domains containing unnatural amino acids and biological probes and tags in NCL
applications. These advances have enabled investigators to design and construct elaborate
protein biomolecules that can be used to address challenging problems not routinely
accessible by traditional methods.
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Chapter 2
Synthesis and characterization of caged phosphopeptides
A significant portion of the work described in this chapter was published in Organic
Letters' and Journal of Organic Chemistry.2 Copyright © 2002 and 2003 American
Chemical Society.
Introduction
Protein phosphorylation is a central regulatory mechanism in signal transduction
pathways and cell cycle regulation. An estimated one third of mammalian proteins
undergo phosphorylation, and this post-translational modification can modulate
enzymatic activity and protein-protein binding interactions.3 Tools for the study of
phosphorylation events in "real time" are essential for dissecting the dynamic role of
phosphorylated residues in complex signaling networks. Increased understanding of
signaling networks is of particular interest in cellular migration and related biological and
medicinal studies.4 Current methods for investigating phosphorylation, including gene
knockout, RNA interference, and point mutation strategies, can be used to verify the
essentiality of a given phosphorylation site, but are limited when probing the temporal
role of phosphorylation in signaling pathways. As a complement to existing genetic
techniques, we have developed caged phosphopeptides, which release a concentration
burst of the corresponding phosphorylated peptides with temporal and spatial control
following irradiation with long wavelength UV light (Fig. 2.1). These photolabile
precursors allow investigators to probe the downstream effects of kinase-mediated
phosphorylation in real time without altering upstream genetics.
The caging, or photolabile protection, of biomolecules enables the controlled
release of an activated species. A caged substrate contains a protecting group that masks
an essential functionality and that can be removed by photolysis to reveal a biologically
active molecule.5 For use in living systems, it is essential that both the caged compound
and photolysis by-product be inert in the cell system. In addition, a useful caging group
should be stable to hydrolysis and enzymatic cleavage under working conditions and
have a fast rate of uncaging compared to the biological event under investigation.6 The
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Figure 2.1. A 2-nitrophenylethyl-caged phosphopeptide. Irradiation with long
wavelength UV light releases the corresponding phosphorylated peptide.
caging group must also release the effector molecule with reasonable quantum efficiency
at a wavelength that does not cause radiative cellular damage. Derivatives of the o-
nitrobenzyl group have been commonly employed to cage biologically active molecules,
including calcium, 7 ATP, and peptides. 8' 9 The o-nitrobenzyl group can be uncaged on a
microsecond to millisecond timescale with long-wavelength UV light (k > 350 nm) that
is non-damaging to cells. A proposed mechanism for the photolysis of o-nitrobenzyl
caged molecules is shown in Scheme 2.1.10 For our syntheses of caged phosphopeptides
for the study of signal transduction, the o-nitrobenzyl derivative 2-nitrophenylethyl was
selected because it retains the desirable qualities of the o-nitrobenzyl moiety and releases
a cellularly inert photo-byproduct. Irradiation of 2-nitropheylethyl-protected molecules
releases 2-nitrosoacetophenone, which is significantly less reactive in the cellular
environment than the corresponding aldehyde produced by the o-nitrobenzyl group or
other derivatives lacking substitution at the benzylic position." In addition, glutathione,
which is naturally present in cells, reacts rapidly with nitroso ketones, preventing
unwanted side reactions with the 2-nitrosoacetophenone.'0,11 The 2-nitrophenylethyl
group has a moderately high extinction coefficient (Emax = 5,700 M-'cm -1 ) with a
maximum absorption at 259 nm. 12 The group has a broad absorption spectrum that
enables high absorption even of long wavelength UV light. Therefore, all uncaging
described in this thesis was carried out on a DNA transilluminator with emission centered
at 365 nm.
Herein are described two synthetic methods for assembling 2-nitrophenylethyl
caged phosphopeptides: 1) an interassembly approach incorporated into Fmoc-based
solid phase peptide synthesis (SPPS), and 2) a building block approach. Each method
relies on a novel phosphitylating reagent to install the caging moiety. The interassembly
approach enables access to caged phosphopeptides in laboratories set up for performing
organic chemistry on solid support and works best for peptides without oxidation-
sensitive residues C-terminal to the phosphitylated amino acid. The building block
approach is accessible to any laboratory equipped for peptide synthesis and can be used
to generate any caged phosphopeptide within the limits of SPPS. A biologically relevant
caged phosphothreonine peptide, Ac-MARHFD(cpT)YLIRR-NH 2 (cpChk2) ('cp' =
caged phospho-) was synthesized via these methods as a potential target for biological
studies. The peptide was characterized by analytical high performance liquid
chromatography (HPLC) and electrospray ionization mass spectrometry (ES-MS), and
the quantum yield of uncaging was measured and found to be comparable to literature
precedent for o-nitrobenzyl-caged molecules.
Scheme 2.1. Photolysis of molecules masked by o-nitrobenzyl-derived caging groups. 10
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Results and Discussion
Both the interassembly and building block strategies utilize a phophitylating agent
for the introduction of a 2-nitrophenylethyl caged phosphite, which is subsequently
oxidized to the corresponding phosphate. The phosphitylating reagent, 0-1-(2-
nitrophenyl)ethyl-O'-f-cyanoethyl-N,N-diisopropylphosphoramidite (1) was synthesized
as shown in Scheme 2.2. First 2-nitroacetophenone (2) was reduced with sodium
borohydride to a racemic mixture of 1(2-nitrophenyl)-ethanol (3). Displacement of the
chloride by the alcohol (3) in the DNA synthesis reagent 2-cyanoethyl
diisopropylchlorophosphoramidite (4) 13 afforded phosphoramidite 1. Importantly the 2-
nitrophenylethyl caging group is stable to the acidic and basic conditions required for
incorporation into peptides in the Fmoc-based SPPS approaches described below.
Scheme 2.2. Synthesis of phosphitylating agent 1.
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2-1. Interassembly approach
The construction of caged phosphopeptides via the interassembly approach is
illustrated with a threonine-containing peptide in Scheme 2.3. The "interassembly"
designation refers to the introduction of a modification onto a growing peptide chain.
Accordingly, peptide 5 was synthesized on a PAL-PEG-PS solid support by standard
Fmoc-based SPPS up to the threonine residue to be modified, which was introduced
without side chain protection. The free threonine residue was phosphitylated with 1
activated by 1H-tetrazole in 1:1 dichloromethane (DCM): tetrahydrofuran (THF),
yielding the phosphite peptide 6 on resin. The trivalent phosphorus species was then
oxidized to the bisprotected phosphate 7 with m-chloroperoxybenzoic acid (mCPBA).
Subsequent treatment with 20% piperidine in N,N-dimethylformamide (DMF) for Fmoc
removal in chain elongation simultaneously removed the cyanoethyl group to afford the
monoprotected caged phosphate 8. While phosphotriesters are highly susceptible to f8-
elimination in the basic Fmoc-removal conditions, phosphodiesters are stable to
deprotection conditions and adequately protect the phosphate moiety from side reactions
during SPPS. 14  Following peptide completion, the peptide was cleaved with
trifluoroacetic acid (TFA) in the presence of scavengers to yield tetrapeptide 9. Caged
phosphoserine and caged phosphotyrosine-containing peptides were accessed using
similar methods.l
As a representative caged phosphothreonine peptide, Ac-MARHFD(cpT)YLIRR-
NH2 (cpChk2) was synthesized via the interassembly approach (Fig. 2.2) and analyzed at
Scheme 2.3. Synthesis of a caged phosphothreonine peptide (9) via the interassembly
approach.
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key intermediates by analytical HPLC and ES-MS. The corresponding uncaged peptide
would be an antagonist of Chk2, a homologue of the human Rad53p checkpoint kinase,
which contains a single forkhead associated (FHA) domain.15 FHA domains are
phosphothreonine-binding modules that can be found in various transcriptional control
proteins, kinases activated by DNA damage, phosphatases, and cell cycle checkpoint
proteins. Chk2 is known to cause cell cycle arrest and is one of several FHA domain-
containing proteins that may play a role in protecting against cancer. It has been
suggested that mutations in Chk2 are involved in the formation of tumors.
15'
,16
In the synthesis of cpChk2, the synthetic intermediate with a cyanoethyl-
protected phophosphorylated threonine (7) appeared as two separate peaks in the HPLC
H
H2N NH2
Figure 2.2. Caged phosphopeptide cpChk2, Ac-MARHFD(cpT)YLIRR-NH 2.
Ppq
chromatogram. The dual peaks likely represent diastereomers resulting from the adjacent
chiral centers at the phosphorus and at the f carbon on the threonine, since the two peaks
showed identical masses in mass spectrometry analysis. After deprotection of the
cyanoethyl group with piperidine, resulting in the loss of chirality at phosphorus, the
HPLC chromatogram showed a single peak for the peptide. Due to the potential for
methionine oxidation, the cpChk2 peptide was dissolved in deoxygenated water and
stored at -20 'C.
With the interassembly approach, residues sensitive to oxidation should only be
included in a caged phosphopeptide sequence N-terminal to the modified residue, such as
in cpChk2. Oxidation of the phosphite intermediate (6) could potentially also affect
susceptible residues, namely tryptophan and methionine, present in the peptide (Fig. 2.3).
NC-
FmocH
H Trp H
Figure 2.3. Possible oxidation of methionine and tryptophan resides during oxidation of
a phosphite intermediate to the corresponding phosphate in the interasssembly approach.
2-2. Building block approach
The synthesis of N-a-Fmoc-protected 2-nitrophenylethyl-caged phosphothreonine
(10), phosphoserine (11), and phosphotyrosine (12) building blocks facilitate the
straightforward assembly of any caged phosphopeptide (Fig. 2.4). Specifically the
building block approach overcomes the two restrictions of the interassembly strategy;
undesired oxidation of tryptophan or methionine residues, and limited accessibility of the
caged phosphopeptides to laboratories not equipped for organic chemistry manipulations
on solid support. With the appropriate building blocks, any researcher can gain access to
the desired caged phosphopeptides through standard SPPS or through a commercial
peptide synthesis facility.
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Figure 2.4. Structure of caged phosphoamino acid building blocks for Fmoc-based
SPPS: 10, N-a-Fmoc-phospho(1-nitro-phenylethyl-2-cyanoethyl)-L-threonine; 11, N-a-
Fmoc-phospho(1-nitro-phenylethyl-2-cyanoethyl)-L-serine; 12, N-a-Fmoc-phospho(1-
nitro-phenylethyl-2-cyanoethyl)-L-tyrosine.
The strategy for constructing caged phosphoamino acids is similar to that of the
interassembly approach and utilizes the identical phosphitylating reagent (1) for the P-O
bond construction. The general synthesis of the caged building blocks is depicted for
caged phosphothreonine (10) in Scheme 2.4. Commercially available N-a-Fmoc-
hydroxytrityl-L-serine (13) was treated with tert-butyl 2,2,2-trichloroacetimidate to yield
the N-a-Fmoc tert-butyl ester 14. The trityl protecting group was then removed under
mild acidic conditions to reveal 15. The N-a-Fmoc tert-butyl ester 15 was
phosphitylated with 1 activated by 4,5-dicyanoimidazole to afford 16. The phosphite was
then oxidized without prior purification to the bisprotected phosphate 17 with mCPBA.
Subsequent removal of the tert-butyl protection with 50% TFA in DCM at room
temperature afforded the caged phosphothreonine building block 10, which was stored at
-20 'C or used directly in SPPS. Importantly, the final deprotection reaction required
temperatures of 23 "C or warmer; deprotection failed at lower "room" temperatures.
Caged phosphoserine (11) and caged phosphotyrosine (12) were similarly synthesized.2
During incorporation into target peptides, the building blocks retain the ,-
cyanoethyl protection. Following the peptide coupling step, the base-mediated Fmoc
deprotection concurrently removes the -cyanoethyl group. The resulting monoprotected
phosphates are ideal for Fmoc-based SPPS because fl-elimination side reactions of
phosphothreonine and phosphoserine residues are suppressed, as discussed in Section 2-
1.14 The building blocks have been used in SPPS for the successful syntheses of a variety
of caged phosphorylated peptides.
Scheme 2.4. Synthesis of N-a-Fmoc-phospho(1-nitro-phenylethyl-2-cyanoethyl)-L-
threonine, 10, for Fmoc-based SPPS.
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2-3. Quantum yield calculation
The quantum yield of photolysis, (, a measure of uncaging efficiency, was
determined for cpChk2 by comparing the percent loss of the caged peptide after
photolysis with that of a standard caged sample with known (, as quantified by analytical
HPLC. Caged phosphate (2-nitrophenylethyl-phosphate, (D = 0.54),17 was used as the
standard for these calculations. Solutions of cpChk2 and the caged phosphate standard
were prepared in water at pH 7.1 with 5 mM DTT and 0.46 mM inosine. The DTT was
added to prevent any back reaction of the photo-byproduct, 2-nitrosoacetophenone, with
the liberated phosphopeptides. The inosine provided a photochemically inert internal
standard to allow for quantification by HPLC analysis of the relative peak areas of
cpChk2 and caged phosphate before and after photolysis.
The solutions of cpChk2 and caged phosphate were each irradiated for 15
seconds with light centered at X = 365 nm and at an intensity of 7,330 pW/cm2 in glass
vessels with path lengths of 1 mm. Analysis by HPLC was performed prior to (t = 0 s)
and immediately after (t = 15 s) irradiation. According to literature precedent, the A350
values of the caged peptide and the caged phosphate were measured and used to calculate
the quantum yield of uncaging with the following equation: 17
ODsample = standad X (%Asample / %Astandard) x (A350standard/A 350sample),
where %A is the percent loss measured by HPLC and A35 0 is the absorbance of the caged
compound at 350 nm, in water at pH 7.1. The experiment was performed in triplicate and
the quantum yield for cpChk2 was found to be 0.33, which is within the range of
reported literature values for o-nitrobenzyl-caged molecules. The D of caged
phosphopeptides appears to be peptide dependent, as (D values determined for several
other caged phosphopeptides were found to range between 0.2 and 0.4.'
Conclusion
The synthesis of caged phosphopeptides has been described using an
interassembly and a building block approach. While both approaches facilitate access to
a wide range of peptides, the building block approach is the most versatile, enabling the
synthesis of peptides with oxidation-sensitive residues anywhere in the sequence. The
caged phosphothreonine peptide cpChk2 was synthesized and the quantum yield of
uncaging was determined. Caged phosphopeptides synthesized using the approaches
described here have been successfully applied to in vitro and in vivo experiments to study
kinase-mediated signal transduction in cellular migration and cell cycle control.18' 19
Methods
General Methods. All peptide synthesis reagents were purchased from Novabiochem and
all other chemicals were purchased from Aldrich. Dry DCM was distilled from calcium
hydride and dry THF was distilled from sodium/benzophenone. HPLC was performed on
a Waters 400 or 600 system with a Waters dual wavelength absorbance detector reading
at 228 and 280 nm. For CIs analytical HPLC a Beckman Ultrasphere ODS, 5 pm, 150 x
4.6 mm column was used and for C18 preparatory HPLC a YMC-Pac Pro, 5 jLm, 250 x 20
mm column was used. The standard HPLC separation gradient was 93:7 to 0:100
water:MeCN with 0.1% TFA over 30 minutes. ES-MS was performed on a PerSeptive
BioSystems Mariner Biospectrometry Workstation. NMR spectra were acquired on a
BrukerAdvance (DPX) 400 MHz instrument, or a Varian Mercury 300 MHz instrument.
Reported chemical shifts are in ppm relative to a standard (TMS for 1H or chloroform for
13C).
General Peptide Synthesis. Peptides were prepared by standard Fmoc SPPS on Fmoc-
PAL-PEG-PS resin. For example, for 0.04 mmol of peptide, 200 mg of Fmoc-PAL-PEG-
PS resin (0.2 mmol/g loading) were added to a peptide synthesis vessel and swollen for
five minutes in 5 mL of DCM, then in 5 mL of DMF. The resin was deblocked with
three five-minute rinses with 5 mL of piperidine, and then rinsed for five one-minute
rinses with 5 mL DMF. An Fmoc-protected amino acid was then coupled as follows.
For each coupling, 80 [tmol of Fmoc-protected amino acid and 80 [tmol of benzotriazole-
1-yl-oxy-tris-pyrrolidino-phosphonium hexafluorophosphate (PyBOP) were dissolved in
5 mL of DMF and then added to the deblocked resin. The couplings were initiated by the
addition of 160 [tmol of diisopropylethylamine (DIEA), and then agitated for at least 30
minutes at room temperature. The resin was rinsed twice with one-minute washes of 5
mL of DMF, then twice with 5 mL washes of DCM. Following each coupling, several
resin beads were tested for free amines with trinitrobenzene sulfonic acid (TNBS). After
a negative test, the amino acid was deblocked as described above and chain elongation
was continued. Peptides were cleaved from the resin under a variety of conditions,
depending on the peptide composition. Cleaved peptides were triturated three times with
cold diethylether, and purified by reverse phase HPLC. The identities of the peptides
were confirmed by ES-MS (turbo ion source). The concentration of caged
phosphopeptide solutions was determined by UV absorption based on the nitrophenyl
group (E259 = 5700 M-lcm -1 in MeOH). The concentration of peptide solutions with
tyrosine or tryptophan residues was determined by UV absorption based on those
residues (E280 = 5500(#Trp) + 1490(#Tyr) M-1cm 1 in water).20 The concentration of all
other peptide solutions was determined by quantitative amino acid analysis.
1(2-nitrophenyl)-ethanol (3)
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To a stirring solution of 2-nitroacetophenone (7.0 g, 42.3 mmol) in 130 mL of
dioxane:methanol (2:3 by volume), sodium borohydride (4.8 g, 126.9 mmol) was added
over a period of 20 minutes and stirred in a water bath at 0 oC. The solution was allowed
to stir for an additional 2.5 hours at room temperature and the progress was monitored by
TLC in chloroform. The reaction was quenched with water (150 mL) and then extracted
into chloroform (3 x 100 mL). The organic fractions were dried over magnesium sulfate
(MgSO4) and concentrated under reduced pressure. The product was further dried in
vacuo overnight to yield an orange-yellow oil, 5.81 g (82.0%). 'H NMR (300 MHz,
CDC13) 8 ppm: 7.9 (d, J = 8.0 Hz, 1 H), 7.7 (t, J = 7.2 Hz, 1 H), 7.4 (t, J = 7.6 Hz, 1 H),
5.4 (q, J = 6.4 Hz, 12.4 Hz, 1 H), 2.4 (s, 1 H), 1.6 (d, J = 6.4 Hz, 3 H). 13C NMR (126
MHz, CDC13) 6 ppm: 148.1, 141.5, 134.1, 128.5, 128.0, 124.7, 65.9, 24.7.
O-1-(2-nitrophenyl)ethyl-O '-fl-cyanoethyl-N,N-diisopropylphosphoramidite (1).
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In the dark, 2-cyanoethyl diisopropylchlorophosphoramidite (470 gL, 2.11 mmol)
was added to a stirring solution of nitrophenylethanol (290 mg, 1.76 mmol) and
triethylamine (590 gLL, 4.23 mmol) in anhydrous DCM (10 mL). The reaction mixture
was stirred overnight at room termperature and the reaction progress was monitored by
TLC (7:3:4 methanol : chloroform : water). The solution was washed with 10%
NaHCO3. The organic layer was dried over MgSO 4, concentrated under reduced
pressure, then further dried overnight in vacuo to yield a deep-yellow oil, 645 mg
(quantitative). 1H NMR (300 MHz, CDC13) 6 ppm: 7.9 (m, 2 H), 7.7 (m, 1 H), 7.4 (m, 1
H), 5.6 (m, 1 H), 3.9 (m, 2 H), 3.7 (m, 2 H), 2.5 (m, 2H), 1.6 (dm, J = 2.4 Hz, 6.8 Hz, 3
H), 1.2 (m, 12H). 31P NMR (121 MHz, CDC13) 8: 148.2 (d, J = 45.6 Hz).
Caged phosphothreonine peptides (interassembly approach). Peptides were built up on a
PAL-PEG-PS solid support by standard Fmoc SPPS up to the threonine residue to be
modified, which was introduced without side-chain protection, and the resulting peptide
on resin was pumped dry overnight. All subsequent steps were carried out in the dark.
The threonine was coupled with 0-1-(2-nitrophenyl)ethyl-O'-p-cyanoethyl-N,N-
diisopropylphosphoramidite (5 equivalents) with 1 H-tetrazole (10 equivalents) in 1:1
DCM:THF for 1 hour. The reaction was quenched with 10% NaHCO 3, and the resin was
washed with 1:1 DCM:THF, followed by DCM. The peptide on resin was oxidized with
mCPBA (2 equivalents) in DCM for 1 hour. The reaction was quenched with 10%
NaHCO 3, and the resin was washed with DCM. Subsequent treatment with 20%
piperidine in DMF for Fmoc deprotection simultaneously removed the the P-cyanoethyl
group. Peptide completion was carried out with standard SPPS protocols. The synthesis
of cpChk is detailed as an example below:
cpChk2: Ac-MARHFD-phospho(nitrophenylethyl)-threonyl-YLIRR-CONH2.
0
H.H
NH2
NH
H
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Fmoc-TYLIRR-(PAL-PEG-PS). Fmoc-TYLIRR-CONH 2 was prepared using standard
Fmoc SPPS as described above on PAL-PEG-PS resin. A test cleavage was run.
Reverse phase HPLC (tR = 27.4 min). Exact mass calcd for C52H75N13010, 1042.3; found
by MS(ESI), 521.8 [M2H] 2+
Fmoc-phosphi-(O-1-(2-nitrophenyl)ethyl-O'-/j-cyanoethyl)threonyl-YLIRR-(PAL-
PEG-PS). Fmoc-TYLIRR-(PAL-PEG-PS) (114 mg resin, 25 ýpmol) was pumped dry in
vacuo overnight. O-1-(2-nitrophenyl)ethyl-O'-/J-cyanoethyl-N,N-
diisopropylphosphoramidite (92 mg, 250 jtmol) was added to the resin and the system
was flushed with argon. The resin was swollen in anhydrous DCM for 15 minutes. The
system was charged with 1H-tetrazole (17.5 mg, 250 gmol), and then flushed again with
argon. The reaction was stirred for overnight in the dark, and saturated NaHCO 3 (4 mL)
was added. The resin was rinsed with 1:1 DCM:THF (2 x 5 mL) and DCM (2 x 5mL).
Fmoc-phospho-(O-1-(2-nitrophenyl)ethyl-O'-/f-cyanoethyl)threonyl-YLIRR-(PAL-
PEG-PS). Fmoc-phosphi-(O- 1-(2-nitrophenyl)ethyl-O '-/f-cyanoethyl)threonyl-YLIRR-
(PAL-PEG-PS) (114 mg resin, 25 ptmol) was swollen with DCM in a peptide synthesis
vessel. To this was added mCPBA (8.6 mg, 50 itmol) in DCM (2.8 mL) and the mixture
was agitated in the dark for 1 hour. Saturated NaHCO 3 (6 mL) was added to the swirling
solution. After 5 minutes the resin was rinsed with DCM (4 x 5 mL). A test cleavage
was run. Two peaks observed by reverse phase HPLC (tR = 28.6 min and 28.8 min).
Exact mass calcd for C63H85N15015P, 1324.5; found by MS(ESI), 662.9 [M2H]2+
Identical mass found for the two HPLC peaks.
Ac-MARHFD-phospho-(1-nitrophenylethyl)-threonyl-YLIRR-CONH2. Sequence
completion was carried out using standard Fmoc SPPS in the dark. The N-terminus was
acetyl capped by coupling with acetic anhydride (26 1tL, 0.28 mmol) and pyridine (23 pL,
0.28 mmol) in DMF (5 mL) for 30 min. The peptide was cleaved from the resin in 92.5%
TFA, 2.5% water, 2.5% TIS, and 2.5% EDT. Reverse phase HPLC (tR = 19.9 min).
Exact mass calcd for C83H124N260 22PS, 1849.0; found by MS(ESI), 662.9 [M2H]2 +
N'-Fmoc-hydroxyltrityl-L-threonine tert-butyl ester (14)
/ \NH
0 Cl O
FmnocHN OH CIDCM:THFO
v
84%
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To Na-Fmoc-hydroxyltrityl-L-threonine (1.89 g, 3.24 mmol) in 4:1 DCM:THF (16
mL) was added tert-butyl 2,2,2-trichloroacetimidate (2.3 mL, 12.95 mmol). The reaction
was stirred for 2 hours at room temperature under argon and reaction progress was
monitored by TLC (1:1 EtOAc:hexanes). The reaction mixture was concentrated, then
redissolved into EtOAc (30 mL). The solution was washed with 10% NaHCO 3 (2 x 60
mL) and saturated sodium chloride (30 mL). The organic layer was dried over MgSO 4,
filtered, and concentrated. The crude product was purified by flash chromatography on a
short plug of basic alumina (1:1 hexanes/EtOAc, Rf = 0.66) to give the product (1.74 g) in
84% yield. 'H NMR (300 MHz, CDCL3) 6 ppm: 7.88 (d, J = 7.5 Hz, 2H), 7.81 (d, J = 7.3
Hz, 1H), 7.78 (d, J = 7.5 Hz, 1H), 7.61-7.34 (m, 19H), 5.98 (d, J = 9.7 Hz, 1H), 4.56 (m,
2H), 4.43 (m, 11H), 4.34 (m, 1H), 4.02 (m, 1H), 1.47 (s, 9H), 1.09 (s, 3H). 13C NMR (126
MHz, CDC13) 6 ppm: 169.9, 156.6, 144.6, 144.0, 143.8, 141.3, 129.0, 127.7, 127.6,
127.2, 127.1, 125.1, 125.2, 120.98, 119.96, 86.3, 81.9, 71.4, 67.1, 60.1, 47.2, 27.9, 18.6.
ESI-MS: [MNa]+ 646.1554 (obsd), 646.1561 (calcd).
Na-Fmoc-L-threonine tert-butyl ester (15)
0• 1% TFA
[On1 5% TIS
II,-\ VCUM
94%
14
FmocHN ....
Na-Fmoc-hydroxyltrityl-L-threonine tert-butyl ester (3.66 g, 5.72 mmol) was
dissolved in 150 mL of 1% TFA and 5% TIS in DCM. The reaction mixture was agitated
at room temperature for 30 min. The solution was diluted with DCM (100 mL) and
washed with 10% NaHCO3 (2 x 120 mL) and concentrated sodium chloride (120 mL).
The organic layer was dried over MgSO 4, filtered, and concentrated. The crude product
was purified by silica gel flash chromatography (hexanes, then 1:1 hexanes/EtOAc, Rf =
0.48) to give the product (2.14 g) in 94% yield. 1H NMR (300 MHz, CDC13) 8 ppm: 7.75
(d, J = 7.4 Hz, 2H), 7.63 (d, J = 7.4 Hz, 2H), 7.39 (t, J = 7.2 Hz, 2H), 7.30 (t, J = 7.4 Hz,
2H), 5.99 (d, J = 9.1 Hz, 1 H), 4.42 (m, 2H), 4.35 (dd, J = 2.2 Hz and 6.3 Hz, 1H), 4.30
(m, 1H), 4.24 (t, J = 7.2 Hz, 1H), 3.07 (bs, 1H), 1.52 (s, 9H), 1.29 (d, J = 6.6 Hz, 3H).
13C NMR (126 MHz, CDC13) 6 ppm: 170.4, 157.0, 143.9, 143.7, 141.3, 127.7, 127.1,
125.2, 120.0, 82.5, 68.2, 67.2, 59.8, 47.1, 28.0, 20.0. ESI-MS: [MNa]÷ 420.1770 (obsd),
420.1781 (calcd).
Na-Fmoc-phosphi( 1-nitrophenylethyl-2-cyanoethyl)-L-threonine tert-butyl ester (16)
0 NO2
,"N -PI-O%.CN
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In a round-bottom flask under argon was dissolved N-a-Fmoc-L-threonine tert-
butyl ester (1.35 g, 3.39 mmol) in anhydrous THF (16 mL). In a pear-shaped flask under
argon were dissolved 0-1-(2-nitrophenyl)-ethyl-O'-f-cyanoethyl-N,N-
diisopropylphosphoramidite (3.74 g, 10.2 mmol) and 4,5-dicyanoimidazole (1.20 g, 10.20
mmol) in anhydrous THF (16 mL), and the solution was mixed for several minutes in the
dark. The phosphoramidite solution was added into the stirring amino acid solution via
cannula under argon positive pressure and allowed to stir at room temperature in the dark
overnight, under argon. The reaction was judged complete by disappearance of the
I I II
starting material and appearance of the product. The crude mixture was concentrated
under reduced pressure and redissolved in EtOAc (100 mL). The solution was washed
with 10% NaHCO3 (2 x 100 mL) and then brine (100 mL). The crude material was dried
over Na2SO 4, filtered, concentrated under reduced pressure, and used immediately in the
following reaction.
N-a-Fmoc-phospho(1-nitrophenylethyl-2-cyanoethyl)-L-threonine tert-butyl ester (17)
NO2  N02
NC,,NO O 2 0 -
O mCPBA U
FmocHN 0< DCM FmocHN O
O 74% over two steps O
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N-a-Fmoc-phosphi(1-nitrophenylethyl-2-cyanoethyl)-L-threonine tert-butyl ester
was dissolved in DCM (130 mL). To this solution was added mCPBA (1.17 g, 6.78
mmol), and the resulting mixture was agitated at room temperature in the dark for 1 hour.
The solution was washed with 10% NaHCO 3 (2 x 120 mL), and the organic layer was
dried over MgSO 4, filtered, and concentrated. The product was purified by silica gel
flash chromatography (1:3 hexanes/EtOAc, Rf= 0.38) to give the product (1.74 g) in 74%
yield over two steps. 'H NMR (300 MHz, CDCl3) 8 ppm: 7.96 (m, 1H), 7.80-7.60 (m,
6H), 7.53-7.33 (m, 5H), 6.12 (m, 1H), 5.45 (m, 1H), 5.03 (m, 2H), 4.44 (m, 2H), 4.24 (m,
3 H), 2.69 (m, 2H), 1.75 (m, 3H), 1.47 (m, 9H), 1.34 (m, 3H). 13C NMR (126 MHz,
CDC13) Orpppm: 168.5, 168.2, 156.8, 147.1, 143.8, 141.5, 136.9, 134.1, 129.4, 128.0,
127.9, 127.8, 127.3, 125.3, 124.8, 120.2, 116.4, 83.6, 73.9, 67.5, 67.4, 62.5, 58.9, 47.3,
28.1, 24.4, 19.8, 18.4. 31P NMR (121.5 MHz, CDC13) 6 ppm: -3.30, -3.20. ESI-MS:
[MNa]+ 702.2194 (obsd), 702.2187 (calcd).
N-a-Fmoc-phospho(1-nitrophenylethyl-2-cyanoethyl)-L-threonine (10)
50%TFA O
DCM FmocHN OH
64% O
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N-a-Fmoc-phospho(1-nitrophenylethyl-2-cyanoethyl)-L-threonine tert-butyl ester
(268 mg, 385 jimol) was dissolved in DCM (55 mL). TFA (55 mL) and TIS (5.5 mL)
were added and the solution was stirred for 2 hours in the dark at 25 'C. The DCM and
TFA were evaporated under a light flow of nitrogen and the resulting residue was
redissolved in EtOAc and washed with 10% NaHCO 3 (2 x 50 mL). The organic layer
was dried over MgSO 4, filtered, and concentrated. The product was purified by silica gel
flash chromatography (EtOAc, then 9:1 EtOAc/MeOH with 1% AcOH, Rf = 0.18) to give
10 (158 mg) in 64% yield. 'H NMR (300 MHz, CDCl3) 8 ppm: 7.97-7.26 (m, 12H), 6.21
(bs, 1H), 6.13 (m, 1H), 5.62 (m, 1H), 5.01 (m, 2H), 4.51-4.11 (m, 5H), 2.70 (m, 2H), 1.75
(m, 3H), 1.30 (m, 3H). 13C NMR (126 MHz, CDCl3) 8 ppm: 170.1, 156.9, 147.1, 143.8,
141.5, 137.2, 134.2, 129.4, 128.0, 127.9, 127.3, 125.3, 124.8, 120.2, 116.6, 73.8, 67.6,
67.1, 63.0, 58.1, 47.3, 19.8, 18.5. 31P NMR (121.5 MHz, CDC13) Orppm: -3.91. ESI-MS:
[MNa]+ 662.2857 (obsd), 662.2877 (calcd).
Quantum yield calculation. The quantum yield, (D, of cpChk2 was calculated by
comparing the percent loss of the caged peptide after photolysis, as quantified by HPLC
analysis, to that of a standard, caged phosphate (cp), with a known D.17 HPLC analysis
was performed prior to (t = 0 s) and immediately after (t = 15 s) irradiation. The
analytical HPLC gradient used for the samples was 93:7 to 65:35 (water:MeCN with
0.1% TFA) over 15 minutes, then 65:35 to 40:60 over 20 minutes at 1.0 mL/minute.
Samples were irradiated for 15 seconds at X = 365 nm and an intensity of 7,330 pgW/cm 2
on a DNA transilluminator in glass vessels with path lengths of 1 mm. Peptide solutions
were prepared in water at pH 7.1 with 5 mM DTT and 0.46 mM inosine. The A350 value
of each sample was measured in water, pH 7.1. Below is the quantum yield calculation
for cpChk2.
ODcpChk2 = 'Dcp x (%AcpChk2 / %Acp) x (A350cp/A 350cpChk2)
OcpChk2 = 0.54 x (14.520 / 19.865) x (0.02119 / 0.02516)
]DcpChk2 = 0.33
Data table for cpChk2
Peak Name Retention Time
(minutes)
Inosine (t=0) 2.97
cpChk2 (t=0) 21.33
Inosine (t=15) 2.93
cpChk2 (t= 15) 21.28
Data table for caged phosphate
Average Area
1.45
3.34
1.50
2.95
Avg Normalized
Area
1.000
2.294
1.000
1.9609
Avg A35so in water,
pH 7.1
0.02516
Peak Name Retention Time Average Area Avg Normalized Avg A3 50 in water,
(minutes) Area pH 7.1
Inosine (t=0) 2.95 1.44 1.000
Caged P (t=0) 18.37 1.91 1.334 0.02119
Inosine (t=15) 2.86 1.43 1.000
Caged P (t=15) 18.35 1.72 1.069
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Chapter 3
Semisynthesis of caged phosphoTyr31 paxillin
Introduction
Na-Fmoc-protected 1-(2-nitrophenyl) ethyl caged phosphoserine,
phosphothreonine, and phosphotyrosine building blocks (Chapter 2) facilitate the
straightforward assembly of any caged phosphopeptide through Fmoc-based SPPS.'
Caged phosphopeptides are valuable tools for biological studies in which the
phosphorylated species is active at the peptide level, and these probes have been utilized
successfully for both in vitro and cellular studies.2 A powerful extension of the caged
phosphopeptide methodology would be the incorporation of caged phosphorylated
residues into complex, multi-domain proteins. The resulting full-length probes would
allow researchers to dissect of the role of individual phosphorylation sites in "real time",
while preserving other phosphorylation sites, binding and localization determinants, or
enzymatically-active domains within the target proteins.
A full-length protein target of significant interest to our lab is a caged
phosphorylated analog of paxillin, a 61-kDa cytoplasmic phosphoprotein. Paxillin
localizes to focal adhesions, which are sites of cellular contact with the extracellular
matrix, and is implicated in cellular adhesion and cell migration (Fig. 3.1). 3 The control
of cellular adhesion and migration is central in the regulation of biological processes,
including embryogenesis, wound repair, and metastasis. 4 Paxillin is a multi-domain
protein that contributes to the control of these processes by acting as a dynamic scaffold
for signaling and structural proteins. Phosphorylation of paxillin at specific serine,
threonine or tyrosine residues spanning the molecule creates distinct protein binding sites
and thereby directs paxillin localization to focal adhesions, or influences the controlled
') 1 xtension 2) Adhesion
direction of migration
3) I ranslocation
cell body movement
.0 ll
4) De-adhesion
focal adhesions old adhesion
Figure 3.1. Cellular migration.5 The movement of cells involves the tightly regulated
formation and subsequent disassembly of focal adhesions.
assembly or dissolution of signaling cascades. 6 Specifically, phosphorylation of paxillin
at Tyr31 creates a binding platform for a Src homology 2 (SH2) domain, facilitating
interaction with SH2 domain-containing proteins such as Crk, an adaptor protein that
recruits other signaling molecules involved in cellular migration.7
In this chapter we describe the semisynthesis of a paxillin analog with a caged
phosphotyrosine (cpTyr) at position 31 of the 557-residue protein, which will be used as
a tool to investigate the impact of Tyr31 paxillin phosphorylation on cellular migration
(Fig. 3.2). The probe was constructed using NCL to install a caged phosphopeptide on
the N-terminus of a biologically expressed fragment of paxillin. To serve as non-
phosphorylated and discreetly phosphorylated biological controls, paxillin variants with a
Tyr or phosphoTyr (pTyr) residue at position 31 were constructed analogously to the
caged phosphorylated construct.
e o ,9O-P=0 O-P=O
31 hv31(365 nm)
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Figure 3.2. Caged phosphoTyr31 paxillin. Uncaging with long-wavelength UV light
releases phosphoTyr31 paxillin. The proteins are shown with N-terminal hexahistidine
and C-terminal FLAG tags
Paxillin structure and overview of selected interactions
Structurally, paxillin includes numerous binding domains that facilitate a range of
protein-protein interactions (Fig. 3.3). Near the N-terminus of paxillin, there are five LD
motifs, which are 8-residue peptide sequences that begin with a leucine-aspartic acid (L-
D) pairing. Modeled as an a-helix, leucine or valine residues lie along one side of these
motifs, presenting a hydrophobic face.8 The LD repeats bind a common domain, the PBS
(paxillin binding subdomain), conserved in various binding partners, including the actin-
binding proteins actopaxin and vinculin, focal adhesion kinase (FAK), a tyrosine kinase
that phosphorylates paxillin, and paxillin kinase linker (PKL), a protein involved in actin
cytoskeleton dynamics. 3 Also on the N-terminal half of paxillin, several proline-rich
regions provide binding sites for SH3 domains found in members of the Src family. SH3
domains are modular adaptor domains that bind with ltM affinity to proline-rich segments
on the surface of target proteins. Additionally, phosphorylation of paxillin on Tyr31 and
Tyrll 18 by Src and FAK creates two binding sites for SH2 domains, enabling interaction
with the adaptor protein Crk, as mentioned above, and Csk (C-terminal Src-kinase), a
tyrosine kinase that negatively regulates Src activity. SH2 domains are phosphorylation-
sensitive adaptor domains that bind peptide sequences with a pTyr-X-X-4 consensus
motif, where X is any amino acid except proline, and D is a hydrophobic residue. The
extent of paxillin phosphorylation is regulated by interaction with the extracellular matrix
(ECM) and extracellular environmental signals provided by growth factors. Other sites
of phosphorylation include Serl88 and Serl90, which are phosphorylated subsequent to
cellular adhesion to fibronectin.6
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Figure 3.3.6,9 a) Paxillin structural domains. The N-terminus includes LD repeats and
Pro-rich SH3 binding regions. The C-terminus comprises four LIM domains. SH2-
binding regions are created by Tyr31 and Tryl 18 phosphorylation. b) Selected paxillin-
interacting proteins, including signaling proteins and structural actin-binding proteins.
The C-terminus of paxillin includes four LIM domains, cysteine/histidine-rich
double zinc fingers that serve as protein-protein binding sites. These domains interact
with both kinases and phosphatases. One such LIM-binding protein is PTP-PEST, 1' a
phosphatase that triggers focal adhesion disassembly by dephosphorylating CAS (Crk-
associated substrate), a protein recruited to the area through its interaction with Crk. The
LIM domains, specifically LIM3, also function as focal-adhesion targeting sites in
paxillin, potentiated by serine/threonine phosphorylation. 11
As suggested by the structural and regulatory roles of the numerous binding
partners described, paxillin is instrumental in the regulation of cell motility, both by
direct interaction with structural elements, as well as by functioning as a scaffold to bring
various signaling proteins into close proximity, facilitating interaction. Paxillin
phosphorylation is critical for the regulation of a number of these processes. For
example, phosphorylation of paxillin at Tyr31 and Tyrl 18 has been shown to increase
during cell spreading.12 In a related study, a Tyr31Phe/Tyrll8Phe mutant was used to
verify the necessity of phosphorylation at those sites for EphB 1 receptor mediated cell
migration. 13 Additionally, signaling through these residues has recently been shown to be
involved in the PTP-PEST-dependent regulation of cellular mobility.14
The involvement of paxillin in cytoskeletal dynamics and cellular migration may
be of great consequence in cancer metastasis. The E6 oncoprotein from papillomavirus,
which leads to cervical carcinomas, binds to the LD motifs of paxillin. This decreases
interaction with normal LD binding partners, including vinculin and FAK, likely
contributing to the disruption of the actin cytoskeleton, which occurs in papillomavirus-
infected cells. 15 Additionally, oncongenic equivalents of Src (v-Src) and Crk (v-Crk)
have been identified, which similarly perturb normal paxillin binding. Specifically, these
mutants disrupt the regulation of the MAPK (mitogen-activated protein kinase) cascade
involved in controlled cell proliferation and gene expression. 16 Phosphorylation of
paxillin has also been directly linked to tumor metastasis. In an investigation of the
invasive capacity of rat ascites hepatoma MM1 cancer cells, it was found that paxillin
phosphorylation on Tyr31 and Tyr 118 was required for transcellular migration. 17
Both for the involvement of paxillin modification in metastasis and in the
regulation of normal cell processes, there is enormous interest in the downstream cellular
effects of paxillin phosphorylation. Specifically, Tyr31 phosphorylation is involved in a
number of regulatory processes, but little is known about the effect of phosphorylation in
"real time," and little work had been done to dissect the isolated effect of Tyr31
phosphorylation from the compound effect of Tyr31/Tyrll8 phosphorylation. A
photolabile precursor of phosphoTyr31 was selected as the target for semisynthesis to
probe the role of Tyr31 on cell migration. The proximity of a critical phosphorylated
residue to the N-terminus made it a promising candidate for semisynthesis through a
single NCL reaction.
Results and Discussion
3-1. Overview of Paxillin Semisynthesis
The semisynthesis of paxillin (Y31Pax), phosphoTyr31 paxillin (pY31Pax), and
caged phosphoTyr31 paxillin (cpY31Pax) was accomplished by the ligations of synthetic
thioesters corresponding to residues 2-36 of paxillin to a biologically expressed segment
comprising residues 37-557 (Fig 3.4). An Asn37Cys mutation was designed to provide a
Gly36-Cys37 junction for NCL. This site was chosen because it is in a region of paxillin
free of any predicted secondary structure, and because the presence of a glycine as the
terminal thioester residue is known to increase ligation efficiency.18 Three peptide
thioesters corresponding to residues 2-36 of paxillin were synthesized, with a Tyr, pTyr,
or cpTyr building block at residue 31 (Fig. 3.4a, 18). An N-terminal hexahistidine tag
was included in the peptides to provide a handle for visualization, as well as purification
of the ligation product away from any unreacted starting material following ligation.
For the C-terminal fragment of paxillin, residues 38-557 were expressed with an
N-terminal purification tag and a protease cleavage sequence (PCS) positioned
immediately preceding the paxillin insert. Treatment of the precursor protein with a
protease resulted in cleavage of the purification tag and exposure of an N-terminal
cysteine residue to produce Cys-paxillin(38-557) for subsequent ligation. Ligation of the
C-terminal fragment with the synthesized thioesters 18a, 18b, and 18c yielded Y31Pax,
pY31Pax, and cpY31Pax respectively.
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Figure 3.4. Semisynthesis of paxillin analogues. (a) Synthetic peptide thioesters
corresponding to the N-terminus of paxillin. (b) Semisynthetic strategy. PCS = protease
cleavage site.
3-2. Synthesis of paxillin peptide thioesters
For the synthesis of the 41-residue N-terminal thioesters (Ac-HHHHHH-
DDLDALLADLESTTSHISKRPVFLSEETP-X-SYPTG, X = Tyr (18a), pTyr (18b), or
cpTyr (18c)), the peptides were prepared on highly acid labile TGT resin using Fmoc-
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based SPPS. The cpTyr building block, synthesized as described in Chapter 2, was used
to install a pTyr masked by the 1-(2-nitrophenyl)ethyl (NPE) caging group in peptide
18c. In a procedure modified from published methods, 19,20 the peptides were cleaved
from the resin with 0.5% TFA to release fully side-chain protected peptides as C-terminal
carboxylic acids. The C-termini were activated with HBTU and DIPEA and reacted with
benzylmercaptan to yield the corresponding thioesters. The amino acid side chains were
subsequently deprotected with TFA in the presence of scavengers to produce 18a, 18b,
and 18c (Scheme 3.1). The thioesters were purified by reverse phase HPLC and stored
as lyophilized powders at -20 oC for subsequent use in NCL. Between 10 and 30 mg of
each thioeste:r variant were synthesized.
Prior to the large-scale thioester syntheses, an initial test synthesis of residues 1-
36 of paxillin was carried out to identify problematic coupling steps. It was important to
maximize the efficiency of the peptide synthesis, since the desired thioesters are long and
require "off-bead" thioesterification following the SPPS. The test peptide, Pax(1-36) was
constructed on an automated peptide synthesizer with an acetic anhydride capping step
following each coupling. Samples were removed from the synthesizer subsequent to the
coupling of Leu25, Lys20, Glul2, and Metl, resulting in a 12-, 17-, 25-, and 36-residue
peptide respectively. Test cleavages of the peptide fragments were monitored by
analytical HPLC followed by ESMS. Analysis of the 12 and 17-residue peptides
revealed a single major peak by HPLC with a mass corresponding to the desired peptide.
However, the 25 and 36-residue fragments produced more complicated spectra, each with
a second large HPLC peak (m/z 1107.5) in addition to the peak corresponding to the
expected product. Based on the mass, it was determined that the probable identity of the
extra peak was Ac-ISKRPVFLSEETPYSYPTG-COOH, resulting from an unsuccessful
coupling of Fmoc-His(Trt)-OH to Ile 18, leading to capping of the 19-residue peptide. It is
reasonable that this would be a difficult coupling step due to steric interactions between
the bulky trityl protecting group on histidine and the fl-branched isoleucine residue.
In subsequent syntheses of the paxillin thioester variants 18a, b and c, the
challenging histidine/isoleucine coupling was performed manually using benzotriazole-1-
yl-oxy-tris-pyrrolidino-phosphonium hexafluorophosphate (PyBOP) and DIPEA as
activating agents. The absence of free amines was confirmed by a TNBS test and the
peptides were completed on a peptide synthesizer to give NH 2-Pax(2-36). The
hexahistidine tag and acetyl cap were added manually to complete the peptides, which
were subsequently converted to thioesters as previously described.
Scheme 3.1. Synthesis of paxillin thioesters.
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3-3. Expression of the C-terminal precursor for NCL
There are several strategies for accessing biochemically-expressed protein
fragments with an N-terminal cysteine residue for use in NCL (see Chapter 1 for a
complete discussion). These approaches include intein-based strategies and exogenous
protease cleavage of a precursor protein. A major disadvantage to an intein method is the
common complication of spontaneous intein cleavage, while a minor drawback is the
need for a specialized vector. A more straightforward method, compatible with virtually
any vector, is the use of a precursor protein expressed with a cysteine residue
immediately C-terminal to a protease cleavage site. In vitro cleavage of the appropriate
precursor protein generates the requisite N-Cys protein fragment.
For the generation of the C-terminal paxillin fragment, Cys-Pax(38-557), a
hexahistidine-fusion protein of Pax(38-557) with a protease cleavage site and a cysteine
flanking the paxillin insert was designed. The DNA encoding His6-PCS-Cys-Pax(38-
557) (PCS = protease cleavage site, discussed in detail in Section 3-4) was transformed
into BL21(DE3) E. coli cells, expressed, and purified on a Ni/NTA column.
Paxillin is known to be a challenging protein to express, with poor yields and high
levels of degradation. Consistent with such reports, attempts at expressing the paxillin
construct resulted in barely detectable levels of paxillin expression, visible only by
sensitive Western blot analysis and accompanied by a large number of degradation and/or
truncation products (Fig. 3.5). Ultimately, to access sufficient quantities of protein and
overcome truncation difficulties, the protein was fermented in 10-L batches using codon-
enhanced cells and the construct was reengineered to incorporate both C-terminal and N-
terminal purification tags. These two key changes, which dramatically increased yield
and purity of the paxillin construct, are discussed below.
truncation and degradation products
Figure 3.5. Representative paxillin expression in the BL21 cell line. Western blot,
probed with an anti-paxillin primary antibody, of Ni/NTA purified His6-PCS-Cys-
Pax(38-557). The full construct is indicated by an arrow.
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Use of a codon-enhanced E. coli cell line
An examination of the paxillin(38-557) DNA revealed the presence of a
significant number of rare codons. The insert includes 27 rare proline, 1 rare isoleucine,
2 rare arginine, and 6 rare glycine codons, totaling 7% of the insert DNA. Further,
paxillin includes several proline-rich regions, meaning those codons tend to be clustered
together, exacerbating the strain on the translational machinery. This suggests that many
of the originally suspected degradation products were actually truncation products due to
excessive demand for tRNAs that are in low abundance in E. coli cells.
To circumvent the problem of rare codons, the paxillin DNA was transformed
into codon-enhanced cells, which contain plasmids that encode rare E. coli tRNAs.
Initially the Novagen Rosetta (DE3) cells were used, which express all of the rare E. coli
tRNAs on a plasmid with chloramphenicol resistance. Unfortunately, standard glycerol
preparations of these cells failed to inoculate subsequent expressions. There have been
reports of plasmid instability for inexplicable reasons with Rosetta cells from greater than
10% glycerol stocks. In our experience there were plasmid instability issues despite
minimal glycerol concentrations. Since the Rosetta system was the only option offering
more than three rare codons in a single codon-enhanced cell line, it is possible that the
observed instability was a result of problematically large plasmids.
The paxillin vector was next transformed into the Stratagene BL21-
CodonPlus®(DE3)-RP competent cells, which code for the AGG (Arg), AGA (Arg), and
CCC (Pro) tRNAs. Expression of the paxillin construct was significantly improved over
that achieved with BL21(DE3) cells, with cleaner gels and higher yields. However, there
was still a major truncation product at about 25 kDa, and there were several other
undesired bands visible by Coomassie and Western blot analysis. A number of
parameters were optimized, including the media (LB or TB), temperature for expression
(16, 24, or 37 OC), OD before induction (0.4 to 0.9), IPTG concentration (0.001, 0.01, 0.1
or 1 mM), and expression time (3, 4, 5, 7, or 20 hours). Induction with 0.1 mM IPTG at
an OD of 0.6 for 24 hours at 16 oC was identified as the optimum set of conditions for
growth, although these conditions do not completely prevent the 25-kDa truncation
product or result in high yields of protein. Ultimately it was determined that the most
significant hurdle remaining was not the modest yield or the truncation product, since E.
coli expression is easy and inexpensive to scale up, but the lack of a second purification
handle that would allow clean separation of the desired protein from the truncation and
degradation products.
Construct redesign: incorporation of a second purification tag
A GST-fusion protein of Pax(38-557) with a C-terminal FLAG tag was designed
to increase protein production and enable purification via the GST and FLAG tags (Fig.
3.6). Since protein biosynthesis proceeds from the amino to the carboxyl terminus, none
of the truncation products should contain the FLAG moiety. The FLAG-affinity resin,
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Figure 3.6. Complete isolation of GST-PCS-Cys-Pax(38-557)-FLAG from the
truncation and degradation products is possible by affinity purification via both the N-
terminal and C-terminal tags.
which is several times more expensive than the GST-affinity resin, retains binding
capacity significantly longer when the protein loaded is partially purified, so the N-
terminal GST-affinity purification was performed first.
A Pax(38-557) insert was prepared for cloning into a pGEX-4T-2 GST-fusion
vector using primers to encode a FLAG tag at the C-terminus and a protease cleavage site
immediately N-terminal to the expressed PAX(38-557) fragment. After PCR and
cloning, the isolated plasmid DNA from an appropriate miniprep was transformed into
BL21-CodonPlus®(DE3)-RP competent cells for the expression of GST-PCS-Cys-
Pax(38-557)-FLAG. Protein expression was carried out in LB-carbenicillin-
chloramphenicol with 0.1 mM IPTG induction, followed by 24 hours of fermentation at
16 oC. After initial test expressions and purifications, subsequent expressions were
carried out by fermentation in 10-L batches. Gel analysis of the crude expression showed
a major truncation product, as seen with the original paxillin construct.
Crude GST-PCS-Cys-Pax(38-557)-FLAG was purified on GST and FLAG
affinity columns to achieve complete separation from the truncation product (Fig. 3.7).
The crude lysate was first purified by batch purification using a GST column and eluted
from the column using 50 mM Tris-HC1, 10 mM reduced glutathione, pH 8.0. A 10-L
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Figure 3.7. Purified GST-paxillin fusion protein following expression in codon-
enhanced cells and purification via the N and C-terminal tags.
fermentation of GST-PCS-Cys-Pax(38-557)-FLAG resulted in 45 mg of protein after the
GST-affinity purification, as quantified using a BioRad protein assay, which is
compatible with the presence of glutathione. Prior to purification on an anti-FLAG
column, the GST-purified protein was dialyzed into TBS to remove the glutathione used
for elution. The FLAG affinity resin is not compatible with reducing agents, such as
glutathione, which could reduce the disulfide bonds in the M2 antibody on the resin. The
dialyzed protein solution was purified on the FLAG column, again using a batch method
for binding to the resin. The FLAG fusion protein was eluted from the column with 1.2-
mL aliquots of 0.1 M glycine HCI, pH 3.5 and collected into eppendorf tubes containing
160 pLL of Tris-HC1, pH 8.0 and 100 pLL of 10 X TBS. The yield of GST and FLAG-
purified protein was 4 to 6 mg from a 10-L fermentation. Since expressions in E. coli are
economical to scale up, obtaining high quantities of pure product was straightforward.
3-4. Protease selection
There are several commercially available proteases that cleave C-terminal to their
recognition sequences, such as Factor Xa,21 which has previously been used to generate
N-terminal cysteine-containing proteins for NCL, as well as enterokinase, ubiquitin C-
terminal hydrolase, and furin, which should have similar utility. Other widely used
proteases, including thrombin, cannot be used in NCL applications because they require
recognition elements C-terminal to their cleavage site, precluding the ability to reveal an
N-terminal cysteine residue. TEV protease, a highly selective cysteine protease, typically
recognizes a serine or a glycine in the Pl' site, but also will accept a cysteine residue at
that position, making it another option for the generation of N-terminal cysteine
containing fragments.22
The original construct for the paxillin C-terminal fragment precursor was
designed with a Factor Xa recognition site. Factor Xa was initially selected based on its
prevalence in NCL applications as well as its use within the Imperiali group for the
removal of affinity tags. However, despite a range of cleavage conditions tested, Factor
Xa treatment consistently resulted in unselective proteolysis of paxillin. Below are
described the paxillin test reactions with Factor Xa and the subsequent screening of other
proteases that lead to the selection of TEV protease for cleavage of GST-PCS-Cys-
Pax(38-557)-FLAG.
A range of cleavage conditions were tested on the GST paxillin fusion GST-
IEGR-Cys-Pax(38-557)-FLAG, which included the Factor Xa recognition motif, IEGR.
Upon successful cleavage of the paxillin construct, gel analysis should have revealed a
loss of the band corresponding to the GST-paxillin fusion (83 kDa) and the appearance of
two new bands from Cys-Pax(38-557)-FLAG (56 kDa) (19) and the liberated GST tag
(27 kDa).
The manufacturer reports 0.2 [ig of Factor Xa proteolyze 95% of 10 [tg of target
protein at room temperature in 6 hours. Initially, 50 to 100-gL test reactions were carried
out at room temperature on 10 tg of purified protein with 0.25, 0.5, 1, and 3 jgg of
protease. In all reactions, Western blot analysis revealed the loss of GST-IEGR-Cys-
Pax(38-557)-FLAG within three hours, resulting exclusively in species with apparent
masses well below the expected 56 kDa (Fig. 3.8a). Further test cleavages were carried
out with increasingly smaller amounts of protease, 0.2 to 0.0125 jig per 10 jg of protein,
in an attempt to prevent proteolysis at secondary sites within paxillin. Aliquots were
analyzed for each concentration of protease after 1, 3, 6, and 20 hours with the goal of
establishing conditions to achieve sufficient cleavage at the primary protease site without
significant cleavage at secondary sites. As the amount of Factor Xa was incrementally
scaled down, the 83-kDa-protein (GST-IEGR-Cys-Pax(38-557)-FLAG) disappeared
more slowly. However, no appropriate band corresponding to the 56-kDa fragment could
be detected at any of the time points. Comparable reactions were carried out at 4 oC, and
again no band above 45 kDa was visible. Controls in which protein was incubated in the
reaction conditions in the absence of Factor Xa confirmed that degradation of the paxillin
fragment was a direct result only of the added protease.
As a final attempt, it was reasoned that secondary site cleavage might be reduced
by the addition of zinc, which could improve folding of the paxillin fragment by
organizing the four paxillin LIM domains, double zinc fingers that bind with nM affinity
to a total of 8 zinc ions. It is possible that the LIM domains were stripped of their zinc in
the purification process. Proteolysis reactions were run at room temperature and at 16 OC
at several Factor Xa concentrations with either 200 or 600 jLg ZnCl (50 to 150
equivalents.) Disappointingly, Western blot analysis of the reactions failed to reveal the
desired product 19.
While paxillin does not contain other IEGR repeats, a glycine-arginine dipeptide
appears in several places in the sequence. Unwanted proteolysis by Factor Xa has been
reported to occasionally occur after glycine-arginine pairs or other basic residues in a
target protein.23 Although this is most common following Gly-Arg-X sites, where X =
isoleucine or threonine, which are not present in paxillin, it is possible that the glycine-
arginine dipeptides are in highly exposed regions of the protein, making them more
susceptible to cleavage. It was therefore determined that the paxillin construct must be
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Figure 3.8. a) Treatment of GST-IEGR-Cys-Pax(38-557)-FLAG with Factor Xa. The
Western blot to the right was probed with an anti-FLAG primary antibody and shows
Factor Xa cleavage with varying amounts of protease monitored at time = 0, 1, 3, and 16
hours. The arrow indicates the expected location of the cleavage product, 19. b)
Screening for nonspecific paxillin degradation by proteases. An anti-FLAG-probed
Western blot monitoring the treatment of GST-IEGR-Cys-Pax(38-557)-FLAG with
enterokinase, furin, TEV, and a negative control with no protease.
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redesigned to incorporate an alternative protease cleavage site. Proteases with orthogonal
recognition determinants were therefore tested for paxillin compatibility.
In order to screen for a compatible protease, GST-IEGR-Cys-Pax(38-557)-FLAG
was incubated with a number of proteases to identify, prior to cloning in a new cleavage
site, proteases that would not cleave elsewhere in the paxillin fragment (Fig. 3.8b). In
each case, the purified paxillin derivative was treated with the protease in the most
concentrated conditions recommended by the respective manufacturer. The first protease
tested was enterokinase, which cleaves C-terminal to a DDDDK recognition sequence.
The C-terminal FLAG tag of GST-IEGR-Cys-Pax(38-557)-FLAG includes the DDDDK
motif, but these are the terminal 5 residues, so enterokinase treatment should have no
effect on the protein. Unfortunately significant proteolysis of the paxillin fragment was
observed in the presence of enterokinase. Similarly, treatment of GST-IEGR-Cys-
Pax(38-557)-FLAG with furin, which cleaves following RX(K/R)R, resulted in
degradation of the protein, although to a lesser extent than with enterokinase or Factor
Xa. Finally TEV protease, which cleaves N-terminal to the cysteine in its
ENLYFQ(X)C cleavage sequence, was tested and found to have no undesired cleavage
with GST-IEGR-Cys-Pax(38-557)-FLAG.
Therefore a new construct was designed to incorporate a TEV cleavage site N-
terminal to the paxillin insert. GST-ENLYFQ-Cys-Pax(38-557)-FLAG (20) was
expressed and purified as described in Section 3-3. For TEV cleavage of 20, the purified
protein was diluted to 0.5 to 1 mg/mL into a TEV cleavage buffer with a final
concentration of 50 mM Tris pH 8.0, 500 [LM EDTA, and 5 mM beta-mercaptoethanol
(BME). Standard TEV cleavage conditions call for dithiothreitol (DTT) in the cleavage
mixture, but DTT can promote unwanted thioester hydrolysis in the subsequent ligation,
so BME was used in its place. Nearly complete cleavage of the GST tag, revealing an N-
terminal cysteine residue, was accomplished by treatment with TEV protease to yield
Cys-Pax(38-557)-FLAG (19) (Fig. 3.9). The protein was concentrated to 2 to 4 mg/mL
and used immediately in NCL.
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Figure 3.9. TEV protease cleavage of GST-ENLYFQ-Cys-Pax(38-557)-FLAG (20). A
Western blot shows the protein immediately prior to protease addition (t = 0) and 2 hours
after addition (t = 2 h) in various reaction conditions. A control with no TEV is also
shown.
3-5. Native Chemical Ligation
In general, NCL reactions were carried out with 50 [tM protein, 0.8 mM peptide,
and 150 mM MESNA in TBS at pH 8.0 for 24 hours at room temperature A number of
conditions were screened to determine this optimized ligation protocol. The effect of the
thiol additive, pH, and peptide and protein concentrations are discussed below, as is the
inhibitory effect of glycerol.
Effect of glycerol on NCL
The expressed and TEV-cleaved C-terminal fragment of paxillin, 19, was stored
in aliquots with 20% glycerol at -20 oC, since paxillin rapidly degrades at 4 oC, having a
shelf life of less than two weeks. Buffer exchange into TBS removed most of the
glycerol prior to ligation. Initial attempts to ligate 19 to the synthetic N-terminal peptide
thioesters 18a and 18b failed to produce significant amounts of ligation product, despite
an extensive investigation of reaction conditions. The reactions were attempted using a
variety of thiol additives, pH ranges, temperatures, and concentrations of both the protein
and peptide fragments. Surprisingly, the only conditions that resulted in any detectable
ligation product, although still with very poor conversion, were those reactions carried
out at low pH (6.0 to 6.5). This was a particularly confusing result, since NCL is
expected to work best at higher pH, where thiols are more nucleophillic.
As was later suggested in an e-mail correspondence by Professor Tom Muir, the
reaction was stunted in all cases, regardless of other reaction conditions, by the exposure
of the protein solution to glycerol. While glycerol itself is not problematic, commercial
glycerol is contaminated with small amounts of glyceraldhyde. The glyceraldehyde
essentially caps the free cysteine residues by reacting to give a thiazolidine derivative
(Fig. 3.10). Since acid shifts the equilibrium towards the free cysteine thiol, it is logical
that the only reaction conditions that resulted in any detectable ligation product were at or
below pH 6.5. This capping complication was easily avoided by exposing the protein to
glycerol only after NCL was complete, meaning paxillin was freshly lysed, purified, and
treated with TEV immediately prior to each ligation. The incompatibility of NCL with
glycerol is not mentioned in any published reports, possibly because the majority of NCL
examples in the literature are on robust protein fragments that do not require freezing for
short term storage.
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Figure 3.10. The reaction of an N-terminal cysteine residue with glyceraldehyde to form
a thiazolidine analog. The protein cannot participate in NCL in the capped form.
Effect of thiol additive, pH and protein/peptide concentrations
Attempts to catalyze the reaction using 1 to 2% (vol/vol) thiophenol,
benzylmercaptan, or a combination of the two thiols resulted in precipitate formation and
no detectable ligation product. While these thiols are ideal additives for peptide ligations,
which can tolerate the addition of organic solvent, their poor water solubility makes them
incompatible with ligations of full-length proteins. In contrast, MESNA (Fig. 1.2c) is a
highly water soluble thiol and was found to successfully promote the ligations at
concentrations ranging from 100 to 200 mM. MPPA, a thiol recently identified as an
ideal NCL catalyst24 (see Chapter 1 for a complete discussion of thiol additives in NCL)
was also tested, but was not found to increase the ligation conversion over MESNA. In
addition, MPPA was found to have low solubility in ligation conditions.
The effect of pH on ligation efficiency was briefly investigated with the reaction
compared at pH 6.1 and pH 8.0 (Table 1). Precipitation occurred at pH 6.1 both with
MESNA and 0.2% thiophenol as the thiol additive. A small amount of ligation product
(- 10% conversion) was visible in each case in the precipitate. As expected, the ligation
was significantly more successful in identical conditions at pH 8.0 (- 80% conversion).
The ligation was also tested at pH 7.5 and 7.0 and found to have approximately 70% and
50% conversion, respectively.
The effects of protein, MESNA, and thioester concentration were also examined.
Increasing by a factor of two either the protein concentration, from 2.5 to 5 mg/mL, or
the MESNA concentration, from 100 to 200 mM, had no effect on ligation efficiency
(Table 1, g-i). Additionally, the ligation was run with thioester concentrations of 0.65, 1,
2, 4, and 8 mM (Table 1, j-n) with no apparent effect on the reaction when the
concentration was at, or under, 4 mM. With 8 mM thioester, the lyophilized peptide
never fully dissolved and the ligation conditions resulted in a large amount of
precipitation after 24 h. Since increasing the excess of thioester did not improve the
ligation efficiency, future ligations were carried out at 0.8 mM thioester.
Table 1 Summary of EPL reactions with Cys-Pax(38-557)-FLAG (19). All reactions
were carried out with 50% v/v 100 mM Tris, 600 mM NaCl, pH 8.0 or 100 mM MES,
600 mM NaCl, pH 6.1.
thioester rxn. protein amt thioester thiol pH precip. product
size (mg/mL) mg/mL additive
a pY31 30 gL 2.2 2.5 100 mM 8.0 no yes
(0.5 mM) MESNA (60%)
b pY31 20 iL 1.7 2.5 100 mM 6.1 yes in pellet
(0.5 mM) MESNA (10%)
c pY31 20 pL 1.7 2.5 0.2% 6.1 yes in pellet
(0.5 mM) thiophenol
d Y31 20 pL 2 3.75 100 mM 8.0 no yes
(0.78 mM) MESNA (50%)
e Y31 20 gL 2 3.75 100 mM 6.1 yes in pellet
(0.78 mM) MESNA (10%)
f Y31 20 gL 2 3.75 0.2% 6.1 yes in pellet
(0.78 mM) thiophenol
g Y31 20 LL 2.5 3.1 100 mM 8.0 no yes
(0.65 mM) MESNA (80%)
h Y31 20 ptL 2.5 3.1 200 mM 8.0 no yes
(0.65 mM) MESNA (80%)
i Y31 20 gL 5 3.1 200mM 8.0 no yes
(0.65 mM) MESNA (80%)
j Y31 20 gL 2.5 5.0 100 mM 8.0 no yes
(1.0 mM) MESNA (80%)
k Y31 20 IL 2.5 10 100 mM 8.0 no yes
(2.0 mM) MESNA (80%)
1 Y31 20 pL 2.5 20 100 mM 8.0 no yes
(4.0 mM) MESNA (80%)
m Y31 20 pL 2.5 40 100 mM 8.0 yes in pellet
(8.0 mM) MESNA (50%)
n Y31 80 gL 2.5 3.1 100 mM 8.0 no yes
(0.65 mM) MESNA (80%)
o Y31 168 gL 2.2 7.1 100 mM 8.0 no yes
(1.5 mM) MESNA (80%)
Using the optimized conditions, ligation of 19 with 18a, 18b, and 18c proceeded
with approximately 80% conversion to Y31Pax (21a), pY31Pax (21b) and cpY31Pax
(21c) respectively. The N-terminal hexahistidine tag, introduced with the thioester
peptides, provided a handle for purification of the final ligation product from any
unligated 19 or uncleaved 20 remaining in the crude ligation mixture. Excess peptide (-5
kDa) was removed by buffer exchange using 50-kDa MWCO centrifugal filters. Gel
analysis of the step-by-step semisynthesis of cpY31Pax (21c) is shown in Figure 3.11.
Conclusion
Here we report the semisynthesis of paxillin analogs using an NCL strategy to
introduce N-terminal peptide thioesters, allowing us to access tens of milligrams of
cpY31Pax (21c), pY31Pax (21b) and Y31Pax (21a). The semisynthetic strategy detailed
demonstrates a straightforward approach for assembling complex eukaryotic proteins via
NCL.
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Figure 3.11. Semisynthesis of caged phosphorylated paxillin, 21c. Coomassie and
Western blot analysis of (lane 1) the purified GST-fusion protein, 20, (lane 2) the TEV
cleavage product mixture, and (lane 3) the NCL product mixture.
The prevalence of reports of semisynthetic proteins modified on the C-terminus
compared to those modified at the N-terminus has been attributed to the challenges of
thioester generation following SPPS. 25 The method we describe is compatible with caged
phosphoamino acids and, combined with the use of an Fmoc-protected caged
phosphoamino acid, requires only a single reaction (thioesterification) beyond standard
SPPS. Importantly, this design allows the incorporation of a variety of probes at the N-
terminus of paxillin. Work is underway toward the construction of a paxillin variant
containing an environment-sensitive fluorophore as a reporter of SH2-domain binding
(with Matthieu Sainlos). Cellular uncaging followed by a fluorescent reporter for binding
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21c
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will allow for time-specific information on the molecular events following
phosphorylation.
The semisynthetic caged phosphoprotein cpY31Pax (21c) can be used to probe
the role of Tyr31 paxillin phosphorylation in the context of the entire paxillin protein
with temporal and spatial control in a cell. The in vitro validation of the binding
interactions and uncaging properties of the probe are detailed in Chapter 4.
Methods
Paxillin(2-26) thioester synthesis (19a, 19b, 19c). Peptides were synthesized manually
and on an automated peptide synthesizer (Advanced ChemTech 396) using standard
Fmoc-based SPPS protocols on preloaded Fmoc-Gly-Novasyn TGT resin
(Novabiochem). Phosphotyrosine was introduced as Fmoc-Tyr(PO(OBzl)OH)-OH, and
caged phosphotyrosine was introduced (manually) as Fmoc-phospho(1-nitrophenylethyl-
2-cyanoethyl)-threonine. Residues Ile18, His l9, and the final four histidine residues of
the hexahistidine tag were always coupled manually. For acetylation of the amino-
terminus of each peptide, 120 pmol of peptide on resin were treated with acetic anhydride
(113 [tL, 1.2 mmol) and pyridine (97 [tL, 1.2 mmol) in 10 mL of DMF for 30 min. The
peptides were individually cleaved from the resin with side-chain protection intact by
agitating with 0.5% TFA in DCM for 1.5 h. The resin was removed by filtration and
rinsed with DCM, the solvent was mostly evaporated under a stream of nitrogen, and the
peptide was triturated with cold hexanes. The hexanes were removed in vacuo, and the
resulting white powder was dissolved in anhydrous THF (50 mL) and treated with HBTU
(180 mg, 480 [tmol), DIPEA (165 [tL, 960 [tmol), and benzylmercaptan (54 JiL, 480
.tmol) under nitrogen overnight. The THF was removed in vacuo and the peptide was
deprotected with 95% (vol/vol) TFA, 2.5% (vol/vol) TIS, and 2.5% (vol/vol) water for 2
h. Peptides were triturated with cold diethyl ether, and purified by reverse phase HPLC
on a Waters 600 instrument with a YMC C18 preparative column, using an elution
gradient of water/acetonitrile with 0.1% TFA. The identities of the peptides as free acids
and of the final peptide thioester products were confirmed by electrospray ionization
(ESI) mass spectrometry on a Perspective Biosystems Mariner Biospectrometry
Workstation (turbo ion source).
Peptide characterization.
Ac-HHHHHHDDLDALLADLESTTSHISKRPVFLSEETP-Y-SYPTG-COOH, Reverse
phase HPLC (tR = 25.4 min). Exact mass calcd for C209H307N59068, 4731.2; found by
MS(ESI), 947.8 [M5H] 5+, 790.0 [M6H]6+.
Ac-HHHHHHDDLDALLADLESTTSHISKRPVFLSEETP-Y-SYPTG-COSBn (19a),
Reverse phase HPLC (tR = 25.7 min). Exact mass calcd for C2 16H3 13N59 0 67S, 4837.3;
found by MS(ESI), 968.7 [M5H] 5+.
Ac-HHHHHHDDLDALLADLESTTSHISKRPVFLSEETP-pY-SYPTG-COOH, Reverse
phase HPLC (tR = 25.4 min). Exact mass calcd for C209H308N590 71P, 4811.2; found by
MS(ESI), 1204.6 [M4H] 4+, 963.9 [M5H] 5
Ac-HHHHHHDDLDALLADLESTTSHISKRPVFLSEETP-pY-SYPTG-COSBn (19b),
Reverse phase HPLC (tR = 25.6 min). Exact mass cald for C216H314N590 70PS, 4917.2;
found by MS(ESI), 1231.9 [M4H]4+, 985.7 [M5H]5+.
Ac-HHHHHHDDLDALLADLESTTSHISKRPVFLSEETP-cpY-SYPTG-COOH,
Reverse phase HPLC (tR = 25.4 min). Exact mass calcd for C217H3 15N 60073P, 4960.3;
found by MS(ESI), 993.1 [M5H] 5÷.
Ac-HHHHHHDDLDALLADLESTTSHISKRPVFLSEETP-cpY-SYPTG-COSBn (19c),
Reverse phase HPLC (tR = 25.7 min). Exact mass calcd for C224H32 1N60 0 72PS, 5066.3;
found by MS(ESI), 1014.9 [M5H] 5+, 845.9 [M6H]6+
Plasmid construction for GST-paxillin(38-557)-FLAG. The gene fragment encoding
residues 38-557 of paxillin (isoform a) was amplified from a paxillin plasmid (supplied
by Professor Martin Schwartz) with primers to insert 5'-EcoR1 and 3'-Notl restriction
sites. The primers also encoded an amino-terminal TEV protease recognition site
(ENLYGQC) and a carboxy-terminal FLAG tag. For this amplification the following
PCR primers were used: 5'- GCC GGA ATT CGT GAA AAC CTG TAT ITT CAG TGC
CAC ACA TAC CAG GAG ATT -3' and 5'- GCC CCC TTT TGC GGC CGC CTA CTT ATC
GTC ATC GTC TIT GTA GTC GCA GAA GAG CTT GAG GAA-3'. The PCR-amplified
fragments were digested with Notl and EcoR1 and ligated to Notl/EcoR1-digested and
CIP-treated pGEX-4T-2 (GE Health Sciences). The ligation mixture was transformed
into DH50x cells and grown on carbenicillin-resistant plates. Plasmid DNA was isolated
from selected colonies and confirmed by sequencing.
GST-paxillin(38-557)-FLAG expression and purification. The paxillin plasmid was
transformed into BL21-CodonPlus®-RP competent cells (Stratagene) and grown with
fermentation at 37 oC to midlog phase in 10 L of LB media with carbenicillin and
chloramphenicol. The culture was cooled to 16 oC, and the cells were induced with 0.1
mM IPTG and fermented for 20 to 24 h. Cells were harvested by centrifugation (4.2 k
rpm for 30 min), and the resulting pellet was frozen at -80 "C. For cell lysis, pellets were
thawed and resuspended in 400 mL of lysis buffer (PBS, 1 mM ZnC12, 1 mg/mL
lysozyme, 1 mM DTT, and 0.1% (vol/vol) of protease inhibitor cocktail III [100 [tM
AEBSF, 80 nM aprotinin, 5 [tM bestatin, 1.5 [M E-64, 2 [iM leupeptin, 1 [LM pepstatin
A] (Calbiochem)) and incubated for 20 min at 4 oC. NP-40 Alternative (1% vol/vol, 4
mL per 400 mL of lysis buffer) was added to the resuspended cells, and the mixture was
agitated at rt for 10m. The lysed cells were sonicated on ice for 3 min at 50% power and
30% duty and then subjected to centrifugation (13,000 rpm for 30 min, then 35,000 rpm
for 30 min).
The soluble fraction was purified using Glutathione Sepharose 4 Fast Flow resin
(GE Health Sciences) following the manufacturer's protocol. Accordingly, the protein
solution was stirred with GST-affinity resin (8 mL) for approximately 1 h at 4 "C. The
resin was washed with PBS (3 x 100 mL), and the GST-tagged protein was eluted by
incubation with elution buffer (50 mM Tris, pH 8, 10 mM reduced glutathione, and 0.1%
(vol/vol) protease inhibitor cocktail III (Calbiochem)) for 3 min at 04 C, followed by
collection of the flow through. For a 10-L preparation, three 8-mL elution fractions were
collected and combined. The protein was dialyzed into TBS (3 x 2 L) using 50-mm flat
width spectra/por membrane (Spectrum), and then purified via the carboxy-terminal tag
with anti-FLAG M2 affinity resin (Sigma) as follows. The dialyzed protein was
incubated with FLAG-affinity resin (3 mL) with gentle agitation at 4 "C, and the resin
was washed with TBS (3 x 30 mL). FLAG-labeled protein was eluted with 1.2-mL
aliquots of 100 mM glycine*HC1, pH 3.5. To each elution was immediately added 160
[tL of 500 mM Tris pH 8.0, and 100 uL of 10 x TBS to neutralize and add salt to the
solution. Typical yields for the doubly-purified protein were 4 to 6 mg per 10-L
fermentation, as quantified using a Biorad protein assay. The protein was analyzed by
10% SDS-PAGE gels, and visualized with Coomassie blue dye and by Western blot with
a mouse anti-FLAG primary antibody.
TEV protease cleavage. The purified protein GST-ENLYFQC-Paxilllin(38-557)-FLAG
(21) was diluted to 0.5 or 1 mg/mL into a TEV cleavage buffer with a final concentration
of 50 mM Tris pH 8.0, 500 tiM EDTA, and 5 mM BME. TEV protease (US Biological)
was added (35 [tL of protease per mg of protein), and the resulting solution was
incubated at 27 'C for 3 h. The protein was dialyzed into TBS (to remove any glycine
present from the FLAG-affinity elution) and incubated with Ni/NTA resin and
glutathione sepharose beads to remove the hexahistidine-tagged TEV protease and the
cleaved GST tag. The flow-through was concentrated using 50 KDa MWCO centrifugal
filters (Millipore) and used immediately in NCL.
Ligations. In general, reactions were carried out with 50 RM protein, 0.8 mM peptide,
and 100 mM MESNA in TBS at pH 8.0. Accordingly, to a solution of Cys-Pax(38-557)-
FLAG (21) (600 jig, 10.7 nmol) in TBS (150 jiL) was added Ac-HHHHHH-
DDLDALLADLESTTSHISKRPVFLSEETP-X-SYPTG-COSBn (lyophilized, then
dissolved into 20 [LL of water for transfer) (800 [tg, 169 nmol for X = Tyr (19a), 163
nmol for X = pTyr (19b), and 158 nmol for X = cpTyr (19c)), 10 [iL of 2 M MESNA,
and 20 [tL of 500 mM Tris pH 8.0. The reaction was incubated for 20 h at 25 oC, then
dialyzed into PBS using a 50-kDa MWCO dialysis membrane to remove excess (4.8 to
5.1 kDa) peptide. Protein was either used directly for assays without a final purification,
or a purified using a Ni/NTA spin column to isolate ligation product via the ligation-
introduced amino-terminal hexahistidine tag. The protein was analyzed by 10% SDS-
PAGE gels, and visualized with Coomassie blue dye, and by Western blot with a mouse
anti-hexahistidine primary antibody. For ligations using 19b, a mouse anti-pY31
antibody was also used for visualization. The purified protein was stored at 4 'C and
used for all in vitro and cellular studies within 2 weeks of lysis and purification. For
longer term storage (up to several months), the protein was stored at 1 mg/mL in PBS
with 20% glycerol at -20 oC.
Acknowledgements: We thank Professor Martin Schwartz for donating the paxillin
construct.
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Chapter 4
In vitro characterization of semisynthetic paxillin analogs and
preliminary cellular studies on adhesion dynamics
Introduction
The properties of the semisynthetic proteins described in Chapter 3, Y31Pax
(21a), pY31Pax (21b), and cpY31Pax (21c) (Fig. 4.1), were characterized through in
vitro binding, phosphorylation, and uncaging studies. Following the in vitro analyses, the
caged phosphoprotein probe 21c was applied in preliminary cellular studies to examine
the influence of Tyr31 paxillin phosphorylation on focal adhesion dynamics in cellular
migration.
NO2
09 O0e.O-P=O O-P=O
31 31
Ac-His LAG Ac-His LAG
21a 21b 21c
Figure 4.1. Semisynthetic paxillin analogs.
In vitro characterization of paxillin analogs
Since paxillin is a molecular adaptor protein with no known enzymatic activity,
direct validation of the functionality of the semisynthetic paxillin derivatives is not
possible by observing reaction turnover. Instead, we examined the properties of the
reconstituted paxillin control, Y31Pax (21a), in vitro by analyzing the ability to bind
known paxillin binding partners and act as a substrate for identified paxillin kinases.
Paxillin-interacting proteins focal adhesion kinase (FAK), GRK interactor 1 (GIT1), and
PTP-PEST were selected to probe binding along the entire length of paxillin. In addition,
the substrate recognition of Y31Pax (21a) by native paxillin kinases was probed with
phosphorylation assays focused on the NCL-introduced N-terminus of paxillin, including
the Tyr31 phosphorylation site (Fig. 4.2). These assays examined the phosphorylation of
paxillin by Src, ERK, and JNK kinases. The binding and phosphorylation experiments
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Figure 4.2. Paxillin with selected binding partners and upstream kinases. Binding
interactions are depicted with solid black lines and phosphorylation is indicated with red
arrows.
confirmed that the semisynthetic reconstituted control, Y31Pax (21a), behaved as
expected, and the function of paxillin was not compromised by the expression or ligation
procedures.
The extent of cpY31Pax (21c) uncaging was quantified following irradiation with
light centered at 365 nm. Close to 90% conversion of 21c to pY31Pax (21b) resulted
from 90 seconds of irradiation on a standard DNA transilluminator. The caged
phosphoprotein probe was then subjected to Crk binding prior to and following uncaging.
The Crk SH2 domain is known to bind paxillin at a site that includes phosphoTyr31, and
the results of the binding assay suggest that 21c effectively exposed a CrkSH2 binding
site after irradiation, resulting in up to a three-fold increase in CrkSH2 binding.
Preliminary cellular focal adhesion experiments
Following the in vitro experiments, cpY31Pax (21c) was used to examine the role
of Tyr31 paxillin phosphorylation on focal adhesion turnover in paxillin-null murine
embryonic fibroblast (MEF) cells. Preliminary experiments were run over a two week
period in the lab of Professor Rick Horwitz (University of Virginia) to assess the
potential of a full investigation and determine the necessary experimental plan and
controls.
Focal adhesions are sites of cellular contact with the extracellular matrix that
facilitate cellular adhesion, migration, and signaling. Adhesions form a physical link
between the external environment and the cytoplasm of a cell, which enables a cell to
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respond to extracellular signals, such as growth factors. Structurally, these cell-matrix
contacts are composed of both structural and signaling proteins, and they include clusters
of integrins, which are heterodimeric transmembrane proteins.' Focal adhesions provide
both rigidity, to enable strong adhesion to the matrix, and plasticity, with the capacity for
rapid formation and disassembly (turnover), to facilitate dynamic cellular responses to
extracellular signals.2 In migrating cells, continuous turnover of focal adhesions occurs
at the leading edge of a cell, and concomitant adhesion disassembly occurs at a cell's
following edge (Fig. 4.3). Adhesion dynamics are tightly regulated, but the process is
currently not well understood and can be difficult to study.3 As discussed in Chapter 3,
paxillin is an adaptor protein that localizes to focal adhesions and mediates protein-
protein signaling interactions. The phosphorylation of paxillin at specific residues creates
protein binding sites and is implicated in the controlled assembly and dissolution of
signaling cascades.4 It has been found that paxillin-null fibroblasts contain abnormal
focal adhesions, suggesting a role for paxillin in adhesion maintenance or turnover.5
direction of cell migration
4
leading edge I
adhesion assembly
and rapid adhesion turnovi
lamel
<ZZJ following edge
adhesion disassembly
(cell protrusions) focal adhesions old adhesion
Figure 4.3. Cartoon of a migrating cell. Adhesions (contacts with the extracellular
matrix) are indicated in red.
In this chapter, we describe the cloning and expression of paxillin-binding
fragments of FAK, GIT1, and PTP-PEST and the results of subsequent binding,
phosphorylation, uncaging, and Crk-association experiments. We also report the
promising results of preliminary focal adhesion turnover experiments using 21c to probe
the effect of Tyr31 paxillin phosphorylation on adhesion dynamics.
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Results and Discussion
4-1. Paxillin binding assays
FAK and GIT are proteins known to bind to the N-terminal LD repeats of paxillin.
FAK, a protein tyrosine kinase, constitutively binds paxillin in vivo, interacting with the
LD2 and LD4 motifs.4 The paxillin-binding region of FAK has been identified by in
vitro deletion analysis to be in the FAK C-terminal domain, within residues 904-1054.6
GIT interacts with the LD4 motif of paxillin, and the 140 C-terminal amino acids of GIT
have been shown to be sufficient for paxillin binding.7 PTP-PEST, a phosphatase, binds
directly to the C-terminal LIM3 and LIM4 domains of paxillin (Fig. 4.2).4 The non-
catalytic C-terminal domain of PTP-PEST has been shown to interact with paxillin in
vitro and in vivo, although the N-terminal 300 residues containing the catalytic domain
have no paxillin association. Deletion constructs have been used to identify the location
of paxillin binding on PTP-PEST to be within residues 300-494.8
For the binding studies presented herein, N-terminal GST tags, which are absent
in the ligated paxillin constructs, were incorporated onto paxillin-binding regions of
FAK, GIT, and PTP-PEST. The three GST-tagged constructs, GST-FAK(857-1057),
GST-GIT(622-761), and GST-PTP-PEST(338-390), were tested for binding with the
semisynthetic Y31Pax (21a) in a modified GST pull-down assay.
Preparation of GST-FAK(857-1053), GST-GIT(622-761), and GST-PTP-PEST(338-390)
Inserts containing the paxillin-interacting regions of FAK and GIT were prepared
for cloning into pGEX-4T-2 GST-fusion vectors using the appropriate primers. After
PCR and cloning, the correct sequences of the isolated plasmid DNA were confirmed by
sequencing, and the vectors were transformed into BL21-CodonPlus®-RP competent cells
for expression of GST-FAK(857-1053) and GST-GIT(622-761). The RP-enhanced cells,
which encode the AGG (Arg), AGA (Arg), and CCC (Pro) tRNAs, were selected to
compensate for the Arg and Pro rare codons present in the FAK and GIT constructs. The
paxillin-interacting region of PTP-PEST was supplied by Professor Mike Schaller in a
vector containing an N-terminal GST fusion to residues 338-390. Isolated DNA from this
vector and an empty pGEX-4T-2 vector were transformed into BL21 CodonPlus®-RIL
cells to produce GST-PTP-PEST(338-390) and GST respectively. Protein expression for
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Figure 4.4. Elutions from GST-affinity purification of a) GST-FAK(857-1053) (49
kDa), b) GST-GIT(622-761) (43 kDa), c) GST-PTP-PEST(338-390) (33 kDa), and d)
GST alone (27 kDa).
all constructs was carried out in LB with the appropriate antibiotics and induced at an
OD600 of 0.6-0.8 with 0.1 mM IPTG followed by four hours of shaking at 37 oC.
The proteins were isolated from their corresponding cell lysates with glutathione
sepharose beads using batch purification and eluted from the resin with 50 mM Tris-HC1,
10 mM reduced glutathione, pH 8.0. Expression yields ranged from 18 to 32 mg/L for
the GST-purified proteins. Coomassie gel analysis indicated the presence of GST, GST-
FAK(857-1053), GST-GIT(622-761), and GST-PTP-PEST(338-390) with calculated
molecular weights of 27, 49, 43, and 33 kDa, respectively (Fig. 4.4). The proteins were
dialyzed into PBS to remove the glutathione prior to the paxillin-binding studies, which
require immobilization on glutathione sepharose beads. The purified proteins were stable
for several weeks when stored at 4 'C, with the exception of GST-FAK(857-1053). The
79 kDa
60 kDa
47 kDa
35 kDa
25 kDa
1 GST-FAK(857-1053)
- GST-FAK(857-1053)
- GST-GIT(622-761) 2 GST alone
3 GST-GIT(622-761)
'- GST-PTP-PEST(338-390)
4 GST-PTP-PEST(338-390)
-GST
1 2 3 4
Figure 4.5. GST and GST fusion proteins, GST-FAK(857-1053), GST-GIT(622-761),
and GST-PTP-PEST(338-390) in PBS, subsequent to 1 week of storage at 4 oC.
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FAK construct partially degraded into two fragments over several days with the
unexplained loss of the GST tag (Fig. 4.5). Complete degradation occurred within
weeks. While there is no obvious mechanism for this cleavage, the unexpected loss of a
GST tag from purified GST-fusion proteins has been observed with other GST-tagged
constructs in the lab.
Y31Pax (21a) binding studies
The three GST-tagged constructs, GST-FAK(857-1057), GST-GIT(622-761), and
GST-PTP-PEST(338-390), were tested for binding with the semisynthetic Y31Pax (21a)
in a modified GST pull-down assay (Fig. 4.6a). The expressed GST tag alone (27 kDa)
was tested as a negative control to rule out non-specific interactions. For this assay, each
of the four proteins was immobilized on glutathione sepharose beads and then incubated
a
21a strip resin
GST-affinity S flo
resin AcH6 Paxin FLAG AcH6- Paxilin FLAG
FAK, GIT or flow
PTP-PEST through probe with an
antihexahistidine
antibody
b
A A
0 1P 0
"0
Figure 4.6. a) In vitro binding assay of semisynthetic paxillin (21a) with a negative
control (GST), and GST-fusions of the paxillin binding regions of FAK, GIT, and PTP-
PEST. The GST and GST fusions were bound to solid support, incubated with 21a,
washed, and then probed for paxillin binding through Western blot analysis. b) An anti-
hexahistidine-probed Western blot of the assay in the absence of ZnCl2 c) An anti-
hexahistidine-probed Western blot of the assay in the presence of ZnC12, including one
lane (as marked) of PTP-PEST incubation in the absence of ZnC12.
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with 21a in the presence of 1% BSA. The beads were copiously washed before being
subjected to Western blot analysis to identify the paxillin containing samples. The
Western blot was probed with an anti-hexahistidine primary antibody to detect the N-
terminal hexahistidine tag of 21a.
Paxillin binding was detected strongly with the FAK and GIT constructs,
negligibly with GST alone, and weakly with the PTP-PEST construct (Fig. 4.6b). Since
PTP-PEST binds at the C-terminal zinc-binding LIM domains of paxillin, we evaluated
whether improper folding of these domains due to insufficient Zn(II) in the purified
construct contributed to the poor PTP-PEST binding characteristics. The addition of
ZnC12 to the paxillin solution significantly increased PTP-PEST binding (Fig. 4.6c). All
subsequent samples of paxillin and semisynthetic paxillin derivatives were purified in the
presence of 1 mM ZnC12. Through these binding experiments, we confirmed that the
semisynthetic paxillin construct interacts with known paxillin binding proteins
comparably to native paxillin.
4-2. In vitro paxillin phosphorylation
Next, to demonstrate that the semisynthetic paxillin analog functioned as a
substrate for selected kinases that natively phosphorylate the protein, phosphorylation of
21a was attempted with three known paxillin kinases and probed with phosphorylation
specific antibodies to four sites within paxillin. Paxillin phosphorylation occurs on
tyrosine, threonine, and serine residues throughout its multiple domains, and kinases that
phosphorylate paxillin include Src, ERK, and JNK.9 Src is a protein tyrosine kinase that
phosphorylates paxillin on Tyr31 and Tyrl18, while ERK and JNK are serine/threonine
kinases that phosphorylate residues Ser126 and Ser178, respectively (Fig. 4.7a). As a
control, and for developing assay conditions for 21a, a full-length paxillin construct
(GST-paxillin(1-557)-FLAG) was expressed and subjected to the kinase assays prior to
the semisynthetic construct.
For the assays, expressed or semisynthetic paxillin was treated with Src, ERK,
and JNK, and the resulting reaction mixtures were visualized by Western blots analysis
using a general anti-paxillin antibody and phosphorylation-specific anti-paxillin [pY31],
[pY118], [pS 126], and [pS 178] antibodies.
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Phosphorylation assays with expressed full-length paxillin
An expressed paxillin construct was used in the kinase assays to establish
appropriate in vitro phosphorylation and chemiluminescent detection conditions. Full-
length paxillin (GST-Pax(1-557)-FLAG) was expressed in BL21-CodonPlus®-RP
competent cells and purified by GST-affinity and FLAG-affinity columns (yield: 5 mg/10
L expression). Following a generic phosphorylation procedure, paxillin was treated with
recombinant human active c-Src, ERK2, or JNK2a2 kinase (Biosource) in the presence
of 15 mM MgC12 and 50 to 500 [tM ATP in TBS. A negative control was run in which
paxillin was subjected to the reaction conditions in the absence of a kinase. For
chemiluminescent detection of paxillin, it was determined that 5 to 20 ng per well of
protein was sufficient for detection by anti-paxillin and phosphospecific anti-paxillin
[pY31] or [pY118] primary antibodies, using HRP-conjugated secondary antibodies. The
less-sensitive anti-paxillin [pS126] and [pS178] antibodies required 200-300 ng of
paxillin per well for visualization. Freshly lysed and purified paxillin was used for all
phosphorylation assays.
As expected, detection of Tyr31 and Tyrll8 phosphorylation in full-length
paxillin was possible only after treatment with Src. Similarly, Ser126 was
phosphorylated exclusively by ERK (Fig. 4.7b). However, Ser178 phosphorylation
could not be detected after incubation with any of the kinases, including JNK2a2. DNA
sequencing confirmed that the primary paxillin sequence was correct, ruling out the
possibility of a mutation at Ser178 or a surrounding residue as the culprit for preventing
JNK2a2 phosphorylation.
A number of conditions were explored in further attempts to achieve Ser178
phosphorylation. While JNK2a2 has been shown by Biosource to phosphorylate paxillin
in vivo, no in vitro assays have yet been reported. However, JNK1 has been used in vitro
to successfully phosphorylate paxillin, so those conditions, which include the addition of
1 mM DTT and 5 mM EGTA, were tested with JNK2a2. Neither the modified
conditions, nor an increase in the amount of kinase by four fold resulted in detectible
levels of phosphorylation. Since JNK1 phosphorylation had been described in the
context of in vitro experiments, JNKlal (Upstate) was obtained and tested, and it was
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found to phosphorylate paxillin exclusively at Ser178 (Fig. 4.7b). This result could be an
indication of differing substrate recognition between the two isoforms of JNK or could
have simply been caused by a poor commercial preparation of JNK2a02.
Src EIRK2 JNK
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anti-paxillin(pan)
anti-pY31 Pax
anti-pY118 Pax
anti-pS126 Pax
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Figure 4.7. a) Paxillin kinases Src, ERK, and JNK. Phosphorylation sites are indicated
by red arrows. Phosphorylation of b) expressed full-length paxillin and c) semisynthetic
Y31Pax (21a) by Src, ERK, and JNK, and visualized by phospho-specific antibodies to
paxillin[pY31], [pY118], [pS126], and [pS128]. The reactions were also probed with a
general anti-paxillin (pan) antibody to demonstrate comparable loading. (-) indicates the
negative control treated with no kinase.
Phosphorylation assays with semisynthetic paxillin
With phosphorylation and detection conditions established for Src, ERK, and JNK
phosphorylation of expressed full-length paxillin, the assays were repeated using the
semisynthetic paxillin construct Y31Pax (21a). Considering the extremely high
sensitivity of chemiluminescent detection, it was encouraging that visualization of ligated
109
Y31 Y11e .S126 •;17e
paxillin (Y31Pax) with the anti-paxillin pan antibody resulted in a clean gel containing
one major band for the ligated paxillin, no detectible band for uncleaved protein (GST-
ENLYFQ-Cys-Pax(38-557)-FLAG), and only a light band for unligated material (Cys-
Pax(38-557) (Fig. 4.8).
Probing each kinase reaction with all five antibodies revealed that residues Tyr31
and Tyrll8 of 21a were phosphorylated exclusively by Src, that residue Ser126 was
phosphorylated only by ERK, and that residue Ser178 was phosphorylated only by JNK
(Fig. 4.7c). The pan paxillin antibody recognized protein in all reactions. Detection of
Src-treated 21a by the pTyr31 phosphorylation-specific antibody validated both the
successful ligation to install the Tyr31 site and the recognition of that site by an upstream
kinase. The identical results for the kinase assays with expressed and semisynthetic
paxillin, as well as the agreement with in vivo and in vitro reports of paxillin
phosphorylation, further confirmed that the semisynthetic proteins behave comparably to
native paxillin.
GST-Paxillin(38-557)-FLAG (20)
Ac-HHHHHH-Paxillin(2-557)-FLAG (21a)
Cys-Paxillin(38-557)-FLAG (19)
1 2
Figure 4.8. Chemiluminescent detection of lane 1) ligated paxillin, 21a, (61 kDa) and
lane 2) GST-Pax(38-557)-FLAG (20) (83 kDa). The blot was probed with a general
mouse anti-paxillin primary antibody.
4-3. Uncaging of cpY31 paxillin
Irradiation of NPE-caged phosphopeptides with long wavelength UV light (> 365
nm) to reveal the corresponding phosphopeptides has been shown to proceed with high
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quantum yields for uncaging, ranging from 0.16 to 0.5, depending on the peptide
sequence. 10 Importantly for cellular applications, the photo-byproduct of NPE-caged
species, o-nitrosoacetophenone, has previously been shown to be cellularly-inert. 11,12
This by-product is less reactive than the analogous o-nitrosobenzaldehyde produced by
irradiation of widely-used ortho-nitrobenzyl-derived caging groups. 13 To ensure that
cpY31Pax (21c) uncaging proceeded efficiently, the extent of uncaging of the ligated
protein was determined following irradiation with a standard DNA transilluminator (Fig.
4.9). In brief, cpY31Pax (21c) was irradiated for 90 seconds with light centered at X =
365 nm. The amount of phosphorylated paxillin (pY31Pax) liberated at t = 0 and t = 90
seconds post photolysis was measured by chemiluminescent detection of the
phosphorylated protein. The phosphorylated species was detected using a paxillin
a b
G
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Figure 4.9. a) Irradiation of cpY31Pax (21c) with 365 nm light releases the caging
group to reveal pY31Pax. b) Western blot analysis with a general anti-paxillin(pan)
antibody and a phosphospecific anti-paxillin[pY31] antibody of 21c prior to irradiation
and following irradiation for 90 s with 365 nm light. c) To quantify uncaging, Western
blots probed with anti-paxillin(pan) and anti[pY3l]paxillin antibodies were visualized by
chemiluminescent detection. Pixel counts are shown in bold below each lane. The gels
include (B1) a blank lane, (U3) semisynthetic pY31Pax (21b) as a standard for pixel
counts, (U2) irradiated 21c, and (Ul) non-irradiated 21c.
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[pY31] phosphorylation-specific antibody. The total amount of protein loaded on the
Western blots was detected using a general anti-paxillin antibody. In addition,
semisynthetic pY31 (21b) was used as a photochemically inert internal standard in the
phosphorylation-specific and general paxillin Western blots. The relative intensity of the
sample at t = 0 and t = 90 seconds was determined for each Western blot as a fraction of
total pixels compared to the internal pY31Pax (21b) standard (Fig. 4.9c). The ratio of
intesity between the phosphospecific and general paxillin blots was determined to
calculate the extent of uncaging. The ratio of uncaged phosphopaxillin to the total
protein amount indicated between 83 and 91% conversion to phosphoTyr31-paxillin. A
minimal amount of uncaged phosphoprotein, typically less than 6% of the total protein,
was detected in the absence of intentional irradiation using minimal precautions against
UV light exposure. A sample uncaging calculation using the Western blot shown in Fig.
4.9 is included in the Methods section.
4-4. Phosphorylation-dependant Crk binding
The SH2 domain of Crk, which recognizes a (Pro)-pTyr-X-X-Pro binding motif,
has been shown to interact with paxillin following phosphorylation at Tyr31 or Tyrl 18 in
vivo. 14,15 The effect of a concentration burst of pTyr31-paxillin on CrkSH2 binding, was
investigated using the caged paxillin probe. Accordingly, the CrkSH2-binding ability of
cpY31Pax (21c) was examined prior to and following uncaging.
As with the FAK, GIT and PTP-PEST binding studies, a CrkSH2 domain with an
N-terminal GST tag was immobilized on glutathione sepharose beads. The beads were
incubated with cpY31Pax (21c) with 1% BSA, either prior to or following 90 seconds of
irradiation with light centered at 365 nm. The beads were washed and boiled in reducing
gel loading buffer, and Western blots probed with an anti-hexahistidine primary antibody
were used to identify paxillin-containing samples. Crk binding was detected up to three-
fold more strongly with uncaged paxillin than with the caged construct (Fig. 4.10),
demonstrating the ability of cpY31Pax to release the corresponding phosphorylated
protein and enhance a downstream molecular interaction. Interestingly, the binding
difference was less pronounced in slightly modified assay conditions. These results
suggest the paxillin-Crk binding interaction is more complicated than an "on/off" event.
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Figure 4.10. Western blot analysis of an in vitro binding assay between the Crk SH2
domain and cpY31 paxillin (21c) prior to and following irradiation. GST-CrkSH2 was
bound to GST resin, incubated with 21c either prior to (lane 1) or following (lane 2)
irradiation for 90 s with 365 nm light. The resin was washed copiously and probed with
an anti-hexahistidine primary antibody to visualize bound paxillin.
4-5. Focal adhesion turnover assays (with Dr. Steve Pratt, UVa)
Next, cpY31Pax (21c) was used to examine the role of Tyr31 paxillin
phosphorylation on focal adhesion turnover in paxillin-null MEF cells. Preliminary
experiments were carried out to assess whether phosphorylation at that site influenced
adhesion dynamics. In collaboration with Professor Rick Horwitz' lab at UVa, we
looked for a difference in the half life (tl/2) of adhesion formation or disassembly in
paxillin null cells microinjected with cpY31Pax (21c) prior to and following irradiation
centered at k = 365 nm. In a two week stay in the Horwitz lab, we were able to optimize
a number of assay conditions, including the cell type, the choice of fluorescent marker,
and the general protocol for cell plating and microinjection with the paxillin proteins.
We then ran one to two trials of the focal adhesion assay each with 21b, and caged and
uncaged 21c.
Focal adhesion turnover was observed using total internal reflection fluorescence
(TIRF) microscopy to monitor GFP-labeled vinculin, which was transfected into cells, as
a marker of focal adhesions. Vinculin is a structural protein that localizes to focal
adhesions, and the use of fluorescently labeled vinculin has been reported for focal
adhesion visualization. 16 The intensity of the focal adhesions over time was quantified
using ImageJ software to determine a t11/2 of assembly.
For these assays, we examined the focal adhesion dynamics of MEF cells injected
with pY31Pax (21b), and with cpY31Pax (21c) prior to and following global irradiation.
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Paxillin-null MEF cells were transfected with GFP-vinculin and plated on fibronectin-
coated plates to provide a surface for the fibroblasts to spread. The plated cells were
microinjected (typically 20 cells per plate) with 21b or 21c in a solution containing red
dextran for visual identification of injected cells. For the uncaging experiment, the entire
plate was irradiated with light centered at . = 365 nm for 60 seconds on a standard DNA
transilluminator following microinjection with 21c. Cells containing both GFP and red
dextran, indicating the presence of both the focal adhesion marker and microinjected
protein, were selected for observation. Time-lapse fluorescence imaging was carried out
for 15 to 30 minutes per cell on a TIRF microscope. Since MEF cells typically migrate
for less than two hours after plating, only one to two cells from each plate were imaged.
The focal adhesion assay is illustrated with 21c-injected and uncaged cells in Fig. 4.11.
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) O (focal adhesion marker)
paxillin -/-
MEF cells
0
identify cells with
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image individual cells and
observe focal adhesion dynamics [21b]
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365 nm
1k
[21c]
Figure 4.11. Assay protocol to probe the effect of Tyr31-paxillin phosphorylation on
focal adhesion dynamics.
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In cells microinjected with cpY31Pax (21c) and observed prior to uncaging, focal
adhesions could be identified, but no new protrusions or focal adhesions formed, and
there was no adhesion turn over. These observations were consistent with the phenotype
of non-injected paxillin-null cells. However, after global uncaging, new protrusions
formed, and focal adhesion formation and turnover was detectible in the protrusive areas.
Similar adhesion turnover was visible in cells injected with pY31Pax (21b) (Fig. 4.12a).
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Figure 4.12. a) Snapshots from focal adhesion movies of MEF cells at time t= 0 and t =
20 minutes of imaging. The microscope imaged GFP-vinculin as a marker of focal
adhesions. Boxes indicate protrusive areas with focal adhesion turnover. B) Graph of
pixel intensity over time for a single focal adhesion with a pY31Pax (21b) microinjected
cell. C) Graph of LN(I/Ifinal) over time, where I = pixel intensity for adhesion
formation. The slope from this graph indicates a tl/2 assembly = LN(2)/0.003 = 231
seconds (3.9 minutes).
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The half life of focal adhesion formation was calculated for several adhesions in the
imaged cells (Fig. 4.12b,c). While too few cells were imaged and adhesions analyzed to
draw statistically significant conclusions, the preliminary data suggests a half life of focal
adhesion formation of 3 to 5 minutes for the cells injected with pY31Pax (21b) or with
cpY31Pax (21c) followed by uncaging. Confirmation of those results would suggest that
phosphorylation at tyrosine 31 is essential for rescuing the adhesion turnover capacity of
the cells.
Future experiments
Based on the promising results from our initial investigations, the following set of
experiments and controls has been planned: 1) performing localized irradiation on
individual cells, 2) imaging a statistically significant number of cells and adhesions for
analysis, and 3) repeating the experiment with controls to standardize the influence of
protein microinjection using expressed full-length paxillin, and Y31F and Y31E paxillin
mutants.
The initial adhesion turnover experiments using cells injected with 21c were
carried out with global uncaging, meaning the entire plate of cells was irradiated prior to
imaging. Future experiments, in contrast, will be performed with local uncaging, using a
laser set up on the TIRF microscope to irradiate an individual cell or subcellular location.
This will enable spatial and temporal information, which was not possible with the
preliminary global uncaging experiments, by allowing comparison of the adhesion
turnover in a single cell prior to and following irradiation and enabling comparison of the
effect of a concentration burst of phosphoprotein between, for example, the leading edge
versus the central region of a cell. In addition, local uncaging will provide a powerful
internal control, since a specific cell can be imaged immediately preceding and
immediately following 21c uncaging. The chance of locating an identical cell prior to
and following global irradiation is very low, since there are hundreds of cells per plate.
In collaboration with Dr. Steve Pratt in the Horwitz lab (UVa), the adhesion
turnover assay will be repeated using laser-mediated uncaging with at least 5 separate
cells to analyze a total of 15 to 30 adhesions. This number is based on related study of
focal adhesion dynamics from the Horwitz lab, 16 and should provide sufficient data to
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draw statistically significant conclusions. The semisynthetic strategy used to construct
21c allowed access to milligram quantities of material, which are sufficient for hundreds
of cell experiments.
Finally, the adhesion assay will be repeated using expressed paxillin controls,
full-length paxillin, Y31F paxillin, and Y31E paxillin. Since the focal adhesion assay
used here has previously been run exclusively with transfected cells, the controls will
allow further investigation of any complications with the microinjection and provide
more traditional biological controls. Mutants with a Tyr to Phe substitution are often
used as phosphorylation-resistant protein mimics. Similarly, Ser to Asp or Ser to Glu
substitutions are used to mimic constitutively phosphorylated Ser residues. The Y31E
paxillin mutant was requested by Professor Horwitz as a possible phosphoTyr31 mimic,
since there is no isosteric option from the 20 natural amino acids. Toward that end, two
paxillin mutants were constructed, GST-ENLYFQ-Gly-Pax(l-557, Y31F)-FLAG, and
GST-ENLYFQ-Gly-Pax(1-557, Y31F)-FLAG. The proteins were expressed, as
described for 20 (Chapter 3) and treated with TEV protease to remove the 27-kDa GST
tag. The resulting proteins, Y31F-FLAG and Y31E-FLAG will be used as described for
21b in the focal adhesion assay.
The outlined experiments should provide sufficient data for dissecting the
individual effect of Tyr31-paxillin phosphorylation on focal adhesion turnover in MEF
cells, with specific temporal and spatial information.
Conclusion
Binding and phosphorylation studies with 21a, including FAK, GIT and PTP-
PEST binding, and phosphorylation by Src, ERK, and JNK, confirm that the
semisynthetic paxillin derivatives function comparably in vitro to native paxillin.
Uncaging and CrkSH2 binding experiments with the semisynthetic caged phosphoprotein
cpY31Pax (21c) verify that the probe releases phosphoTyr31 paxillin upon irradiation
and creates a CrkSH2 binding platform for increased association with Crk. Therefore,
the semisynthetic probe enables the isolated investigation of a single phosphorylation site
in the context of the entire paxillin protein. Apart from residue 31, all phosphorylation
and binding sites can participate in signaling and localization as with native paxillin.
117
Following the in vitro characterization described in this chapter, 21c was used to
investigate the influence of paxillin phosphorylation on focal adhesion turnover in
paxillin-null MEF cells. Preliminary results from the adhesion turnover experiments
suggest a crucial role for tyrosine 31 phosphorylation in focal adhesion dynamics.
Ongoing experiments will provide time- and location-specific information on the
downstream effects of tyrosine 31 phosphorylation. Further, the probe can be applied to
additional in vivo assays to investigate other aspects of cellular migration.
Methods
Cloning of GIT(622-761) into pGEX-4T-2. A kan-resistant GIT construct (supplied by
Rick Horwitz) was transformed into DH5cc cells and grown up on an LB-kan agar plate.
Several colonies were selected and grown up in 3 mL of LB-kan overnight with shaking
at 37 oC. The plasmids from these cultures were isolated using a perfect prep plasmid
mini kit (Eppendorf) following the manufacturer's instructions. G1T(622-761) was
amplified from the plasmid DNA from a single miniprep using primers to introduce a 5'
EcoR1 site and a 3' Not site for incorporation into a pGEX-4T-2 vector, which provides
an N-terminal glutathione S-transferase (GST) moiety. For this amplification the
following primers were used: FORGIT121804: 5'- GCC GGA ATT CGT GAA GAC TTC
CAC CCA GAG CTG GAA AGC -3' and BACGIT121804: 5'- GCC CCC TTT TGC GGC
CGC TCA CTG CTT CTT CTC TCG GGT GGT GAT GGT-3' (Invitrogen). Five 50-gL PCR
reactions were run, each with 40 gLL sterile DI water, 5 gL 10X Taq HIFI buffer, 0.35 tL
100 mM dNTPs, 2 ýJL 50 mM MgCl 2, 0.65 glg each of FORGIT121804 and
BACGIT121804, 0.7 tiL of GIT miniprep A DNA template, and 0.5 [tL of Taq HIFI
(added last). The reactions were run in the thermal cycler as depicted below:
X2 X2 X2 X2 X2 X2 X25
94 94 '94 j94 :94 9494
3 min :30 72 72 72 72 72 72 :30 72 72
1:0063 _F0 61 59 58 56 55 54
:45 :45 4
The purified GIT insert and a pGEX-4T-2 vector were digested with EcoR1 and
Notl. To 43.5 gLL of purified PCR product in EB were added 5.0 jgL 10X EcoR1 buffer,
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0.5 pLL 100X BSA, and 2.5 gL Notl. The digestion was incubated overnight at rt, 2.5 giL
of EcoR1 were added, and the mixture was further incubated for 1 hour at 37 oC. To this
solution was then added 12.5 IiL 5X nucleic acid loading buffer, and the digested insert
was electrophoresed on a 1.5% agarose DNA gel for purification. For the pGEX-4T-2
vector digestion, 750 ng of vector (10 [tL) were combined with 5.0 tL 10X EcoR1
buffer, 0.5 jiL 100X BSA, 29.5 pgL sterile water, and 2.5 giL Notl, and the mixture was
incubated overnight at rt. EcoR1 (2.5 tL ) was added, and the mixture was incubated as
described for the purified PCR product. The enzymes were deactivated by heating for 20
min at 65 'C, and 15 jtL of CIP was subsequently added to the vector digestion and
incubated for 1 hour at 37 OC. To the solution was then added 12.5 giL of 5X nucleic acid
loading buffer, and the cut/CIP-treated vector was electrophoresed on a 1.5% agarose gel.
The vector and insert were excised and purified with a gel extraction kit (Qiagen). The
DNA was eluted with 30 CpL of sterile water and used directly in ligations without further
concentration. DNA not immediately ligated was stored at -20 oC.
Ligation of the GIT(622-761) insert into the pGEX-4T-2 vector was accomplished
by combining 3 giL vector, 5 gLL PCR insert, 1 IiL T4 ligase, and 1 giL 10X T4 ligase
buffer in a sterile eppendorf. The tube was gently flicked, then incubated overnight
(although 2-3 h should be sufficient) at room temperature. A vector-only control ligation
was also performed using 3 gL vector, 1 giL T4 ligase, 1 IiL 10X T4 ligase buffer, and 5
pL sterile water. The mixtures were placed on ice and used immediately for
transformation into MAX Efficiency DH5a chemically competent cells.
Cloning of FAK(857-1053) into pGEX-4T-2. An amp-resistant FAK construct (donated
by Tom Parson) was transformed into DH5a cells and grown up on an LB-carbenicillin
agar plate. Several colonies were selected and grown up in 3 mL of LB-carbenicillin
overnight with shaking at 37 TC. The plasmids from these cultures were isolated using a
perfect prep plasmid mini kit (Eppendorf). FAK(857-1053) was amplified from plasmid
DNA with PCR using the following primers to introduce a 5' EcoR1 site and a 3' NOT1
site for incorporation into a pGEX-4T-2 vector: FORFAK121804: 5'- GCC GGA ATT
CGT GCT GGT AAC CAG CAC ATA TAT CAG CCT -3' and BACFAK121804: 5'-
GCC CCC TTT TGC GGC CGC TTA GTG GGG CCT GGA CTG GCT GAT CAT
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TTT-3' (Invitrogen). The PCR-amplified fragment was digested with EcoR1 and Notl
and ligated to the EcoR1/Notl digested and CIP-treated pGEX-4T-2 vector as described
above with GIT.
Transformation of GIT and FAK constructs into DH5a cells. A 90-[1L aliquot of MAX
Efficiency DH5a chemically competent cells was thawed on ice. The cells were mixed
gently with a pipette, and 30-gpL aliquots were transferred into each of 3 pre-chilled
Falcon tubes. As a positive control, 1 gL (10 pg) of supplied pUC19 DNA was added to
one of the Falcon tubes and carefully mixed by flicking. To the remaining two Falcon
tubes were added 1 gLL of the GST-GIT(622-761) or GST-FAK(857-1053) ligation
mixtures. After gentle tapping, the cells were incubated on ice for 30 min, heat shocked
in a 42 oC water bath for exactly 45 seconds and placed on ice for 2 min. Room
temperature SOC media (0.27 mL) was added to each tube, and the tubes were incubated
at 37 OC for one hour. 100 pgL of each sample were spread onto separate LB-carbenicillin
agar plates along with enough SOC media to bring the final volume to 100 gL. The
plates were incubated at 37 oC overnight and stored at 4 OC. Hundreds of colonies grew
up on the positive control, on the FAK, and 30 on the GIT vector/insert ligation plates.
To screen the transformants, five colonies were selected from each plate and
grown up in 3 mL of LB-carbenicillin overnight with shaking at 37 OC. The plasmids
from these cultures were isolated using plasmid mini kit. The isolated plasmids were
then screened for the presence of GIT(622-761) or FAK(857-1053) with Not/EcoR1
digestion to excise the 423 and 594 bp insertions. The constructs were then confirmed by
DNA sequencing. For each submission, the following was added to a 600-[tL eppendorf
tube: 0.62 [tL (3.2 pmol) of 5' pGEX primer, 6 gtL (estimated between 200-500 ng) of a
GIT or FAK miniprepped DNA, and 5.36 giL sterile water.
Preparation of GST-PTP-PEST(338-390) for transformation and expression. A stab
culture of pGEX PTP-PEST(338-390) in amp-resistant DH5a cells (donated by Mike
Schaller) was grown up in LB with carbenicillin and then reselected on an
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LB/carbenicillin plate at 370 C for 16 h. Hundreds of colonies grew up, and two were
selected and miniprepped for subsequent transformation into an expression cell line.
Expression and GST-affinity purification of GST, GST-GIT(622-761), GST-FAK(857-
1057), and GST-PTP-PEST(338-390). The isolated plasmids from an empty pGEX-4T-2
vector, and from GIT, FAK and PTP-PEST minipreps were transformed into BL21-
CodonPlus®-RP or RIL competent cells (Stratagene) and grown to midlog phase in 1 L of
LB media with carbenicillin and chloramphenicol at 37 'C. The cells were induced with
0.1 mM IPTG, and protein expression proceeded for 4 hours at 37 'C. Cells were
harvested by centrifugation, and the pellets (ranging from 6 to 9 g) were stored at -80 oC.
For cell lysis, pellets were thawed and resuspended in 35 mL of lysis buffer (PBS, 1
mg/mL lysozyme, 1 mM DTT, and protease cocktail III [100 tM AEBSF, 80 nM
aprotinin, 5 giM bestatin, 1.5 [tM E-64, 2 jiM leupeptin, 1 [iM pepstatin A]
(Calbiochem))and incubated for 20 min. at 4 oC. The cells were lysed with 1% NP-40
alternative, then sonicated and subjected to centrifugation at 13,000 rpm for 30 min,
followed by 35,000 rpm for 30 min or by filtration through a 0.2 micron filter.
The soluble fraction for each protein was purified using Glutathione Sepharose 4
Fast Flow resin (Amersham Biosciences). Each protein solution was incubated with 3
mL of resin at 4 'C for 1 hour. The resin was washed with cold PBS (150 mL), and four
3-mL elutions were collected. For each elution, the resin was incubated with 10 mM
glutathione in 50 mM Tris, pH 8.0 for 3-5 min at rt. Elutions for each protein were
combined and dialyzed into PBS for subsequent binding studies. The proteins were
analyzed by 10% SDS-PAGE gels and visualized with Coomassie blue dye. The purified
protein was stored at 4 'C and used within three weeks of purification.
GST pull-downs of AcHis6-Pax(2-557)-FLAG, with FAK, GIT, PTP-PEST, and GST.
Glutathione sepharose beads were loaded with GST-FAK(857-1053), GST-GIT(622-
761), GST-PTP-PEST(338-390), and GST by incubating 50 [L of resin (maximum
binding capacity = 500 jg) in each of 4 1.5-mL eppendorf tubes with 1 mg of protein
(500 jiL of 2 mg/mL solutions) in PBS for 30 min. The tubes were sedimented by
centrifugation at 1000 g, and the supernatant was discarded. The resin was washed with
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3 x 500 tL of PBS. To each tube was added semi-synthetic Y31Pax (- 200 [tg) in 600
tiL of PBS with 1% BSA. The mixture was agitated for 1 hour, and the glutathione
sepharose beads were sedimented by centrifugation. The resin was washed with PBS (3
x 500 [IL) and boiled in 2X SDS reducing gel loading buffer (100 !tL). The samples
were analyzed by 10% SDS-PAGE gels, and visualized by Western blot analysis with a
mouse anti-hexahistidine primary antibody and a goat anti-rabbit alkaline phosphatase
secondary antibody.
Src, ERK, and JNK phosphorylation of expressed and semisynthetic paxillin (21c). For
the kinase assays, all kinases were stored in 1 to 4 gL aliquots at -80 oC. The kinases
(Biosource) were used as described below: Src (PHO3114), ERK2(PHO3104),
JNK2a2(PHO3014), and JNKlal (Upstate). For long term storage 2.66 M MgCl2 was
kept at room temperature in a 0.1 M HCI solution to prevent crashing out. Prior to use, a
1/10 dilution was prepared in TBS.
To 2 Ig of paxillin was added 8 gpL of 1 mM ATP (200 p.M final concentration),
2.25 pgL of 226 mM MgCl 2 (15 mM final concentration), and 1.5 gpL c-Src (450 units), or
4 pLL ERK2 (148 units), or 2 pL of JNK (128 units). TBS, pH 7.5, was added to a final
volume of 40 gL, and the contents were mixed by pipetting seven times and gently
flicking. The reaction was incubated for 15 min at 30 oC and quenched with the addition
of 40 plL of 2X SDS reducing gel loading buffer to give a final substrate concentration of
25 ng/p.L. A 1/5 dilution of this solution was prepared for the more sensitive Western
blots. For detection by pan and pY-specific antibodies, 20 to 30 ng (4 to 6 p.L of the 1/5
dilution) were loaded per well. For detection by pSer-specific antibodies, 250 ng of
substrate (10 RLL) were loaded per well. Gels were run on a 10% PAGE at 140V for
about 2 hours before being transferred to nitrocellulose.
Western blotting for chemiluminescent detection. The following primary and secondary
antibodies (Biosource) were used to probe for various sites of paxillin phosphorylation:
mouse (monoclonal) anti-human paxillin (AH00492), rabbit (polyclonal) anti-
paxillin[pY31] (44-720G), rabbit (polyclonal) anti-paxillin[pY118] (Biosource), rabbit
(polyclonal) anti-paxillin[pS126] (44-1022G), rabbit (polyclonal) anti-paxillin[pS178]
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(44-1026G), goat anti-rabbit HRP conjugate (ALI3403), and goat anti-mouse HRP
conjugate (AMI4404).
Each Western blot nitrocellulose membrane was blocked for 1.5 to 2 hours at RT
with Superblock (Pierce) with 0.05% Tween-20 and washed three times with 20 mL of
TBST for 5 min. each. The membrane was then incubated with a pan (1/1,000 dilution)
or phospho-specific (1/2,000 dilution) paxillin primary antibody in TBST for 1 hour at
RT. The membrane was rinsed with 5 x 5 minute washes of TBST. A goat anti-mouse
(1/10,00 dilution) or goat anti-rabbit (1/20,000 dilution) HRP-conjugated secondary
antibody in TBST was incubated with the membrane for 1 hour at RT. The membrane
was rinsed again with 5 x 5 min. washes of TBST. Supersignal west chemiluminescent
substrate (Pierce, 34080) was added in a sufficient amount to fully cover the block (about
5 mL per blot) and incubated for 3 to 5 min. The chemiluminescent substrate was
decanted, and the corner of the membrane was touched onto a paper towel to remove as
much of the reagent as possible. The membrane was placed into a clear plastic pocket
and exposed for 3 to 5 minutes.
Uncaging calculations. For uncaging quantification, a 1.2 mg/mL solution of cpY31Pax
(21c) in TBS with 2.5 mM DTT was irradiated for 90 s in a glass cell (pathlegnth 1 mm)
at 365 nm with an intensity of 7,330 [tW/cm 2 on a DNA transilluminator. Semisynthetic
pY31Pax (21b) and equal amounts of caged and uncaged protein were run on 10% SDS
gels and transferred to nitrocellulose. Western blots were developed with mouse
(monoclonal) anti-human paxillin and phosphospecific rabbit (polyclonal) anti-
paxillin[pY31] primary antibodies and visualized by chemiluminescence. Pixel counting
was used to calculate the relative amount, compared to a pY31Pax (21b) standard, of
phosphoprotein at t = 0 and t = 90 seconds after uncaging of cpY31Pax (21c). A sample
calculation is shown below with data from the Western blot shown in Fig. 4.9c.
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% uncaged = normalized intensity of total pY3 Ipaxillin detected
normalized intensity of total paxillin detected
% of pY31Pax uncaged at t = 0 seconds = 0.040/0.619 = 0.06 = 6%
% of pY31Pax uncaged at t = 90 seconds = 0.524/0.599 = 0.87 = 87%
Data table for the anti-paxillin (pan) probed Western blot
Pixel count Pixel count - blank normalized intensity
Blank (B1) 2211 -
pY31Pax (U3) 7711 5500 1
cpY31Pax, t = 90 (U2) 5508 3297 0.599
cpY31Pax, t = 0 (U1) 5615 3404 0.619
Data table for the anti-[pY31]paxillin (phosphospecific) probed Western blot
Pixel count Pixel count - blank normalized brightness
Blank (B1) 2272
pY31Pax (U3) 10650 8378 1
cpY31Pax, t = 90 (U2) 6660 4388 0.524
cpY31Pax, t = 0 (U1) 2609 337 0.040
Crk-Binding Assay. Glutathione sepharose beads were loaded with GST-CrkSH2 by
incubating 40 tiL of resin (maximum binding capacity = 400 [ig) in two 1.5-mL
eppendorf tubes with 500 gLg each of GST-CrkSH2 (1.2 mL) in PBS for 1 hour. The
supernatant was discarded, and the resin was washed with PBS (3 x 1.2 mL).
Meanwhile, 35 [tg of cpY31Pax (21c) in PBS (100 jtL) with 5 mM DTT was irradiated
with light centered at 365 nm in a 1 mm glass cell on a DNA transilluminator for 90 s.
The solution was diluted to a final volume of 1.2 mL PBS with 1% BSA. A second
sample of cpY31Pax was prepared identically but was spared the UV irradiation. The
GST-CrkSH2-loaded resin was incubated with either the caged or uncaged 21c solution
for 2 h. The paxillin solution was removed, and the resin was washed with PBS (2 x 1.3
mL) prior to being boiled in 2X SDS reducing gel loading buffer (100 [iL). The samples
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were analyzed by 10% SDS-PAGE gels and visualized by Western blot analysis probed
with a mouse anti-hexahistidine primary antibody and a goat anti-rabbit alkaline
phosphatase secondary antibody.
Transfection with GFP-vinculin. Paxillin-null MEF cells were provided by the Horwitz
lab (University of Virginia). For transfection, a GFP-vinculin construct (1.5 igL of a 0.7
mg/mL solution) was re-suspended by tapping and added to a 1.5-mL eppendorf tube.
Pre-warmed Opti-MEM-1 reduced serum media (100 QL), and liptofectamine (5 gL )
were added, and the mixture was flicked to mix. Following incubation at rt for 30 to 60
min, additional Opti-MEM-1 reduced serum media (900 gL) was added. Paxillin-null
MEF cells were removed from incubation at 37 'C and washed twice with Opti-MEM-1
reduced serum media. The media was removed from the cell plates, and 1 mL of the
DNA mixture was slowly added drop-by-drop over the MEFs. The cells were incubated
for 3 hours at 37 'C and washed with complete media. The cells were then incubated
overnight in complete media (3 mL) and used within 24 to 36 hours.
Focal adhesion dynamics assay. Paxillin-null MEF cells transfected with GFP-vinculin
were plated on fibronectin-coated tissue culture dishes. In brief, the cells were washed
with PBS, and trypsin/EDTA (0.75 mL) was added to the cells and incubated for 5 min at
37 'C. Meanwhile, Opti-MEM complete media (2 mL) was added to a fibronectin-coated
(1 gg/mL) glass-bottomed plate. Complete media (4 mL) was added to the cells, and 1/5
of the total volume of cells in media was added to the fibronectin-coated plate. The
plated cells were incubated at 37 'C for 20 to minutes, and then 20 to 30 cells per plate
were microinjected with pY31Pax (21b) or cpY31Pax (21c) (0.5 mg/mL) in PBS with red
dextran. All microinjection was performed by Brian Hall in the (Schwartz lab,
University of Virginia). Microinjection typically lasted 20 to 30 min. The cell media
was exchanged with fresh Opti-MEM complete media, and the cells were either observed
immediately or first irradiated for 60 sec on a standard DNA transilluminator (7,330
jtW/cm 2) with light centered at X = 365 nm. Cells visible via GFP and red dextran
imaging were identified, and one to two cells per plate were observed using time lapse
fluorescence imaging (10 sec/frame) for 30 min using a TIRF microscope (Olympus).
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The live cell imaging was performed by Steve Pratt (Horwitz lab, Universtiy of Virginia).
Analysis was carried out using ImageJ software to quantify the fluorescence intensity of
individual focal adhesions, using GFP-labeled vinculin as a marker for focal adhesions,
over time. The semilogarithmic plots of the background-subtracted fluorescence
intensity over time was linear, and the half life of adhesion formation was determined
from the resulting slopes. 3
GST-paxillin(1-55 7)-FLAG, Y31E, and Y31F paxillin mutants. The full-length paxillin
construct and the Y31E and Y31F mutants were expressed and purified by GST and
FLAG-affinity purification as described for GST-paxillin(38-557)-FLAG (21) in Chapter
3. TEV protease cleavage, performed as described in Chapter 3, yielded native, Y31E,
and Y31F Gly-paxillin(l-557)-FLAG. The proteins were stored at 1 mg/mL in PBS with
20% glycerol at -20 'C.
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Chapter 5
Semisynthesis of a Sox-based chemosensor for ERK2 phosphorylation
Introduction
Sensors for kinase-mediated phosphorylation enable the investigation of kinase
activities in signal transduction pathways. Aberrant kinase activity is known to be
involved in a number of human diseases, including many forms of cancer.' Therefore,
kinase-activity :sensors can be valuable for screening potential kinase inhibitors for
therapeutic applications. 2 Furthermore, kinase sensors provide a tool to help dissect the
role of individual molecules in complex phosphorylation-based signaling cascades.
Sox-based fluorescent chemosensors of protein kinase activity
Sox-based chemosensors are short peptides sensors that include a kinase
recognition motif and a chelation-sensitive fluorophore, the 8-hydroxyquinoline moiety,
incorporated into the non-natural amino acid Sox (Fig. 5.1a).3 The sensors rely on the
Mg2+-chelating property of the phosphate group to sense phosphorylation within an
optimized target peptide sequence. Prior to phosphorylation, the Mg2+ binding affinity of
the sensors is weak. Upon phosphorylation, however, the Mg2+ binding affinity
significantly increases, and chelation between the Mg 2+ and Sox results in chelation-
enhanced fluorescence (CHEF) (Fig. 5.1b).4 The optimal position of the Sox fluorophore
relative to the phosphorylated residue for Mg 2+ chelation is set by a l-turn designed into
the linear peptide or by conjugating the Sox chromophore on the side chain of an
appropriately-spaced cysteine residue. When the Sox chromophore is appended to a
cysteine side chain, both N- and C-terminal kinase recognition elements can be
incorporated into the sensor, which can lead to improved sensitivity and specificity. Sox-
based sensors have a number of important properties that make them ideal for assaying
kinase activity; they demonstrate a large fluorescence increase upon phosphorylation
(typically three- to eight-fold), 2 they enable continuous fluorescence monitoring, and they
can be applied to serine, threonine, or tyrosine kinases.4  Sox-based peptide
chemosensors have been developed for a number of important: kinases in signal
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transduction pathways, and the versatile sensor design is applicable to any kinase that
phosphorylates a distinct linear peptide recognition motif.
2
,4,5
a b Sox
S0 2NMe 2
N
H2N OH OH
Figure 5.1. a) The Sox amino acid, which includes the 8-hydroxyquinoline chelation-
sensitive fluorophore. b) Sox-based fluorescent chemosensors for kinase activity, shown
here with a threonine as the phosphorylated residue.
Sox-based sensing of ERK2 activity
Two significant challenges in the design of phosphorylation sensors are achieving
high specificity for detecting the activity of a single protein kinase and designing
sensitive probes for kinases that have minimal recognition sequences. An individual
kinase can have tens or hundreds of substrates. 6 Similarly, many phosphorylation sites
can be phosphorylated with varying efficiency by a number of different kinases or kinase
isoforms. The major recognition element for most kinases is the phosphorylation motif
of the target substrate, a linear peptide sequence that is typically composed of eight or
fewer residues. Intrinsically, a phosphorylation sensor can be only as specific or
sensitive as the given kinase is for the linear target sequence on which the sensor is
modeled.
In addition to recognizing a linear phosphorylation sequence, some kinases,
particularly those that phosphorylate substrates with shorter or less unique consensus
motifs, rely on recognition of extended regions, resulting in protein-protein interactions
that extend beyond the active site. The mitogen-activated protein kinase (MAPK) ERK2
phosphorylates the transcription factor Ets-1 at Thr38 in the short T-P consensus motif.7
ERK2 has been shown to interact with the pointed (PNT) domain of Ets-1, a five-helix
bundle spanning- residues 54-135 of the protein and flanking the unstructured N-terminus
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MP2
(Fig. 5.2a).8 An Ets-1 construct composed of residues 1-138 (EtsAl138) was recently
investigated by Dalby and coworkers in a study that demonstrates the essentiality of the
PNT domain for optimal ERK2 phosphorylation.9
a
b
RK2
dues 1-138)
\\ /t,~
Me2N(
ERK2, ATP
Mg2+
Figure 5.2. a) (Figure modified from Rainey and coworkers.) 9 Structure of the kinase
ERK2 with the active site aspartic acid shown in red and the PNT docking site indicated
with a yellow star. The structure of Ets-l residues 1-138, including the PNT domain,
which interacts with ERK2, and the TP phosphorylation motif, shown with the Sox
amino acid. b) The Sox-based ERK2 kinase sensor. The sensor includes the PNT
domain of Ets-1 and an ERK2 recognition motif that contains the phosphorylated residue
(Thr38) and the Sox amino acid.
Previous attempts at designing a Sox-based sensor for ERK2 phosphorylation
using linear peptide sequences have failed to achieve acceptable specificity, which could
be explained by the more complex recognition strategy of ERK2. In this chapter, we
describe the design and semisynthesis of a Sox-based ERK2 sensor that incorporates the
entire PNT domain in addition to an ERK2 recognition motif (Fig. 5.2b). The
contribution of the extended recognition element, the PNT domain, should confer the
ERK2 sensor with excellent specificity. The sensor was constructed using NCL to
conjugate the TP recognition motif for ERK2 and the Sox sensing module onto a
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biologically expressed fragment comprising the Ets-1 PNT domain. The ligation design
elements developed with the paxillin system (Chapter 3) were fully transferable to the
semisynthesis of the ERK2 sensor.
Results and Discussion
5-1. Design of the Sox-based ERK2 phosphorylation sensor
The design for the ERK2 phosphorylation sensor (22a) incorporates a Sox-
containing recognition peptide fused to a biologically-expressed fragment comprising
residues 46 through 138 of Ets-l and including the PNT domain. An optimized
phosphorylation motif (V-P-C(Sox)-L-T-P-G-G-R-R) was used in place of the
phosphorylated region of Ets-1 (L-L-T-P-S-S-K-E) in the sensor, and the native distance
between the recognition sequence, T-P, and the PNT domain was preserved (Fig. 5.3a).
The residue replacements occur in the unstructured N-terminal region of Ets-1, so
secondary structures within the protein would not be predicted to be disrupted by the
semisynthesis. Construction of the sensor by NCL required a C-terminal thioester on the
N-terminal fragment and an N-terminal cysteine residue on the C-terminal fragment.'l
Accordingly, the ligation joined a synthetic Sox-containing peptide thioester, either Ac-
VPC(Sox)LTPGGRRG-SBn (PNTD-S-SBn, 23a) or Ac-VPC(Sox)LpTPGGRRG-SBn
(PNTD-P-SBn, 23b), to the expressed PNT domain. The design and construction of the
ERK2 sensor (22a) and the phosphorylated ERK2 sensor (22b) are shown in Figure 5.3.
A Gly-Cys ligation site was included to eliminate the possibility of epimerization at the
C-terminal residue in the peptide synthesis and to increase ligation efficiency, as has been
shown when Gly is the terminal thioester residue for NCL.11
For the C-terminal fragment of the sensor, residues 46-138 of Ets-1 were
expressed as a GST-fusion protein with a hexahistidine tag included at the C-terminus to
provide two handles for purification. A recognition peptide, ENLYFQ(X)C, for TEV
protease was positioned immediately N-terminal of the insert. Treatment of GST-
ENLYFQC-PNT(46-138)-His 6 (24) with TEV protease resulted in the loss of the GST tag
to expose an N-terminal cysteine residue and produce Cys-PNT(46-138)-His 6 (25).
Ligation of the C-terminal fragment 25 with the synthesized Sox-containing thioesters
yielded the ERK2 sensor (22a) and the corresponding phosphorylated sensor (23b). The
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Ets-I (440 aa)
PNT domain: 54-135
Ets-1(38-138)
BioSource ERK2
substrate
T38-P-S-S-K-E-M-M-S-Q-A-L-K-A-T-F-PNT domain
Sox-P-R-T38-P-G-G-R-R
ERK2 sensor V-P-C(Sox)-L-T38-P-G-G-R-RR G-CJS-Q-A-L-K-A-T-F-PNT domain
optimized linear phosphorylation
motif with Sox
PNT domain and
flanking residues
SH biologically expressed
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H O 24
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Figure 5.3. a) ERK2 Sox-sensor design. The sensor includes a linear recognition motif
for ERK2 and the PNT domain of Ets-1. b) Semisynthesis of the ERK2 sensor (22a) and
phosphorylated sensor (22b).
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phosphorylated sensor (22b) was constructed in parallel to determine the fluorescence
difference of 22a prior to and following threonine phosphorylation for sensor calibration.
5-2. Preparation of the C-terminal sensor fragment (25)
PNT(46-138) was cloned from a kanamycin-resistant pET28a vector encoding Ets
S26A. The PNT(46-138) insert was prepared for cloning into a pGEX-4T-2 GST-fusion
vector using primers to create a hexahistidine tag at the C-terminus and a TEV protease
site immediately N-terminal to the expressed PNT(46-138) fragment. Following PCR
and ligation into the pGEX vector, the isolated plasmid DNA was confirmed by DNA
sequencing to contain the correct insert. The DNA was transformed into BL21(DE3)
competent cells for expression of GST-ENLYFQ-Cys-PNT(46-138)-His 6 (24). Protein
expression was induced with 0.2 mM IPTG in LB-carbenicillin at 30 oC and carried out
for 4 to 5 hours. Crude 24 was purified on a GST-affinity column and eluted from the
column with 10 mM reduced glutathione. Gel analysis revealed a single species
corresponding to the 38.5 kDa construct. As quantified using a BioRad protein assay,
which is compatible with the presence of glutathione, a 1 L expression of 24 yielded 25
to 30 mg of GST-purified protein. Complete cleavage of the GST tag, revealing an N-
terminal cysteine residue, was accomplished by treatment with TEV protease. By gel
analysis, incubation of 24 with TEV protease for 3 hours resulted in the disappearance of
the 38.5 kDa species and the concomitant appearance of an 11.5 kDa fragment, consistent
with the calculated molecular weight for Cys-PNT(46-138)-His 6 (25) (Fig. 5.4).
5-3. Synthesis of peptide thioesters
Ac-DYKDDDDKG-COSBn (26) synthesis for test ligations
To establish NCL conditions with the C-terminal fragment of the PNT domain
(25), and also for general use as a tagged-thioester for test ligations with other proteins
expressed in the lab, a thioester peptide containing the FLAG sequence (DYKDDDDK)
was synthesized. A FLAG-tagged thioester is a useful fragment for test ligations both
because it enables detection of the ligation product with high specificity and sensitivity
by the FLAG antibody for use in Western blotting, and because it readily dissolves in
134
27 kDa 11.5 kDa
ii H Thy
-His 6protease
H
mm.
4- a
anti-His 6
SGST
- 25
GST-purified TEV cleaved GST-purified TEV cleaved
24 24
Figure 5.4. Expression and TEV proteolysis of GST-ENLYFQ-Cys-PNT(46-138)-His 6(39.5 kDa). Coomassie and anti-hexahistidine Western blot analysis of the GST-affinity
purified protein 24 and of the product mixture following TEV proteolysis.
standard ligation buffers. For the FLAG thioester synthesis, the peptide was prepared on
Gly-loaded TGT resin and cleaved from the resin with 0.5% TFA in DCM to yield a
carboxylic acid at the C-terminus without effecting side chain protection.
Thioesterification was accomplished by activating the carboxylic acid with HBTU and
DIPEA and reacting it with benzylmercaptan, as described for paxillin thioesters in
Chapter 3 (Scheme 3.1). Peptide cleavage and side chain deprotection afforded the
FLAG thioester, Ac-DYKDDDDKG-COSBn (26). The peptide was purified by reverse
phase HPLC, lyophilized, and stored in 400 ptg (328 nmol) aliquots at -20 oC for
subsequent ligations.
PNTD peptide thioester synthesis
Two peptides were supplied by Elvedin Lukovic on TGT resin for
thioesterification and subsequent ligation to 25: PNTD-S (Ac-VPC(Sox)LTPGGRRG-
(TGT)); and PNTD-P, (Ac-VPC(Sox)LTPGGRRG-(TGT)). The "S" designation refers
to non-phosphorylated "substrate" peptide and the "P" designation refers to
phosphorylated peptide. The peptide sequences were based on the ERK2
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phosphorylation motif of the myelin basic protein (MBP).12  For peptide
thioesterification, the standard conditions used for paxillin and FLAG thioesters were
attempted, in which the peptide was activated with HBTU and DIPEA in dry THF and
reacted with benzylmercaptan. However, the reaction yielded a single product by HPLC
that was 26 to 27 mass units less than that expected for the corresponding PNTD
thioester. The identity of this unexpected product could not be determined. While the
mass could correspond to hydrolysis of the Sox sulfonamide to sulfonic acid (loss of -
NMe2 and gain of -OH for a net loss of 27 Da), peaks in the MALDI spectrum of the
purified peptide suggest that the Sox moiety remains intact. In MALDI spectra of Sox-
containing peptides, Sox is often cleaved by the laser, resulting in a second peak at M-
264 mass units. If hydrolysis of Sox had occurred, there should have been an M-237
peak in the MALDI, but instead only an M-264 peak was present.
Thioesterification was next attempted using phosphonium reagents in a variety of
conditions. These reactions failed to produce the desired thioester and resulted in
recovered starting material or in conversion to an unknown product that was 51 mass
units smaller than that expected for the thioester. Ultimately activation with HATU and
PNTD-S-SBn H2N NH2
SO2NMe 2
PNTD-P-SBn H2N NH2
7Th MH
Figure 5.5. PNTD peptide thioesters for ligation to Cys-PNT(46-138)-His 6 (25).
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HOAT with collidine in DCM resulted in the desired thioester products, PNTD-S-SBn
(23a) and PNTD-P-SBn (23b) (Fig. 5.5). Final side-chain deprotection of the peptide
thioesters was tested both in the presence and absence of EDT in the cleavage cocktail,
since inclusion of EDT is recommended for cysteine-containing peptides. Both cleavage
conditions prevented unwanted cysteine oxidation, so subsequent preparations were
conducted in the absence of EDT. The peptide concentrations were determined using the
Sox fluorophore (E355 = 8,247 M'cm-1 in 0.1 M NaOH and 1 mM EDTA), and the
peptides were stored as lyophilized 100 nmol aliquots at -20 oC for subsequent ligation to
Cys-PNT(46-138)-His 6 (25).
5.4 Test ligation and product isolation with Cys-PNT(46-138)-His 6
The ligation of the FLAG thioester, 26, to the PNT fragment 25 was
accomplished in a Tris buffer, pH 8, catalyzed by the addition of MESNA. The ligation
was run with either 1.5 or 3 equivalents of peptide over protein. With 1.5 equivalents of
thioester peptide, the protein conversion to Ac-DYKDDDDKGC-PNT(54-138)-His 6 (27),
as estimated by Coomassie gel analysis, was 60%. With 3 equivalents of thioester the
protein conversion was approximately 90%.
The semisynthesis was designed to enable complete purification of the ligation
product by buffer exchange and a single affinity column, based on the N-terminal FLAG
tag. This means that a separate purification step was not required following the TEV
protease cleavage prior to ligation. The crude ligation mixture therefore contained
cleaved GST tag (27 kDa), hexahistidine-tagged TEV protease (- 28 kDa), NCL product
(27) (12.7 kDa), unligated PNT domain (25) (11.5 kDa), unligated thioester (26) (1.2
kDa) and MESNA (Fig. 5.6a). Exchange into TBS with 10 kDa MWCO centrifugal
filters concurrently removed the MESNA and excess thioester. Incubation with FLAG-
affinity resin isolated 27 as the sole FLAG-tagged moiety in the NCL mixture.
Coomassie and anti-hexahistidine Western blot analysis revealed complete separation of
ligated product from the unligated material, as well as excellent separation from cleaved
GST (Fig. 5.6b). This purification strategy can be applied to ERK2 sensor isolation if an
N-terminal purification handle is included on the peptide thioester. In that case, the
ligation would be run with 1.5 equivalents of thioester to minimize the use of excess Sox-
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containing peptides. However, the first generation sensor does not include an N-terminal
handle, since the FLAG sequence was found to decrease chelation-enhanced fluorescence
of test peptides. Purification is more complicated in the absence of an N-terminal tag, so
6 equivalents of thioester over PNT domain were used to increase product conversion for
the ERK2 sensor, as described in Section 5.5.
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Figure 5.6. Test ligation and purification of Ac-FLAG-Cys-PNT(46-138)-His 6 (27). a)
Coomassie and anti-FLAG Western blot analysis of (lane 1) the purified GST-fusion
construct 24, (lane 2) the TEV cleavage product 25, and (lane 3) the crude NCL product
mixture. Only the ligated product should be visible on an anti-FLAG Western blot. b)
Coomassie and anti-hexahistidine Western blot analysis of FLAG-affinity purified 27,
The red stars indicate the desired ligation product, 27.
Stability and buffer compatibility of the ligated PNT domain
GST-ENLYFQ-Cys-PNT(46-138)-His 6 (24) is very stable prior to cleavage of the
GST tag and may be stored at 0.5 mg/mL for over one month at 4 oC without any
detectible precipitation or degradation. Following GST cleavage and concentration (to 3
mg/mL) of the resulting protein construct 25, some precipitation was observed, which
could be avoided by immediate ligation with an N-terminal fragment. To probe the
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stability of the ligated PNT domain, Ac-DYKDDDDKGC-PNT(46-138)-His 6 (27) was
dialyzed into four different buffers at 0.1 mM immediately following NCL and stored for
one week at 4 'C. The protein was also analyzed in the crude ligation mixture at 0.25
mM. Stability was examined in TBS, PBS, 20 mM hepes, pH 7.4 and 20 mM hepes, pH
7.4 with 100 mM NaCl, the standard buffer for Sox fluorescence assays. The protein was
found to be stable and free of precipitation in all conditions tested (Fig. 5.7).
241 anti-FLAG
GST
* 27
25 4:-27
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Figure 5.7. Coomassie and anti-FLAG probed Western blot analysis of PNT stability
following NCL. (lane 1) purified GST-fusion construct 24, (lane 2) crude NCL product,
and (lane 3-7) NCL product after 1 week at 4 oC in (lane 3) ligation buffer (2.5 mg/mL),
(lane 4) TBS (1 mg/mL), (lane 5) PBS (lmg/mL), (lane 6) hepes (1 mg/mL), and (lane 7)
hepes with 100 mM NaC1.
5.5 NCL of the ERK2 kinase sensor (22a)
Following the validation of ligation conditions and product stability using the
FLAG thioester 26, PNTD-S-SBn (23a) was ligated to Cys-PNT(54-138)-His 6 (25) in
Tris buffer, pH 8 with 150 mM MESNA. The peptide and PNT domain concentrations
were 0.8 mM and 0.25 mM, respectively, and the conversion to ligation product, Ac-
VPC(Sox)LTPGGRRG-PNT(54-138)-His 6 (22a), was approximately 70%. Increasing
the thioester excess from 3 to 6 equivalents resulted in over 90% conversion (Fig. 5.8).
Isolation of 22a (13 kDa), from unligated thioester (- 1.5 kDa) (23a) was performed by
Elvedin Lukovic using size exclusion chromatography. The phosphorylated version of
the sensor (22b) was constructed using the identical ligation conditions to conjugate 25 to
PNTD-P-SBn (23b).
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Figure 5.8. NCL to generate Ac-VPC(Sox)LTPGGRRG-Cys-PNT(46-138)-His 6 (22a)
and Ac-VPC(Sox)LpTPGGRRG-Cys-PNT(46-138)-His 6 (22b). Coomassie gel of (lane
1) the TEV cleavage product 25 (11.5 kDa), (lane 2) the crude NCL product 22a (13
kDa), and (lane 3) the crude NCL product 22b (13 kDa).
Fluorescence assays performed by Elvedin Lukovic revealed a three-fold increase
in fluorescence of the phosphorylated sensor (22b) over the substrate sensor (22a). In
addition, the ERK2 sensor (22a) demonstrated excellent sensitivity to ERK2 activity.
Under identical assay conditions, the protein sensor was found to be approximately 10-
fold more sensitive than the corresponding peptide probe, 23a, for monitoring ERK2
kinase activity (Fig. 5.9).
Conclusion
The semisynthesis of the ERK2 kinase activity sensor described in this chapter
extends the Sox-sensing strategy to an 11.5-kDa protein domain for the creation of a
sensor that comprises both an ERK2 phosphorylation motif and the Ets-1 PNT domain
for ERK2 docking. The details of sensor construction were based on the successful use
of tags and a TEV cleavage site for the semisynthesis of paxillin analogs (Chapter 3).
Results from fluorescence assays on the completed sensor indicate that the PNT domain
confers sensitivity for ERK2 activity that was not possible with a linear peptide-probe for
ERK2 phosphorylation. We have therefore demonstrated the use of semisynthesis to
140
- GST
- 22a/22b
- 25
46 kDa,
enhance the sensitivity of kinase sensors by incorporating extended recognition elements
onto the peptide recognition core.
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Figure 5.9. (Assays performed by Elvedin Lukovic.) Direct comparison of the Sox-
protein (22a) versus the Sox-peptide (23a) as sensors for ERK2 phosphorylation. The
graph on the left shows the fluorescence intensity of the probes over time following
treatment with ERK2. The bar graph on the right demonstrates the percentage of the
Sox-peptide slopes with respect to the protein slope with 10, 100 and 250 gLM of peptide
sensor (23a).
Methods
Ac-DYKDDDDKG-COSBn (26).
@ NH3
H
: N ON N NH H
0 0
) NH3
The peptide (50 ltmol on 250 mg of resin) was synthesized on an automated
Advanced ChemTech 396 peptide synthesizer using standard Fmoc-based SPPS
protocols on preloaded Fmoc-Gly-Novasyn TGT resin (Novabiochem). The peptide was
cleaved from the resin with side-chain protection intact by agitating with 0.5% TFA in
141
o00
~ --- --
DCM for 1.5 h. The resin was removed by filtration and rinsed with DCM. The solvent
was evaporated under a stream of nitrogen, and the peptide was triturated with cold
hexanes. The hexanes were removed in vacuo and the resulting white powder was
dissolved in anhydrous THF (17 mL), then treated with HBTU (75 mg, 200 [lmol),
DIPEA (69 ptL, 400 [tmol), and benzylmercaptan (23 jiL, 200 [tmol) under nitrogen
overnight. The THF was removed in vacuo and the peptide was deprotected with 95%
(vol/vol) TFA, 2.5% (vol/vol) TIS, and 2.5% (vol/vol) water for 2 hours. The peptide
was triturated with cold diethylether, and purified by reverse phase HPLC on a Waters
600 instrument with a YMC C18 preparative column using an elution gradient of
water/acetonitrile with 0.1% TFA. The identities of the peptide as a free acid and of the
final peptide thioester product were confirmed by electrospray ionization (ESI) mass
spectrometry on a Perspective Biosystems Mariner Biospectrometry Workstation (turbo
ion source).
Ac-DYKDDDDKG-COOH, Reverse phase HPLC (tR = 18.1 min). Exact mass calcd for
C45H65Nl 10 22, 1112.1; found by MS(ESI), 1112.3 [MH]'1 , 556.7 [MH 2]2+
Ac-DYKDDDDKG-COSBn (26), Reverse phase HPLC (tR = 21.3 min). Exact mass
calcd for C52 H71N 110 21S, 1217.8; found by MS(ESI), 1218.4 [MH] , 609.7 [MH 2]2+.
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Sox-containing peptides thioesters. Peptides were constructed by Fmoc-based SPPS on
Fmoc-Gly-Novasyn TGT resin and derivatized to the corresponding thioesters as
described below for PNTD-S-SBn.
PNTD-S-SBn (Ac-VPC(Sox)LTPGGRRG-COSBn) (23a).
ED
H O
0
NN
H2N NH2(D
Following SPPS on Fmoc-Gly-Novasyn TGT resin, the peptide (10 glmol from 50
mg of resin) was cleaved from the resin with side-chain protection intact by agitating
with 0.5% TFA in DCM for 1.5 h. The resin was removed by filtration and rinsed with
DCM, the solvent was mostly evaporated under a stream of nitrogen, and the peptide was
triturated with cold hexanes. The hexanes were removed in vacuo, and the resulting
white powder was dissolved in 16 mL of anhydrous DCM and treated with HATU (30
mg, 80 [tmol) and HOAT (10.8 mg, 80 tmol) dissolved in 0.5 mL dry DMF, collidine
(21 tiL, 160 jimol), and benzylmercaptan (19 [tL, 160 [tmol). The reaction was stirred
under nitrogen overnight. The solvent was removed in vacuo, and the peptide was
deprotected with 95% (vol/vol) TFA, 2.5% (vol/vol) TIS, and 2.5% (vol/vol) water for 3
h. The peptide was triturated with cold diethylether, and purified by reverse phase
HPLC.
PNTD-S: Ac-VPC(Sox)LTPGGRRG-COOH, Reverse phase HPLC (tR = 25.8 min).
Exact mass calcd for C60H95N190 17S2, 1417.7; found by MS(MALDI), 1419.3 [MH] .
PNTD-S-SBn: Ac- VPC(Sox)LTPGGRRG -COSBn (23a), Reverse phase HPLC (tR =
27.2 min). Exact mass calcd for C67 H101N19 0 16S3, 1523.7; found by MS(MALDI), 1524.8
[MH]' + .
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PNTD-P-SBn: Ac- VPC(Sox)LpTPGGRRG -COSBn (23b).
H2N NH2
INH
H O H o
N :N
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3U 2 NM e 2
PNTD-P: Ac-VPC(Sox)LpTPGGRRG-COOH, Reverse phase HPLC (tR = 25.8 min).
Exact mass calcd for C60H96N190 20PS2, 1497.6; found by MS(MALDI), 1498.4 [MH] .
PNTD-P-SBn: Ac- VPC(Sox)LpTPGGRRG -COSBn (23b), Reverse phase HPLC (tR =
27.2 min). Exact mass calcd for C67H102N190 19PS 3, 1603.7; found by MS(MALDI),
1605.9 [MH] +
Plasmid construction for GST-ENLYFQC-PNT(46-138)-His6 (24). A kanamycin-
resistant Ets S26A construct in a pET28 vector was transformed into DH5u cells and
grown up on an LB-kan agar plate. Several colonies were selected and grown up in 3 mL
of LB-carbenicillin overnight with shaking at 37 oC. The plasmids from these cultures
were isolated using a perfect prep plasmid mini kit (Eppendorf). PNT(46-138) was
amplified from the plasmid DNA from Ets miniprep #4 using primers to introduce a 5'
EcoR1 site and a 3' Notl site for incorporation into a pGEX-4T-2 vector. The primers
also encoded an amino-terminal TEV protease recognition site (ENLYGQXC) and a
carboxy-terminal hexahistidine tag. For this amplification the following primers were
used: FORETS1: 5'- GCC GGA ATT CGT GAA AAC CTG TAT TTT CAG TGC TCC
CAA GCC TTG AAA GCT -3;, and BACETS1: 3'- GCC CCC TTT TGC GGC CGC
CTA GTG ATG GTG ATG GTG ATG ACC TTT CAC ATC CTC TTT CTG -5'.
Five PCR reactions were run simultaneously with 50 ýtL each of the following
reaction mixture: 200 [tL of sterile DI water, 25 jtL of 10X Taq HIFI buffer, 16.25 itL of
10 mM dNTPs, 9.75 jtL of 50 mM MgC12, 3.25 pL (0.5 mg/mL) each of FORETS 1 and
BACETS 1 primers, 3.5 LtL of ETS 1 miniprep 4 DNA template, and 2.5 ýtL of Taq HIFI
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(added last). The reactions were run in the thermal cycler as shown and electrophoresed
on an agarose gel. The desired DNA fragment (354 bp) was excised and purified with a
gel extraction kit (Qiagen).
X2 X2 X2 X2 X2 X2 X25
94 ' 94 '4 9 4 ' 94 ,94 94 ,94
3 min: :30 72 72 72 72 72 72 :30 72 72
63 61 59 58 56 55 54
:45 :45 4
The PCR-amplified fragments were digested with Notl and EcoR1 and ligated to
Notl/EcoR1-digested and CIP-treated pGEX-4T-2. To 43.5 gLL of purified PCR product
in EB were added 5.0 gL of 10X EcoR1 buffer, 0.5 jtL of 100X BSA, and 2.5 glL of
Notl. The digestion was incubated overnight at rt, and then 2.5 jgL of EcoR1 were
added, and the mixture was further incubated for 1 hour at 37 oC. To this solution was
added 12.5 [tL of 5X nucleic acid loading buffer and the digested insert was
electrophoresed on a 1% agarose DNA gel for purification. The insert band was excised
and purified with a gel extraction kit (Qiagen). The DNA was eluted with 30 gL of 1:9
elution buffer: sterile water and used directly in ligations without any further
concentration.
To ligate the PNT(46-138)-His 6 insert into the pGEX-4T-2 vector, 3 gLL of
digested and CIP-treated vector, 5 pL of digested (334 bp) PCR insert, 1 [pL of T4 ligase,
and 1 [tL of 10X T4 ligase buffer were combined in a sterile eppendorf. The tube was
gently flicked and then incubated 2.5 h at rt. A vector-only control ligation was similarly
run. The ligation mixture was transformed into DH5a cells and grown on carbenicillin-
resistant plates. Eight colonies grew up on the vector/insert ligation plate with only two
colonies on the negative control. Plasmid DNA was isolated from selected colonies and
confirmed by sequencing. Miniprep #2 was found to contain the correct insert.
Expression and purification of GST-ENLYFQC-PNT(46-138)-His6 (24). The PNT
domain plasmid was transformed into BL21(DE3) competent cells (Stratagene) and
grown at 37 'C to midlog phase (OD = 0.55) in 1 L of LB media with carbenicillin. The
culture was cooled to 30 oC, and the cells were induced with 0.2 mM IPTG and grown
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for an additional 4.5 h. Cells were harvested by centrifugation and frozen at -80 oC. For
cell lysis, the pellet from a 1-L expression was thawed and resuspended in 40 mL of lysis
buffer (PBS, 1 mg/mL lysozyme, 1 mM DTT, and protease cocktail III [100 tM AEBSF,
80 nM aprotinin, 5 [iM bestatin, 1.5 [tM E-64, 2 [iM leupeptin, 1 [tM pepstatin A]
(Calbiochem)) and incubated for 20 min at 4 'C. The cells were lysed with 1% NP-40
Alternative, then sonicated and subjected to centrifugation at 9,000 rpm for 25 min,
followed by filtration through a 0.2 micron filter. The supernatant was transferred to a
50-mL conical tube for purification.
The soluble fraction was incubated with 3 mL of Glutathione Sepharose 4 Fast
Flow resin (Amersham Biosciences), following the manufacturer protocol. After 35 min
of incubation at 4 oC and copious washing with PBS, the protein was eluted from the
resin with four 3-mL batches of 10 mM glutathione in 50 mM Tris, pH 8.0, following
incubation for 3-5 min. The elutions were combined and dialyzed into 3 X 2 L of PBS to
remove the glutathione. A l-L prep afforded 25 to 30 mg of GST-ENLYFQC-PNT(46-
138)-His6. The 38.5-kDa protein was analyzed by 10% SDS-PAGE gels and visualized
with Coomassie blue dye and by Western blot with a mouse anti-hexahistidine primary
antibody. Purified 24 was stored at 4 oC.
TEV proteolysis. Cys-PNT(46-138)-His6 (25): Purified GST-ENLYFQC-PNT(46-138)-
His6 was diluted to 1 mg/mL into a TEV cleavage buffer with a final concentration of 50
mM Tris pH 8.0, 500 tiM EDTA, and 5 mM BME. TEV protease (43 tiL of protease per
mg of protein) was added, and the resulting solution was incubated at 27 'C for 3 hours.
The protein was concentrated in a swinging bucket centrifuge at 2 K rpm using 5-KDa
MWCO Amicon Ultra-15 centrifugal filters (Millipore) and used immediately in NCL
without removal of the TEV or the cleaved GST tag. Cleavage of 10 mg of GST-
ENLYFQC-PNT(46-138)-His 6 resulted in 3 mg of Cys-PNT(46-138)-His 6 with complete
conversion.
Ligations
NCL was carried out with 250 jiM protein, 0.8 mM peptide thioester, and 150
mM MESNA in TBS at pH 8.0, unless noted otherwise in the text. For example, to a
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solution of Cys-PNT(46-138)-His 6 (104 tg, 104 nmol) in 330 itL of TBS was added
PNTD-S-SBn (lyophilized, then dissolved into 20 [tL of water for transfer) (327 nmol),
30 [iL of 2 M MESNA, and 30 tiL of 500 mM Tris pH 8.0. The reaction was incubated
for 20 h at 25 oC, and then dialyzed into PBS using a 10 MWCO dialysis membrane to
remove excess peptide thioester. The protein was analyzed by 10% SDS-PAGE gels, and
visualized with Coomassie blue dye.
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13C NMR of N-a-Fmoc-phospho( 1 -nitrophenylethyl-2-cyanoethyl)-L-threonine (10)
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